Our O
data O
suggest O
that O
lipoxygenase B
metabolites I
activate O
ROI O
formation O
which O
then O
induce O
IL B
- I
2 I
expression O
via O
NF B
- I
kappa I
B I
activation O
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact B
promoter I
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

Transient O
transfection O
experiments O
show O
that O
several O
elements O
in O
the O
promoter B
- I
proximal I
region I
of O
the O
IL B
- I
2R I
alpha I
gene I
contribute O
to O
IL B
- I
1 I
responsiveness O
, O
most O
importantly O
an O
NF B
- I
kappa I
B I
site I
conserved O
in O
the O
human B
and I
mouse I
gene I
. O

Transient O
transfection O
experiments O
show O
that O
several O
elements O
in O
the O
promoter B
- I
proximal I
region I
of O
the O
IL B
- I
2R I
alpha I
gene I
contribute O
to O
IL B
- I
1 I
responsiveness O
, O
most O
importantly O
an O
NF B
- I
kappa I
B I
site I
conserved O
in O
the O
human B
and I
mouse I
gene I
. O

IL B
- I
2 I
responsiveness O
, O
on O
the O
other O
hand O
, O
depends O
on O
a O
78 B
- I
nucleotide I
segment I
1 O
. O
3 O
kilobases O
upstream O
of O
the O
major B
transcription I
start I
site I
. O

IL B
- I
2 I
responsiveness O
, O
on O
the O
other O
hand O
, O
depends O
on O
a O
78 B
- I
nucleotide I
segment I
1 O
. O
3 O
kilobases O
upstream O
of O
the O
major B
transcription I
start I
site I
. O

Transcripts O
encoding O
gp350 B
/ I
220 I
, O
the O
major B
coat I
protein I
of O
EBV O
, O
were O
identified O
, O
but O
we O
did O
not O
find O
any O
evidence O
of O
transcription O
from O
the O
LMP B
- I
2A I
or O
EBER B
- I
1 I
loci I
in O
infected O
thymocytes O
. O

We O
demonstrate O
, O
through O
the O
deletion O
of O
the O
human B
UDG I
promoter I
sequences I
, O
that O
expression O
of O
E2F B
- I
1 I
activates O
the O
UDG B
promoter I
through O
several O
E2F B
sites I
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA B
binding I
protein I
complexes I
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA B
binding I
protein I
complexes I
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

We O
examined O
alpha B
A1 I
( O
an O
alpha B
A I
- I
gene I
product I
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha B
B I
- I
encoded I
isomers I
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

When O
either O
serine O
- O
32 O
or O
serine O
- O
36 O
of O
I B
kappa I
B I
- I
alpha I
was O
mutated O
, O
the O
protein O
did O
not O
undergo O
signal O
- O
induced O
phosphorylation O
or O
degradation O
, O
and O
NF B
- I
kappa I
B I
could O
not O
be O
activated O
. O

Regulation O
of O
transcription O
of O
the O
human B
erythropoietin I
receptor I
gene I
by O
proteins O
binding O
to O
GATA B
- I
1 I
and I
Sp1 I
motifs I
. O

The O
deduced O
amino O
acid O
sequence O
similarity O
to O
the O
proteins O
encoded O
by O
these O
two O
latter O
genes O
is O
approximately O
65 O
% O
and O
includes O
domains O
and O
amino O
acid O
residues O
( O
the O
leucine B
zipper I
- I
like I
and O
the O
RGD B
domain I
, O
a O
serine O
and O
a O
histidine O
residue O
in O
the O
NH2 B
- I
and O
in O
the O
COOH B
- I
terminal I
portion I
of O
the O
protein O
, O
respectively O
) O
postulated O
to O
be O
important O
for O
nm23 B
function O
. O

The O
deduced O
amino O
acid O
sequence O
similarity O
to O
the O
proteins O
encoded O
by O
these O
two O
latter O
genes O
is O
approximately O
65 O
% O
and O
includes O
domains O
and O
amino O
acid O
residues O
( O
the O
leucine B
zipper I
- I
like I
and O
the O
RGD B
domain I
, O
a O
serine O
and O
a O
histidine O
residue O
in O
the O
NH2 B
- I
and O
in O
the O
COOH B
- I
terminal I
portion I
of O
the O
protein O
, O
respectively O
) O
postulated O
to O
be O
important O
for O
nm23 B
function O
. O

Genomic O
sequence O
upstream O
of O
the O
Fc B
gamma I
RIC I
gene I
was O
cloned O
and O
subjected O
to O
primer O
extension O
analysis O
, O
which O
demonstrated O
a O
single O
transcription B
initiation I
site I
without O
a O
TATA B
box I
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
of O
the O
guanylate B
binding I
protein I
and O
to O
X B
box I
elements I
of O
class B
II I
MHC I
genes I
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
of O
the O
guanylate B
binding I
protein I
and O
to O
X B
box I
elements I
of O
class B
II I
MHC I
genes I
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

We O
provide O
evidence O
for O
an O
additional O
binding B
site I
, O
the O
MIP B
- I
1 I
alpha I
nuclear I
protein I
( I
MNP I
) I
site I
, O
which O
overlaps O
the O
ICK B
- I
1 I
site I
. O

The O
retinoblastoma B
gene I
product I
negatively O
regulates O
transcriptional O
activation O
mediated O
by O
the O
human B
cytomegalovirus I
IE2 I
protein I
. O

We O
found O
that O
the O
retinoblastoma B
susceptibility I
gene I
product I
( O
Rb B
) O
dramatically O
suppressed O
this O
IE2 B
transactivation O
of O
various B
promoters I
. O

Retinoblastoma B
protein I
( O
RB B
) O
is O
a O
tumor O
suppressor O
and O
functions O
as O
a O
transcriptional B
repressor I
by O
binding O
and O
inactivating O
the O
transactivator B
E2F I
- I
I I
. O

We O
have O
recently O
demonstrated O
that O
stimulation O
of O
human O
T O
and O
natural O
killer O
cells O
with O
IL B
- I
12 I
induces O
tyrosine O
phosphorylation O
of O
the O
Janus B
family I
tyrosine I
kinase I
JAK2 B
and O
Tyk2 B
, O
implicating O
these O
kinases B
in O
the O
immediate O
biochemical O
response O
to O
IL B
- I
12 I
. O

Furthermore O
, O
we O
show O
that O
IL B
- I
12 I
stimulates O
formation O
of O
a O
DNA B
- I
binding I
complex I
that O
recognizes O
a O
DNA O
sequence O
previously O
shown O
to O
bind O
STAT B
proteins I
and O
that O
this O
complex O
contains O
STAT4 B
. O

The O
tyrosine O
kinase O
inhibitors O
genistein O
and O
herbimycin O
A O
block O
both O
integrin B
- O
mediated O
tyrosine O
phosphorylation O
and O
increases O
in O
IL B
- I
1 I
beta I
message O
levels O
, O
indicating O
a O
causal O
relationship O
between O
the O
two O
events O
. O

These O
observations O
indicate O
that O
the O
Syk B
tyrosine O
kinase O
may O
be O
an O
important O
component O
of O
an O
integrin B
signaling O
pathway O
in O
monocytic O
cells O
, O
leading O
to O
activation O
of O
NF B
- I
kappa I
B I
and O
to O
increased O
levels O
of O
cytokine B
messages O
. O

Activation O
of O
NF B
- I
kappa I
B I
by O
various O
cellular O
stimuli O
involves O
the O
phosphorylation O
and O
subsequent O
degradation O
of O
its O
inhibitor O
, O
I B
kappa I
B I
alpha I
, O
although O
the O
underlying O
mechanism O
remains O
unclear O
. O

Activation O
of O
NF B
- I
kappa I
B I
by O
various O
cellular O
stimuli O
involves O
the O
phosphorylation O
and O
subsequent O
degradation O
of O
its O
inhibitor O
, O
I B
kappa I
B I
alpha I
, O
although O
the O
underlying O
mechanism O
remains O
unclear O
. O

Together O
, O
these O
results O
suggest O
that O
phosphorylation O
of O
I B
kappa I
B I
alpha I
, O
mediated O
through O
both O
the O
TNF B
- I
alpha I
- O
inducible O
and O
the O
PP B
- I
2A I
- I
opposing I
kinases I
, O
may O
serve O
to O
target O
I B
kappa I
B I
alpha I
for O
proteasome B
- O
mediated O
degradation O
. O

Together O
, O
these O
results O
suggest O
that O
phosphorylation O
of O
I B
kappa I
B I
alpha I
, O
mediated O
through O
both O
the O
TNF B
- I
alpha I
- O
inducible O
and O
the O
PP B
- I
2A I
- I
opposing I
kinases I
, O
may O
serve O
to O
target O
I B
kappa I
B I
alpha I
for O
proteasome B
- O
mediated O
degradation O
. O

The O
5 B
' I
flanking I
region I
of O
the O
human B
alpha I
- I
globin I
gene I
is O
highly O
G O
+ O
C O
rich O
and O
contains O
multiple O
copies O
of O
the O
consensus B
sequence I
for O
the O
Sp1 B
binding I
site I
. O

Finally O
, O
we O
show O
by O
both O
footprint O
analysis O
and O
functional O
assays O
that O
the O
ability O
of O
the O
G B
+ I
C I
- I
rich I
region I
to O
increase O
alpha B
- I
globin I
promoter I
activity O
from O
a O
stably O
integrated O
alpha B
- I
globin I
gene I
is O
mediated O
by O
its O
multiple B
binding I
sites I
for O
the O
transcription B
factor I
Sp1 B
. O

Finally O
, O
we O
show O
by O
both O
footprint O
analysis O
and O
functional O
assays O
that O
the O
ability O
of O
the O
G B
+ I
C I
- I
rich I
region I
to O
increase O
alpha B
- I
globin I
promoter I
activity O
from O
a O
stably O
integrated O
alpha B
- I
globin I
gene I
is O
mediated O
by O
its O
multiple B
binding I
sites I
for O
the O
transcription B
factor I
Sp1 B
. O

LFA B
- I
3 I
induced O
moderate O
levels O
of O
AP B
- I
1 I
, O
but O
did O
not O
influence O
the O
levels O
of O
NF B
- I
kappa I
B I
, O
while O
B7 B
costimulation O
strongly O
induced O
both O
AP B
- I
1 I
and O
substantially O
enhanced O
NF B
- I
kappa I
B I
binding I
proteins I
. O

The O
Ah B
receptor I
recognizes O
DNA B
binding I
sites I
for O
the O
B B
cell I
transcription I
factor I
, O
BSAP B
: O
a O
possible O
mechanism O
for O
dioxin O
- O
mediated O
alteration O
of O
CD19 B
gene I
expression O
in O
human O
B O
lymphocytes O
. O

Delayed O
administration O
of O
rBPI21 B
also O
affected O
LPS O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
, O
NF B
- I
kappa I
B I
. O

Two O
to O
4 O
h O
following O
LPS O
addition O
to O
endothelial O
cells O
, O
when O
NF B
- I
kappa I
B I
was O
already O
activated O
, O
addition O
of O
rBPI21 B
resulted O
in O
marked O
reduction O
of O
NF B
- I
kappa I
B I
detectable O
at O
4 O
or O
6 O
h O
. O

Two O
to O
4 O
h O
following O
LPS O
addition O
to O
endothelial O
cells O
, O
when O
NF B
- I
kappa I
B I
was O
already O
activated O
, O
addition O
of O
rBPI21 B
resulted O
in O
marked O
reduction O
of O
NF B
- I
kappa I
B I
detectable O
at O
4 O
or O
6 O
h O
. O

Costimulatory O
signals O
, O
such O
as O
activation O
of O
the O
CD28 B
cell I
surface I
molecule I
on O
T O
cells O
, O
lead O
to O
activation O
through O
a O
distinct O
region O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
promoter I
. O

Formation O
of O
the O
NFAT B
- I
1 I
transcriptional I
complex I
on O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
IL B
- I
2 I
transcription O
. O

Primer O
extension O
and O
ribonuclease B
protection O
analyses O
indicate O
a O
single O
major B
transcriptional I
start I
site I
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal B
transducers I
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo B
- I
and I
heterodimers I
varies O
between O
the O
two O
cell O
types O
. O

The O
generation O
of O
second O
messengers O
in O
T O
cells O
normally O
leads O
to O
downstream O
signaling O
that O
results O
in O
transcriptional O
activation O
of O
the O
IL B
- I
2 I
gene I
. O

Levels O
of O
the O
octamer O
, O
NF B
- I
kappa I
B I
( O
p50 B
- I
p65 I
heterodimer I
) O
, O
and O
AP B
- I
1 I
transcriptional I
factors I
are O
constitutively O
elevated O
in O
freshly O
isolated O
Ipr O
CD4 O
- O
8 O
- O
T O
cells O
, O
consistent O
with O
the O
activated O
phenotype O
of O
these O
cells O
. O

Levels O
of O
the O
octamer O
, O
NF B
- I
kappa I
B I
( O
p50 B
- I
p65 I
heterodimer I
) O
, O
and O
AP B
- I
1 I
transcriptional I
factors I
are O
constitutively O
elevated O
in O
freshly O
isolated O
Ipr O
CD4 O
- O
8 O
- O
T O
cells O
, O
consistent O
with O
the O
activated O
phenotype O
of O
these O
cells O
. O

Here O
, O
we O
report O
that O
nitric O
oxide O
( O
NO O
) O
activates O
p21ras B
in O
human O
T O
cells O
as O
evidenced O
by O
an O
increase O
in O
GTP B
- I
bound I
p21ras I
. O

Furthermore O
, O
we O
demonstrate O
that O
p21ras B
is O
essential O
for O
NO O
- O
induced O
downstream O
signaling O
, O
such O
as O
NF B
- I
kappa I
B I
activation O
, O
and O
that O
endogenous O
NO O
can O
activate O
p21ras B
in O
the O
same O
cell O
. O

These O
studies O
identify O
p21ras B
as O
a O
target O
of O
NO O
in O
T O
cells O
and O
suggest O
that O
NO O
activates O
p21ras B
by O
an O
action O
which O
mimics O
that O
of O
guanine B
nucleotide I
exchange I
factors I
. O

In O
the O
present O
study O
we O
analyzed O
the O
control O
of O
IL B
- I
2 I
promoter I
activity O
in O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
transformed O
B O
cell O
clones O
which O
are O
capable O
of O
secreting O
IL B
- I
2 I
at O
a O
low O
level O
after O
stimulation O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
the O
Ca2 O
+ O
ionophore O
ionomycin O
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

In O
seven O
EBV O
- O
B O
cell O
clones O
or O
lines O
differing O
in O
their O
capacity O
to O
secrete O
IL B
- I
2 I
, O
the O
activity O
of O
the O
IL B
- I
2 I
promoter I
correlated O
well O
with O
the O
status O
of O
IL B
- I
2 I
secretion O
. O

Latent B
membrane I
protein I
- I
1 I
induces O
cyclin B
D2 I
expression O
, O
pRb B
hyperphosphorylation O
, O
and O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
EBV O
- O
positive O
B O
cells O
. O

Here O
, O
we O
show O
that O
the O
presence O
of O
either O
wild O
- O
type O
EBV O
or O
its O
transforming B
latent I
membrane I
protein I
- I
1 I
( O
LMP B
- I
1 I
) O
results O
in O
the O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
human O
B O
cells O
. O

We O
have O
identified O
an O
in O
vivo O
footprint O
over O
the O
PuF B
site I
on O
the O
translocated O
c B
- I
myc I
allele I
in O
Burkitt O
' O
s O
lymphoma O
cells O
. O

These O
results O
indicate O
that O
the O
5 B
' I
- I
UTR I
of O
the O
gamma B
- I
gene I
contains O
sequences O
that O
may O
be O
important O
for O
its O
transcriptional O
and O
developmental O
regulation O
. O

However O
, O
this O
deletion O
mutation O
prevented O
the O
induced O
phosphorylation O
, O
degradative O
loss O
, O
and O
functional O
release O
of O
I B
kappa I
B I
alpha I
from O
NF B
- I
kappa I
B I
in O
Tax O
- O
expressing O
cells O
. O

However O
, O
this O
deletion O
mutation O
prevented O
the O
induced O
phosphorylation O
, O
degradative O
loss O
, O
and O
functional O
release O
of O
I B
kappa I
B I
alpha I
from O
NF B
- I
kappa I
B I
in O
Tax O
- O
expressing O
cells O
. O

Alanine O
substitutions O
introduced O
at O
two O
serine O
residues O
positioned O
within O
this O
N B
- I
terminal I
regulatory I
region I
of O
I B
kappa I
B I
alpha I
also O
yielded O
constitutive O
repressors O
that O
escaped O
from O
Tax B
- O
induced O
turnover O
and O
that O
potently O
inhibited O
immune O
activation O
pathways O
for O
NF B
- I
kappa I
B I
induction O
, O
including O
those O
initiated O
from O
antigen B
and I
cytokine I
receptors I
. O

Alanine O
substitutions O
introduced O
at O
two O
serine O
residues O
positioned O
within O
this O
N B
- I
terminal I
regulatory I
region I
of O
I B
kappa I
B I
alpha I
also O
yielded O
constitutive O
repressors O
that O
escaped O
from O
Tax B
- O
induced O
turnover O
and O
that O
potently O
inhibited O
immune O
activation O
pathways O
for O
NF B
- I
kappa I
B I
induction O
, O
including O
those O
initiated O
from O
antigen B
and I
cytokine I
receptors I
. O

Alanine O
substitutions O
introduced O
at O
two O
serine O
residues O
positioned O
within O
this O
N B
- I
terminal I
regulatory I
region I
of O
I B
kappa I
B I
alpha I
also O
yielded O
constitutive O
repressors O
that O
escaped O
from O
Tax B
- O
induced O
turnover O
and O
that O
potently O
inhibited O
immune O
activation O
pathways O
for O
NF B
- I
kappa I
B I
induction O
, O
including O
those O
initiated O
from O
antigen B
and I
cytokine I
receptors I
. O

Together O
, O
these O
in O
vivo O
studies O
define O
a O
critical O
signal O
response O
domain O
in O
I B
kappa I
B I
alpha I
that O
coordinately O
controls O
the O
biologic O
activities O
of O
I B
kappa I
B I
alpha I
and O
NF B
- I
kappa I
B I
in O
response O
to O
viral O
and O
immune O
stimuli O
. O

Together O
, O
these O
in O
vivo O
studies O
define O
a O
critical O
signal O
response O
domain O
in O
I B
kappa I
B I
alpha I
that O
coordinately O
controls O
the O
biologic O
activities O
of O
I B
kappa I
B I
alpha I
and O
NF B
- I
kappa I
B I
in O
response O
to O
viral O
and O
immune O
stimuli O
. O

Together O
, O
these O
in O
vivo O
studies O
define O
a O
critical O
signal O
response O
domain O
in O
I B
kappa I
B I
alpha I
that O
coordinately O
controls O
the O
biologic O
activities O
of O
I B
kappa I
B I
alpha I
and O
NF B
- I
kappa I
B I
in O
response O
to O
viral O
and O
immune O
stimuli O
. O

These O
included O
vimentin B
, O
correlating O
to O
cell O
shape O
changes O
, O
cytokeratins B
8 I
and I
18 I
, O
associated O
with O
differentiated O
cell O
types O
of O
prostate O
epithelia O
, O
and O
neuron B
- I
specific I
enolase I
and O
serotonin O
, O
associated O
with O
neuroendocrine O
cells O
. O

These O
included O
vimentin B
, O
correlating O
to O
cell O
shape O
changes O
, O
cytokeratins B
8 I
and I
18 I
, O
associated O
with O
differentiated O
cell O
types O
of O
prostate O
epithelia O
, O
and O
neuron B
- I
specific I
enolase I
and O
serotonin O
, O
associated O
with O
neuroendocrine O
cells O
. O

Human O
peripheral O
blood O
monocytes O
responded O
to O
stimulation O
of O
platelet B
- I
activating I
factor I
( O
PAF B
) O
with O
up O
- O
regulation O
of O
the O
transcript O
for O
heparin B
- I
binding I
epidermal I
growth I
factor I
- I
like I
growth I
factor I
( O
HB B
- I
EGF I
) O
, O
a O
potent B
mitogen I
for O
vascular O
smooth O
muscle O
cells O
. O

These O
functions O
of O
PAF B
appeared O
to O
be O
mediated O
through O
the O
cell B
surface I
PAF I
receptors I
, O
as O
two O
PAF B
receptor O
antagonists O
, O
WEB O
2086 O
and O
L O
- O
659 O
, O
989 O
, O
blocked O
both O
the O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF B
. O

These O
functions O
of O
PAF B
appeared O
to O
be O
mediated O
through O
the O
cell B
surface I
PAF I
receptors I
, O
as O
two O
PAF B
receptor O
antagonists O
, O
WEB O
2086 O
and O
L O
- O
659 O
, O
989 O
, O
blocked O
both O
the O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF B
. O

The O
antagonists O
, O
however O
, O
had O
no O
effect O
on O
phorbol O
ester O
- O
induced O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
. O

The O
DQB B
X2 I
- I
box I
was O
able O
to O
restore O
expression O
to O
the O
silent B
DRA I
reporter I
construct I
. O

The O
DQB B
X2 I
- I
box I
was O
able O
to O
restore O
expression O
to O
the O
silent B
DRA I
reporter I
construct I
. O

Moreover O
, O
replacement O
of O
the O
DQB B
X2 I
- I
box I
with O
the O
DRA B
X2 I
- I
box I
markedly O
diminished O
the O
activity O
of O
the O
DQB B
promoter I
in O
the O
mutant O
cell O
. O

Moreover O
, O
replacement O
of O
the O
DQB B
X2 I
- I
box I
with O
the O
DRA B
X2 I
- I
box I
markedly O
diminished O
the O
activity O
of O
the O
DQB B
promoter I
in O
the O
mutant O
cell O
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

Expression O
of O
erythroid B
- I
specific I
genes I
in O
acute O
megakaryoblastic O
leukaemia O
and O
transient O
myeloproliferative O
disorder O
in O
Down O
' O
s O
syndrome O
. O

Erythroid B
- I
specific I
mRNAs I
encoding O
gamma B
- I
globin I
and O
erythroid B
delta I
- I
aminolevulinate I
synthase I
were O
found O
to O
be O
expressed O
in O
blasts O
from O
most O
of O
these O
cases O
, O
indicating O
that O
majorities O
of O
the O
blasts O
in O
M7 O
and O
TMD O
cases O
have O
erythroid O
and O
megakaryocytic O
phenotypes O
. O

In O
vitro O
translated O
Spi B
- I
B I
protein I
can O
bind O
to O
PU B
. I
1 I
binding I
sites I
in O
myeloid B
promoters I
and O
transactivate O
these O
promoters B
in O
nonmyeloid O
cells O
. O

When O
transfected O
into O
K562 O
cells O
, O
which O
express O
zeta B
- I
globin I
, O
comparable O
amounts O
of O
activity O
were O
obtained O
from O
the O
- B
557 I
and I
- I
417 I
zeta I
- I
luciferase I
constructs I
and O
the O
alpha B
- I
luciferase I
constructs I
when O
no O
enhancers B
or O
the O
alpha B
- I
globin I
locus I
enhancers I
were O
used O
. O

From O
supershift O
experiments O
it O
was O
concluded O
that O
one O
DNA B
- I
binding I
complex I
contained O
Stat1 B
alpha I
, O
probably O
as O
a O
homodimer O
. O

It O
was O
found O
that O
the O
propagation O
of O
the O
Tat B
mutants I
containing O
wild B
- I
type I
LTRs I
was O
less O
efficient O
than O
that O
of O
the O
LTR B
- I
modified I
Tat I
mutants I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

We O
conclude O
that O
distinct O
sets O
of O
transcription B
factors I
are O
involved O
in O
the O
two O
modes O
of O
HLA B
- I
DRA I
expression O
, O
and O
that O
HMG B
I I
/ I
Y I
may O
be O
important O
for O
B O
cell O
- O
specific O
expression O
, O
and O
is O
essential O
for O
IFN B
- I
gamma I
induction O
. O

A O
previously O
unrecognized O
element O
, O
located O
downstream O
of O
the O
start B
site I
of I
transcription I
in O
the O
first O
exon B
of O
the O
DR B
alpha I
gene I
, O
has O
been O
defined O
that O
enhances O
promoter O
activity O
up O
to O
eightfold O
in O
a O
position O
- O
dependent O
manner O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

HIV B
- I
1 I
Tat I
potentiates O
TNF B
- O
induced O
NF B
- I
kappa I
B I
activation O
and O
cytotoxicity O
by O
altering O
the O
cellular O
redox O
state O
. O

HIV B
- I
1 I
Tat I
potentiates O
TNF B
- O
induced O
NF B
- I
kappa I
B I
activation O
and O
cytotoxicity O
by O
altering O
the O
cellular O
redox O
state O
. O

In O
HeLa O
cells O
stably O
transfected O
with O
the O
HIV B
- I
1 I
tat I
gene I
( O
HeLa O
- O
tat O
cells O
) O
, O
expression O
of O
the O
Tat B
protein I
enhanced O
both O
TNF B
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
and O
TNF B
- O
mediated O
cytotoxicity O
. O

EBNA B
- I
2 I
is O
known O
to O
interact O
with O
the O
cellular B
DNA I
- I
binding I
protein I
J B
kappa I
and O
is O
recruited O
to O
promoters B
containing O
the O
GTGGGAA O
J B
kappa I
recognition I
sequence I
. O

Thus O
, O
although O
the O
kappa B
3 I
element I
has O
little O
sequence O
similarity O
to O
other O
NFATp B
- I
binding I
sites I
, O
it O
appears O
to O
function O
as O
a O
cyclosporin B
- I
sensitive I
promoter I
element I
in O
T O
cells O
by O
virtue O
of O
its O
ability O
to O
bind O
NFATp B
. O

Various O
reports O
have O
delineated O
the O
cis B
- I
acting I
elements I
of O
the O
LMP B
promoter I
through O
which O
EBNA B
- I
2 I
mediates O
trans O
- O
activation O
. O

We O
have O
previously O
shown O
that O
treatment O
of O
Jurkat O
T O
cells O
with O
phytohemaglutinin B
( O
PHA B
) O
and O
the O
phorbol O
ester O
, O
PMA O
, O
activated O
transcription O
initiation O
from O
the O
IL B
- I
3 I
gene I
. O

When O
restimulated O
, O
however O
, O
anergic O
T O
cells O
fail O
to O
up O
- O
regulate O
transcription O
of O
the O
IL B
- I
2 I
gene I
and O
in O
consequence O
do O
not O
produce O
IL B
- I
2 I
. O

Expression O
of O
the O
kappa O
immunoglobulin O
light O
chain O
gene O
requires O
developmental O
- O
and O
tissue O
- O
specific O
regulation O
by O
trans B
- I
acting I
factors I
which O
interact O
with O
two O
distinct O
enhancer B
elements I
. O

This O
parallels O
the O
increased O
I B
kappa I
B I
alpha I
synthesis O
secondary O
to O
increased O
I B
kappa I
B I
alpha I
gene O
transcription O
, O
i O
. O
e O
. O
, O
increased O
RNA O
and O
transcriptional O
activity O
of O
its O
promoter O
- O
enhancer O
. O

This O
parallels O
the O
increased O
I B
kappa I
B I
alpha I
synthesis O
secondary O
to O
increased O
I B
kappa I
B I
alpha I
gene O
transcription O
, O
i O
. O
e O
. O
, O
increased O
RNA O
and O
transcriptional O
activity O
of O
its O
promoter O
- O
enhancer O
. O

Transcriptional O
activity O
of O
p105 B
is O
also O
increased O
in O
infected O
cells O
and O
is O
also O
mediated O
by O
NF B
- I
kappa I
B I
through O
a O
specific O
kappa B
B I
motif I
. O

In O
this O
study O
, O
we O
show O
that O
an O
activation B
- I
deficient I
glucocorticoid I
receptor I
mutant I
is O
as O
effective O
as O
the O
wild B
- I
type I
receptor I
in O
repression O
of O
AP B
- I
1 I
activity O
, O
inhibition O
of O
interleukin B
- I
2 I
production O
, O
inhibition O
of O
c B
- I
myc I
expression O
and O
induction O
of O
apoptosis O
. O

HIV O
type O
1 O
protease B
activation O
of O
NF B
- I
kappa I
B I
within O
T O
lymphoid O
cells O
. O

It O
has O
been O
reported O
that O
HIV B
- I
1 I
protease I
may O
cleave O
the O
NF B
- I
kappa I
B I
precursor O
to O
its O
active O
form O
in O
vitro O
. O

It O
has O
been O
reported O
that O
HIV B
- I
1 I
protease I
may O
cleave O
the O
NF B
- I
kappa I
B I
precursor O
to O
its O
active O
form O
in O
vitro O
. O

Insertion O
of O
this O
chimeric B
promoter I
( O
ISG15 B
LTR I
) O
upstream O
of O
the O
human B
IFNA2 I
gene I
directed O
high O
levels O
of O
IFN B
synthesis O
in O
Tat O
- O
expressing O
cells O
, O
while O
this O
promoter O
was O
not O
responsive O
to O
tumor B
necrosis I
factor I
alpha I
- O
mediated O
activation O
. O

Selected O
transfected O
clones O
produced O
low O
levels O
of O
IFN B
A I
( O
IFNA B
) O
constitutively O
, O
and O
their O
abilities O
to O
express O
interleukin B
- I
2 I
and O
interleukin B
- I
2 I
receptor I
upon O
stimulation O
with O
phytohemagglutinin B
and O
phorbol O
myristate O
acetate O
were O
retained O
. O

Taken O
together O
, O
we O
report O
that O
IL B
- I
2 I
induces O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
and O
an O
as O
yet O
undefined O
84 B
- I
kDa I
protein I
in O
antigen O
- O
specific O
human O
T O
cell O
lines O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B
activation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
involves O
phosphorylation O
and O
degradation O
of O
I B
kappa I
B I
alpha I
and O
RelA B
( O
p65 B
) O
- O
mediated O
induction O
of O
the O
c B
- I
rel I
gene I
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B
activation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
involves O
phosphorylation O
and O
degradation O
of O
I B
kappa I
B I
alpha I
and O
RelA B
( O
p65 B
) O
- O
mediated O
induction O
of O
the O
c B
- I
rel I
gene I
. O

In O
contrast O
to O
prior O
in O
vitro O
studies O
, O
at O
least O
a O
fraction O
of O
the O
phosphorylated O
form O
of O
I B
kappa I
B I
alpha I
remains O
physically O
associated O
with O
the O
NF B
- I
kappa I
B I
complex I
in O
vivo O
but O
is O
subject O
to O
rapid O
degradation O
, O
thereby O
promoting O
the O
nuclear O
translocation O
of O
the O
active O
NF B
- I
kappa I
B I
complex I
. O

Therefore O
we O
investigated O
the O
modifications O
imposed O
on O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
components I
following O
stimulation O
and O
show O
that O
the O
final O
step O
of O
NF B
- I
kappa I
B I
induction O
in O
vivo O
involves O
phosphorylation O
of O
several O
members O
of O
the O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
protein I
families I
. O

GIG10 B
is O
a O
novel O
sequence O
and O
GIG18 B
is O
the O
mouse O
homologue O
of O
a O
human B
expressed I
sequence I
tag I
isolated O
from O
activated O
B O
lymphocytes O
. O

Consistent O
with O
the O
activity O
of O
B95 B
- I
8 I
, O
EBNA B
- I
2 I
transcripts I
were O
identified O
within O
infected O
thymocyte O
populations O
. O

These O
results O
indicate O
that O
the O
regulation O
of O
NF B
- I
kappa I
B I
activation O
during O
T O
cell O
activation O
by O
TcR B
/ I
CD3 I
signals O
is O
biphasic O
: O
TcR B
/ I
CD3 I
triggers O
its O
immediate O
translocation O
, O
which O
is O
transient O
if O
no O
TNF B
- I
alpha I
is O
present O
. O

The O
cis B
- I
acting I
region I
, O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
( O
positions B
- I
95 I
and O
- B
73 I
) O
, O
within O
the O
murine B
GM I
- I
CSF I
gene I
promoter I
is O
required O
for O
maximal O
induction O
by O
stimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
in O
T O
cells O
. O

A O
factor O
that O
regulates O
the O
class B
II I
major I
histocompatibility I
complex I
gene I
DPA B
is O
a O
member O
of O
a O
subfamily O
of O
zinc B
finger I
proteins I
that O
includes O
a O
Drosophila B
developmental I
control I
protein I
. O

It O
encodes O
a O
protein O
predicted O
to O
contain O
688 O
amino O
acid O
residues O
, O
including O
11 O
zinc B
finger I
motifs I
of O
the O
C2H2 B
type I
in O
the O
C B
- I
terminal I
region I
, O
that O
are O
Kruppel O
- O
like O
in O
the O
conservation O
of O
the O
H B
/ I
C I
link I
sequence I
connecting O
them O
. O

This O
protein O
appears O
to O
require O
both O
the O
S B
and I
J I
elements I
, O
which O
are O
separated O
by O
10 O
bp O
for O
optimal O
binding O
. O

These O
initial O
pathways O
culminate O
in O
a O
common O
pathway O
through O
which O
all O
of O
the O
stimulating O
agents O
ultimately O
signal O
NF B
- I
kappa I
B I
activation O
. O

An O
NF B
- I
kappa I
B I
binding O
site O
is O
an O
essential O
component O
of O
the O
element O
but O
alone O
is O
not O
sufficient O
to O
account O
for O
the O
activity O
or O
the O
specificity O
of O
the O
element O
. O

A O
similar O
increase O
in O
IL B
- I
2R I
alpha I
by O
TG O
was O
also O
observed O
in O
human O
peripheral O
T O
cells O
. O

However O
, O
TG O
and O
PMA O
exhibited O
a O
synergistic O
action O
on O
IL B
- I
2R I
alpha I
expression O
, O
suggesting O
that O
TG O
and O
PMA O
induce O
IL B
- I
2R I
alpha I
through O
distinct O
pathways O
. O

However O
, O
TG O
and O
PMA O
exhibited O
a O
synergistic O
action O
on O
IL B
- I
2R I
alpha I
expression O
, O
suggesting O
that O
TG O
and O
PMA O
induce O
IL B
- I
2R I
alpha I
through O
distinct O
pathways O
. O

Pyrrolidine O
dithiocarbamate O
, O
a O
potent O
inhibitor O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
activation O
, O
prevents O
apoptosis O
in O
human O
promyelocytic O
leukemia O
HL O
- O
60 O
cells O
and O
thymocytes O
. O

Pyrrolidine O
dithiocarbamate O
, O
a O
potent O
inhibitor O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
activation O
, O
prevents O
apoptosis O
in O
human O
promyelocytic O
leukemia O
HL O
- O
60 O
cells O
and O
thymocytes O
. O

It O
is O
surprising O
that O
the O
faster B
- I
migrating I
complex I
was O
composed O
also O
of O
p50 B
and O
p65 B
. O

OBF B
- I
1 I
, O
a O
novel B
B I
cell I
- I
specific I
coactivator I
that O
stimulates O
immunoglobulin B
promoter I
activity O
through O
association O
with O
octamer B
- I
binding I
proteins I
. O

The O
OBF B
- I
1 I
mRNA I
is O
expressed O
in O
a O
highly O
cell O
- O
specific O
manner O
, O
being O
most O
abundant O
in O
B O
cells O
and O
essentially O
absent O
in O
most O
of O
the O
other O
cells O
or O
tissues O
tested O
. O

The O
T B
cell I
surface I
molecule I
CD28 B
binds O
to O
ligands O
on O
accessory O
cells O
and O
APCs O
, O
playing O
an O
important O
costimulatory O
role O
in O
the O
response O
of O
T O
cells O
to O
Ags B
. O

Enhanced O
responsiveness O
to O
nuclear B
factor I
kappa I
B I
contributes O
to O
the O
unique O
phenotype O
of O
simian O
immunodeficiency O
virus O
variant O
SIVsmmPBj14 O
. O

Mutagenesis O
studies O
, O
and O
the O
use O
of O
a O
reporter O
construct O
containing O
an O
enhancerless O
promoter O
, O
indicate O
that O
these O
transcriptional O
effects O
are O
due O
principally O
to O
the O
22 B
- I
bp I
sequence I
duplication I
and O
the O
NF B
kappa I
B I
site I
contained O
within O
it O
. O

In O
such O
cells O
, O
DNA O
binding O
activity O
of O
NF B
- I
kappa I
B I
can O
be O
detected O
without O
intentional O
stimulation O
. O

Using O
LPS O
- O
free O
and O
serum O
- O
free O
conditions O
, O
constitutive O
NF B
- I
kappa I
B I
can O
be O
detected O
in O
different O
cell O
lines O
of O
the O
monocytic O
lineage O
( O
HL60 O
, O
U937 O
, O
THP O
- O
1 O
, O
Mono O
Mac O
1 O
and O
Mono O
Mac O
6 O
) O
, O
but O
not O
in O
Molt O
4 O
T O
cells O
or O
K562 O
stem O
cells O
. O

The O
constitutive O
NF B
- I
kappa I
B I
appears O
to O
be O
functionally O
active O
, O
since O
a O
low O
level O
of O
tumour B
necrosis I
factor I
( I
TNF I
) I
transcript I
is O
detectable O
in O
monocytes O
, O
and O
this O
level O
can O
be O
increased O
by O
blocking O
transcript O
degradation O
using O
cycloheximide O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
alpha I
) O
is O
particularly O
important O
in O
this O
process O
because O
of O
its O
ability O
to O
regulate O
other O
inflammatory O
mediators O
in O
an O
autocrine O
and O
paracrine O
fashion O
. O

We O
present O
data O
to O
show O
that O
the O
expression O
of O
TNF B
alpha I
is O
regulated O
by O
the O
transcription B
factor I
C B
/ I
EBP I
beta I
( O
NF B
- I
IL6 I
) O
. O

However O
, O
the O
role O
of O
CaM B
- I
K I
II I
remains O
unknown O
. O

We O
have O
used O
mutants O
of O
these O
kinases B
and O
phosphatases B
( O
gamma B
B I
* I
CaM I
- I
K I
and O
delta B
CaM I
- I
AI I
, O
respectively O
) O
to O
explore O
their O
relative O
role O
in O
cytokine B
gene I
transcription O
and O
their O
interactions O
with O
PKC B
- O
dependent O
signaling O
systems O
. O

When O
both O
mutants O
were O
used O
in O
combination O
, O
gamma B
B I
* I
CaM I
- I
K I
inhibited O
the O
induction O
of O
the O
IL B
- I
2 I
promoter I
by O
delta B
CaM I
- I
AI I
. O

When O
both O
mutants O
were O
used O
in O
combination O
, O
gamma B
B I
* I
CaM I
- I
K I
inhibited O
the O
induction O
of O
the O
IL B
- I
2 I
promoter I
by O
delta B
CaM I
- I
AI I
. O

Similar O
results O
were O
obtained O
when O
a O
construct O
containing O
the O
IL B
- I
4 I
promoter I
also O
was O
used O
. O

One O
of O
these O
, O
previously O
called O
B1 B
, O
is O
a O
97 B
- I
kDa I
protein I
which O
is O
secreted O
in O
large O
amounts O
and O
has O
been O
purified O
from O
protein O
- O
free O
, O
conditioned O
medium O
. O

The O
IL B
- I
1 I
- O
induced O
NF B
- I
kappa I
B I
DNA O
nuclear O
localization O
is O
transient O
and O
can O
be O
prolonged O
either O
by O
an O
antigen O
receptor O
- O
initiated O
signal O
or O
by O
inhibiting O
protein O
synthesis O
. O

A O
synthetic O
oligodeoxyribonucleo O
containing O
an O
SP1 B
- I
box I
( O
5 O
' O
- O
GGGCGG O
) O
could O
compete O
with O
factors O
binding O
to O
the O
12 B
- I
bp I
insert I
. O

Functional O
Myc B
- I
Max I
heterodimer I
is O
required O
for O
activation O
- O
induced O
apoptosis O
in O
T O
cell O
hybridomas O
. O

The O
proto B
- I
oncogene I
c I
- I
fos I
is O
an O
immediate B
- I
early I
gene I
, O
and O
one O
of O
the O
first O
genes O
transcribed O
after O
stimulation O
of O
most O
cells O
with O
a O
variety O
of O
ligands O
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream B
and I
downstream I
positive I
regulatory I
elements I
. O

These O
findings O
suggest O
a O
molecular O
mechanism O
of O
positive O
regulation O
of O
PAFR B
gene O
expression O
by O
PAF B
through O
NF B
- I
kappa I
B I
, O
possibly O
by O
a O
phosphorylation O
reaction O
involving O
protein B
kinase I
C I
by O
PAF B
. O

These O
inhibitors O
specifically O
prevented O
degradation O
of O
I B
kappa I
B I
alpha I
and O
nuclear O
translocation O
of O
c B
- I
Rel I
/ I
p65 I
heterodimers I
. O

In O
contrast O
, O
TPCK O
and O
TLCK O
did O
not O
block O
induction O
of O
an O
immediate B
- I
early I
gene I
encoding O
the O
transcription B
factor I
, O
Egr B
- I
1 I
. O

Studies O
of O
these O
females O
show O
that O
the O
XIST B
locus I
on O
their O
tiny B
ring I
X I
chromosomes I
is O
either O
not O
present O
or O
not O
expressed O
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa B
B I
- I
like I
sequence I
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa B
B I
- I
like I
sequence I
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

The O
activity O
of O
constructs O
containing O
5 B
' I
deletion I
mutants I
of O
the O
alpha B
4 I
gene I
promoter I
was O
compared O
in O
transfection O
assays O
into O
cell O
lines O
that O
express O
alpha B
4 I
and O
cell O
lines O
that O
do O
not O
. O

The O
activity O
of O
constructs O
containing O
5 B
' I
deletion I
mutants I
of O
the O
alpha B
4 I
gene I
promoter I
was O
compared O
in O
transfection O
assays O
into O
cell O
lines O
that O
express O
alpha B
4 I
and O
cell O
lines O
that O
do O
not O
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C B
- I
terminal I
end I
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

However O
, O
reagents O
such O
as O
nerve B
growth I
factor I
( O
NGF B
) O
and O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
, O
which O
induce O
phenotypical O
differentiation O
of O
the O
SH O
- O
SY5Y O
neuroblastoma O
cell O
line O
, O
activated O
NF B
- I
kappa I
B I
, O
but O
only O
in O
that O
particular O
cell O
line O
. O

We O
have O
cloned O
the O
gene O
for O
a O
new O
ets B
- I
related I
transcription I
factor I
, O
ERP B
( O
ets B
- I
related I
protein I
) O
, O
from O
the O
murine O
pre O
- O
B O
cell O
line O
BASC O
6C2 O
and O
from O
mouse O
lung O
tissue O
. O

Two O
cis B
- I
acting I
elements I
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
and O
CLE0 B
, O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
are O
required O
for O
maximal O
induction O
in O
Jurkat O
T O
cells O
by O
costimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
( O
A23187 O
) O
. O

Nonpituitary B
human I
prolactin I
gene I
transcription O
is O
independent O
of O
Pit B
- I
1 I
and O
differentially O
controlled O
in O
lymphocytes O
and O
in O
endometrial O
stroma O
. O

One O
of O
the O
nuclear B
factors I
( O
NFs B
) O
that O
regulates O
the O
response O
of O
the O
IL B
- I
5 I
promoter I
to O
cAMP O
and O
PMA O
has O
properties O
similar O
to O
NF B
for O
activated O
t O
cell O
. O

In O
vivo O
protein O
- O
DNA O
contacts O
are O
detectable O
at O
Ii B
kappa I
B I
- I
1 I
in O
cell O
lines O
in O
which O
this O
site O
is O
functional O
as O
either O
a O
positive B
or I
negative I
regulator I
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

In O
cells O
stimulated O
with O
anti B
- I
CD3 I
mAb I
, O
PGE2 B
inhibited O
cell O
proliferation O
and O
the O
production O
of O
all O
the O
cytokines B
examined O
. O

It O
seems O
therefore O
that O
PGE2 B
, O
by O
elevating O
cAMP O
levels O
, O
interferes O
with O
the O
activation O
pathway O
for O
NF B
- I
kappa I
B I
but O
not O
for O
NF B
- I
AT I
, O
AP B
- I
1 I
or O
CLE0 B
binding I
protein I
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

During O
treatment O
with O
Hm B
, O
K562 O
cells O
constitutively O
expressed O
c B
- I
myb I
mRNA I
, O
and O
50 O
% O
of O
them O
began O
to O
synthesize O
hemoglobin B
( O
Hb B
) O
. O

HRBC O
and O
LPS O
indeed O
stimulated O
the O
maternal O
immune O
system O
as O
revealed O
by O
specific O
anti B
- I
HRBC I
antibody I
production O
and O
enhanced O
IL O
- O
1 O
beta O
mRNA O
expression O
in O
splenocytes O
, O
respectively O
. O

The O
RAR B
alpha I
rearranged O
band O
in O
the O
Southern O
blot O
analysis O
and O
a O
chimaeric B
product I
of O
PML B
- I
RAR I
alpha I
by O
polymerase O
chain O
reaction O
were O
strongly O
visible O
before O
ATRA O
treatment O
, O
but O
at O
the O
time O
of O
maximal O
basophilia O
both O
of O
them O
were O
markedly O
diminished O
. O

Activation O
of O
the O
interleukin B
6 I
gene I
by O
Mycobacterium O
tuberculosis O
or O
lipopolysaccharide O
is O
mediated O
by O
nuclear B
factors I
NF I
- I
IL6 I
and O
NF B
- I
kappa I
B I
[ O
published O
erratum O
appears O
in O
Proc O
Natl O
Acad O
Sci O
U O
S O
A O
1995 O
Apr O
11 O
; O
92 O
( O
8 O
) O
: O
3632 O
] O

LAM B
and O
LPS O
were O
potent O
inducers O
of O
IL B
- I
6 I
gene I
expression O
in O
peripheral O
blood O
monocytes O
. O

The O
glutathione O
- O
depleting O
agent O
diethyl O
maleate O
( O
DEM O
) O
prevented O
the O
development O
of O
differentiated O
features O
in O
response O
to O
phorbol O
esters O
, O
including O
adherence O
of O
the O
cells O
to O
plastic O
surfaces O
and O
repression O
of O
the O
myeloperoxidase B
and I
CD34 I
genes I
. O

Human O
immunodeficiency O
virus O
type O
1 O
Nef O
protein O
down O
- O
regulates O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
in O
human O
T O
cells O
in O
vitro O
after O
T O
- O
cell O
receptor O
stimulation O
. O

When O
cells O
were O
preincubated O
with O
dihydrolipoic O
acid O
( O
0 O
. O
2 O
mM O
) O
the O
expression O
of O
c B
- I
fos I
mRNA I
was O
suppressed O
at O
30 O
min O
after O
stimulation O
of O
TPA O
( O
0 O
. O
5 O
microM O
) O
whereas O
in O
the O
case O
of O
preincubation O
of O
alpha O
- O
lipoic O
acid O
( O
0 O
. O
2 O
microM O
) O
, O
the O
expression O
was O
enhanced O
at O
30 O
min O
. O

Another O
limitation O
is O
that O
antioxidant O
concentrations O
high O
enough O
to O
block O
NK B
- I
kappa I
B I
activation O
were O
shown O
to O
have O
a O
suppressive O
effect O
on O
immune O
functions O
in O
vitro O
, O
because O
NAC O
and O
BHA O
blocked O
IL O
- O
2 O
- O
induced O
PBMC O
proliferation O
. O

Treatment O
of O
human O
resting O
T O
cells O
with O
phorbol O
esters O
strongly O
induced O
the O
expression O
of O
IL B
- I
2R I
alpha I
and O
the O
activation O
of O
NF B
. I
kappa I
B I
. O

Treatment O
of O
human O
resting O
T O
cells O
with O
phorbol O
esters O
strongly O
induced O
the O
expression O
of O
IL B
- I
2R I
alpha I
and O
the O
activation O
of O
NF B
. I
kappa I
B I
. O

Retinoid B
- I
like I
receptors I
play O
a O
central O
role O
in O
hormonal O
responses O
by O
forming O
heterodimers B
with O
other O
nuclear B
hormone I
receptors I
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

The O
expression O
of O
the O
M B
- I
CSF I
gene I
, O
that O
has O
been O
recently O
reassigned O
to O
the O
short B
arm I
of I
chromosome I
1 I
( O
lp B
) O
, O
was O
also O
investigated O
. O

Recent O
reports O
demonstrated O
that O
ionizing O
radiation O
in O
the O
dose O
range O
of O
2 O
- O
50 O
Gy O
results O
in O
expression O
of O
NF B
- I
kappa I
B I
in O
human O
KG O
- O
1 O
myeloid O
leukemia O
cells O
and O
human O
B O
- O
lymphocyte O
precursor O
cells O
; O
the O
precise O
mechanism O
involved O
and O
the O
significance O
are O
not O
yet O
known O
. O

The O
present O
report O
demonstrates O
that O
even O
lower O
doses O
of O
ionizing O
radiation O
, O
0 O
. O
25 O
- O
2 O
. O
0 O
Gy O
, O
are O
capable O
of O
inducing O
expression O
of O
NF B
- I
kappa I
B I
in O
EBV O
- O
transformed O
244B O
human O
lymphoblastoid O
cells O
. O

The O
two O
human B
GATA3 I
zinc I
fingers I
are O
encoded O
by O
two O
separate O
exons B
highly O
conserved O
with O
those O
of O
GATA1 B
, O
but O
no O
other O
structural O
homologies O
between O
these O
two O
genes O
can O
be O
found O
. O

Thus O
antioxidants O
vary O
widely O
in O
potency O
as O
inhibitors O
of O
the O
activation O
of O
transcription B
factors I
and O
of O
the O
transcription O
of O
genes B
for O
pro B
- I
inflammatory I
cytokines I
. O

Examination O
of O
the O
primary O
amino O
acid O
sequence O
of O
this O
protein O
indicates O
that O
it O
is O
a O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
family I
of O
DNA B
binding I
proteins I
, O
hereby O
designated O
IL B
- I
4 I
Stat I
. O

Such O
observations O
indicate O
that O
IL B
- I
4 I
Stat I
has O
the O
same O
functional B
domain I
for O
both O
receptor O
coupling O
and O
dimerization O
. O

The O
mechanisms O
involved O
in O
the O
inhibition O
of O
growth O
of O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
by O
anti B
- I
MHC I
class I
II I
antibodies I
( O
Ab B
) O
were O
compared O
with O
those O
in O
anti B
- I
IgM I
Ab I
- O
induced O
B104 O
growth O
inhibition O
. O

Stimulation O
of O
the O
CD28 B
cell I
surface I
molecule I
delivers O
costimulatory O
signals O
essential O
for O
lymphokine B
production O
in O
activated O
T O
cells O
via O
a O
conserved B
sequence I
element I
found O
in O
the O
promoter B
of O
several O
lymphokine B
genes I
. O

Wortmannin O
, O
an O
inhibitor O
of O
receptor O
- O
coupled O
PLD B
activation O
, O
blocked O
the O
anti B
- I
CD3 I
- O
induced O
increases O
in O
both O
PLD B
activity O
and O
AP B
- I
1 I
enhancer I
activity O
. O

We O
found O
a O
good O
correlation O
in O
the O
transfected O
cells O
between O
PLD B
activation O
and O
induction O
of O
AP B
- I
1 I
enhancer I
activity O
under O
different O
experimental O
conditions O
. O

We O
therefore O
reexamined O
this O
issue O
by O
using O
two O
different O
experimental O
approaches O
that O
allowed O
LMP1 B
- O
induced O
effects O
to O
be O
monitored O
immediately O
following O
expression O
of O
the O
viral O
protein O
and O
in O
the O
absence O
of O
selective O
pressures O
; O
activation O
of O
the O
NF B
- I
kappa I
B I
transcription B
factor I
and O
upregulation O
of O
the O
cell B
adhesion I
molecule I
ICAM B
- I
1 I
were O
used O
as O
early O
indices O
of O
LMP1 B
function O
. O

In O
the O
same O
experiments O
, O
all O
three O
non O
- O
B O
- O
cell O
lines O
showed O
NF B
- I
kappa I
B I
activation O
and O
ICAM B
- I
1 I
upregulation O
but O
never O
any O
effect O
upon O
Bcl B
- I
2 I
. O

To O
tie O
these O
events O
to O
gene O
activation O
, O
we O
measured O
NF B
- I
kappa I
B I
and O
NF B
- I
AT I
activity O
in O
the O
nucleus O
after O
anti B
- I
CD3 I
stimulation O
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Site B
D I
( O
nt B
4816 I
to I
4851 I
) O
specifically O
bound O
a O
ubiquitously B
expressed I
factor I
. O

NF B
- I
kappa I
B I
is O
a O
rapidly O
inducible O
transcriptional B
activator I
that O
responds O
to O
a O
variety O
of O
signals O
and O
influences O
the O
expression O
of O
many O
genes O
involved O
in O
the O
immune O
response O
. O

Sequence O
analyses O
show O
that O
this O
protein O
has O
significant O
homology O
with O
the O
human B
cytomegalovirus I
UL44 I
gene I
coding O
for O
the O
ICP36 B
family I
of O
early B
- I
late I
- I
class I
phosphoprotein I
. O

LPS O
- O
stimulated O
translocation O
of O
NF B
- I
kappa I
B I
in O
CHO O
/ O
CD14 O
cells O
resembled O
the O
same O
response O
in O
the O
murine O
macrophage O
- O
like O
cell O
line O
RAW O
264 O
. O
7 O
. O

The O
stimulatory O
effect O
of O
gp160 O
on O
NF B
- I
kappa I
B I
activation O
is O
protein O
synthesis O
independent O
, O
is O
dependent O
upon O
protein O
tyrosine O
phosphorylation O
, O
and O
abrogated O
by O
inhibitors O
of O
protein B
kinase I
C I
. O

The O
CD14 B
LPS O
receptor O
is O
, O
however O
, O
up O
- O
regulated O
( O
not O
down O
- O
regulated O
) O
in O
tolerant O
cells O
, O
and O
LPS O
can O
, O
in O
fact O
, O
still O
lead O
to O
activation O
of O
tolerant O
cells O
as O
evidenced O
by O
mobilization O
of O
the O
transcription B
factor I
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

The O
CD14 B
LPS O
receptor O
is O
, O
however O
, O
up O
- O
regulated O
( O
not O
down O
- O
regulated O
) O
in O
tolerant O
cells O
, O
and O
LPS O
can O
, O
in O
fact O
, O
still O
lead O
to O
activation O
of O
tolerant O
cells O
as O
evidenced O
by O
mobilization O
of O
the O
transcription B
factor I
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

Resolution O
of O
the O
NF B
- I
kappa I
B I
complex I
in O
gel O
shift O
analysis O
shows O
that O
the O
binding B
protein I
, O
mobilized O
in O
naive O
Mono O
Mac O
6 O
cells O
, O
consists O
mainly O
of O
p50 B
- I
p65 I
heterodimers I
, O
while O
in O
tolerant O
cells O
, O
the O
p50 B
homodimer I
is O
predominant O
. O

The O
response O
of O
mammalian O
cells O
to O
stress O
is O
controlled O
by O
transcriptional B
regulatory I
proteins I
such O
as O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
to O
induce O
a O
wide O
variety O
of O
early B
response I
genes I
. O

The O
response O
of O
mammalian O
cells O
to O
stress O
is O
controlled O
by O
transcriptional B
regulatory I
proteins I
such O
as O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
to O
induce O
a O
wide O
variety O
of O
early B
response I
genes I
. O

In O
comparison O
to O
other O
activators O
of O
NF B
- I
kappa I
B I
such O
as O
phorbol O
myristate O
acetate O
or O
tumor B
necrosis I
factor I
, O
we O
did O
not O
detect O
changes O
in O
the O
tyrosine O
phosphorylation O
status O
of O
I B
kappa I
B I
alpha I
following O
treatment O
with O
either O
of O
these O
agents O
. O

In O
comparison O
to O
other O
activators O
of O
NF B
- I
kappa I
B I
such O
as O
phorbol O
myristate O
acetate O
or O
tumor B
necrosis I
factor I
, O
we O
did O
not O
detect O
changes O
in O
the O
tyrosine O
phosphorylation O
status O
of O
I B
kappa I
B I
alpha I
following O
treatment O
with O
either O
of O
these O
agents O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

Phorbol O
myristate O
acetate O
induced O
Egr B
- I
1 I
mRNA I
expression O
but O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
did O
not O
. O

Acetylsalicylic O
acid O
and O
sodium O
salicylate O
inhibit O
LPS O
- O
induced O
NF B
- I
kappa I
B I
/ I
c I
- I
Rel I
nuclear O
translocation O
, O
and O
synthesis O
of O
tissue B
factor I
( O
TF B
) O
and O
tumor B
necrosis I
factor I
alfa I
( O
TNF B
- I
alpha I
) O
in O
human O
monocytes O
. O

Interferon O
augments O
PML B
and O
PML B
/ I
RAR I
alpha I
expression O
in O
normal O
myeloid O
and O
acute O
promyelocytic O
cells O
and O
cooperates O
with O
all O
- O
trans O
retinoic O
acid O
to O
induce O
maturation O
of O
a O
retinoid O
- O
resistant O
promyelocytic O
cell O
line O
. O

The O
transmembrane O
domains O
are O
well O
conserved O
, O
but O
there O
is O
striking O
sequence O
divergence O
of O
the O
carboxy B
- I
terminal I
cytoplasmic I
domain I
essential O
for O
B O
- O
cell O
immortalization O
and O
interaction O
with O
the O
tumor B
necrosis I
factor I
receptor I
signaling O
pathway O
. O

Octamer O
independent O
activation O
of O
transcription O
from O
the O
kappa B
immunoglobulin I
germline I
promoter I
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

While O
Jurkat O
cells O
co O
- O
expressed O
two O
discrete O
cell B
- I
surface I
isoforms I
of O
CD43 B
, O
recognized O
by O
mAb B
J393 I
and O
mAb B
G10 I
- I
2 I
, O
respectively O
, O
only O
J393 B
/ I
CD43 I
signaled O
apoptosis O
. O

While O
Jurkat O
cells O
co O
- O
expressed O
two O
discrete O
cell B
- I
surface I
isoforms I
of O
CD43 B
, O
recognized O
by O
mAb B
J393 I
and O
mAb B
G10 I
- I
2 I
, O
respectively O
, O
only O
J393 B
/ I
CD43 I
signaled O
apoptosis O
. O

To O
understand O
the O
mechanism O
by O
which O
PRL B
regulates O
the O
biphasic O
expression O
of O
IRF B
- I
1 I
, O
we O
cloned O
the O
rat B
IRF I
- I
1 I
gene I
and O
functionally O
characterized O
the O
IRF B
- I
1 I
promoter I
. O

Hence O
, O
the O
PRL B
- O
induced O
biphasic O
expression O
of O
the O
IRF B
- I
1 I
gene I
appears O
to O
be O
controlled O
by O
separate O
PRL B
- I
responsive I
elements I
: O
elements O
in O
the O
first O
0 O
. O
2 O
kb O
of O
the O
IRF B
- I
1 I
promoter I
region I
act O
during O
early O
activation O
, O
and O
elements O
between O
0 O
. O
2 O
and O
1 O
. O
7 O
kb O
act O
in O
concert O
with O
the O
proximal O
0 O
. O
2 O
- O
kb O
region O
during O
S O
phase O
progression O
. O

Hence O
, O
the O
PRL B
- O
induced O
biphasic O
expression O
of O
the O
IRF B
- I
1 I
gene I
appears O
to O
be O
controlled O
by O
separate O
PRL B
- I
responsive I
elements I
: O
elements O
in O
the O
first O
0 O
. O
2 O
kb O
of O
the O
IRF B
- I
1 I
promoter I
region I
act O
during O
early O
activation O
, O
and O
elements O
between O
0 O
. O
2 O
and O
1 O
. O
7 O
kb O
act O
in O
concert O
with O
the O
proximal O
0 O
. O
2 O
- O
kb O
region O
during O
S O
phase O
progression O
. O

Signals O
transduced O
via O
the O
TCR B
activate O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
, O
in O
turn O
, O
is O
critical O
to O
the O
transcriptional O
induction O
of O
many O
genes O
important O
for O
the O
proliferation O
and O
expression O
of O
a O
differentiated O
phenotype O
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

TSC2 B
is O
a O
gene O
on O
chromosome B
16p13 I
. I
3 I
associated O
with O
the O
autosomal O
dominant O
neurocutaneous O
disorder O
, O
tuberous O
sclerosis O
complex O
( O
TSC O
) O
. O

However O
, O
in O
contrast O
to O
human O
lymphocytes O
, O
IFN B
- I
gamma I
production O
was O
inhibited O
and O
IFN B
- I
gamma I
mRNA I
levels O
were O
unaffected O
at O
24 O
h O
and O
only O
slightly O
upregulated O
at O
48 O
and O
72 O
h O
of O
culture O
in O
murine O
splenocytes O
incubated O
with O
cipro O
( O
20 O
micrograms O
/ O
ml O
) O
. O

Other O
I B
kappa I
B I
proteins I
are O
rather O
involved O
in O
terminating O
NF B
- I
kappa I
B I
' O
s O
activity O
in O
the O
nucleus O
. O

Other O
I B
kappa I
B I
proteins I
are O
rather O
involved O
in O
terminating O
NF B
- I
kappa I
B I
' O
s O
activity O
in O
the O
nucleus O
. O

The O
intracellular O
events O
that O
lead O
to O
the O
inactivation O
of O
I B
kappa I
B I
, O
i O
. O
e O
. O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
are O
complex O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
amino B
- I
terminal I
portion I
of O
Sp140 B
was O
similar O
to O
Sp100 B
, O
a O
previously O
identified O
NB B
protein I
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

Two O
pp56 B
( I
lck I
) I
mutants I
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR B
- I
regulated I
nuclear I
factor I
of I
activated I
T I
cells I
( I
NF I
- I
AT I
) I
region I
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
stimulates O
IL B
- I
2R I
alpha I
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous B
reporter I
gene I
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon B
- I
alpha I
and I
- I
gamma I
) O
and O
interferon B
regulatory I
factor I
1 I
. O

Binding O
of O
the O
cDNA B
fusion I
protein I
, O
similarly O
to O
the O
results O
obtained O
with O
purified O
Jurkat O
protein O
, O
was O
decreased O
by O
introduction O
of O
site O
- O
specific O
mutations O
in O
the O
DRE B
1 I
regulatory I
sequence I
. O

HIV B
- I
1 I
LTR I
activity O
in O
human O
CD40 O
- O
activated O
B O
lymphocytes O
is O
dependent O
on O
NF B
- I
kappaB I
. O

In O
these O
cells O
, O
nuclear B
factors I
involved O
in O
activation O
of O
the O
HIV B
- I
1 I
LTR I
, O
which O
contains O
the O
transcriptional B
control I
elements I
of O
the O
virus O
, O
are O
unknown O
. O

This O
effect O
is O
blocked O
by O
anti B
- I
VCAM I
antibodies I
. O

Moreover O
, O
ZK161422 O
, O
but O
not O
ZK157202 O
, O
showed O
preference O
for O
gene O
activation O
from O
a O
promoter B
carrying O
a O
VD B
response I
element I
with O
a O
palindromic O
arrangement O
of O
two O
hexameric B
receptor I
binding I
sites I
spaced O
by O
9 O
nucleotides O
( O
IP9 O
) O
rather O
than O
for O
activation O
from O
a O
response B
element I
formed O
by O
a O
direct O
repeat O
spaced O
by O
3 O
nucleotides O
( O
DR3 O
) O
. O

The O
involvement O
of O
p21 B
( I
ras I
) I
in O
the O
regulation O
of O
calcium O
- O
dependent O
signals O
has O
been O
suggested O
through O
analysis O
of O
its O
role O
in O
the O
activation O
of O
NF B
- I
AT I
. O

The O
expression O
of O
activated O
p21 B
( I
ras I
) I
negatively O
regulated O
the O
induction O
of O
IE B
genes I
by O
calcium O
ionophore O
. O

A O
later O
result O
of O
inhibition O
of O
this O
activation O
pathway O
by O
p21 B
( I
ras I
) I
was O
down O
- O
regulation O
of O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
and O
subsequent O
coordinate O
reductions O
in O
IL B
- I
2 I
gene I
expression O
and O
protein O
production O
. O

A O
later O
result O
of O
inhibition O
of O
this O
activation O
pathway O
by O
p21 B
( I
ras I
) I
was O
down O
- O
regulation O
of O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
and O
subsequent O
coordinate O
reductions O
in O
IL B
- I
2 I
gene I
expression O
and O
protein O
production O
. O

Calcineurin B
acts O
in O
synergy O
with O
PMA O
to O
inactivate O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

Calcineurin B
stimulates O
the O
NF B
- I
kappa I
B I
element I
by O
enhancing O
inactivation O
of O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
, O
thereby O
increasing O
the O
amount O
of O
nuclear O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
. O

Calcineurin B
stimulates O
the O
NF B
- I
kappa I
B I
element I
by O
enhancing O
inactivation O
of O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
, O
thereby O
increasing O
the O
amount O
of O
nuclear O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
. O

Inhibition O
of O
membrane O
IL B
- I
2R I
alpha I
and O
IL B
- I
2R I
beta I
expression O
by O
10 O
( O
- O
6 O
) O
M O
DM O
was O
partially O
reversible O
by O
recombinant B
human I
IL I
- I
2 I
( O
rhIL B
- I
2 I
) O
. O

Inhibition O
of O
membrane O
IL B
- I
2R I
alpha I
and O
IL B
- I
2R I
beta I
expression O
by O
10 O
( O
- O
6 O
) O
M O
DM O
was O
partially O
reversible O
by O
recombinant B
human I
IL I
- I
2 I
( O
rhIL B
- I
2 I
) O
. O

The O
mechanism O
of O
action O
of O
DM O
on O
IL B
- I
2R I
alpha I
transcription O
was O
examined O
by O
determining O
the O
mRNA O
levels O
of O
the O
p50 O
subunit O
of O
nuclear O
factor O
kappa O
B O
( O
NF B
- I
kappa I
B I
) O
, O
a O
transcription B
factor I
that O
stimulates O
IL B
- I
2R I
alpha I
gene O
expression O
. O

The O
mechanism O
of O
action O
of O
DM O
on O
IL B
- I
2R I
alpha I
transcription O
was O
examined O
by O
determining O
the O
mRNA O
levels O
of O
the O
p50 O
subunit O
of O
nuclear O
factor O
kappa O
B O
( O
NF B
- I
kappa I
B I
) O
, O
a O
transcription B
factor I
that O
stimulates O
IL B
- I
2R I
alpha I
gene O
expression O
. O

The O
mechanism O
of O
action O
of O
DM O
on O
IL B
- I
2R I
alpha I
transcription O
was O
examined O
by O
determining O
the O
mRNA O
levels O
of O
the O
p50 O
subunit O
of O
nuclear O
factor O
kappa O
B O
( O
NF B
- I
kappa I
B I
) O
, O
a O
transcription B
factor I
that O
stimulates O
IL B
- I
2R I
alpha I
gene O
expression O
. O

The O
protein B
- I
tyrosine I
kinase I
ZAP B
- I
70 I
is O
implicated O
, O
together O
with O
the O
Src B
kinase I
p56 B
( I
lck I
) I
, O
in O
controlling O
the O
early O
steps O
of O
the O
T O
- O
cell O
antigen O
receptor O
( O
TCR B
) O
signaling O
cascade O
. O

The O
protein B
- I
tyrosine I
kinase I
ZAP B
- I
70 I
is O
implicated O
, O
together O
with O
the O
Src B
kinase I
p56 B
( I
lck I
) I
, O
in O
controlling O
the O
early O
steps O
of O
the O
T O
- O
cell O
antigen O
receptor O
( O
TCR B
) O
signaling O
cascade O
. O

Furthermore O
, O
overexpression O
and O
constitutive O
nuclear O
localization O
of O
NF B
- I
AT I
, O
but O
not O
Jun B
, I
Fos I
, I
NF I
- I
kappaB I
, I
Oct I
or I
Ets I
family I
members I
, O
renders O
the O
interleukin B
- I
2 I
enhancer I
in O
Jurkat O
T O
lymphocytes O
resistant O
to O
FK506 O
and O
cyclosporin O
A O
. O

First O
, O
anti B
- I
CD45 I
antibodies I
did O
not O
affect O
basal O
but O
decreased O
activated O
levels O
of O
expression O
from O
the O
HIV B
- I
1 I
LTR I
. O

First O
, O
anti B
- I
CD45 I
antibodies I
did O
not O
affect O
basal O
but O
decreased O
activated O
levels O
of O
expression O
from O
the O
HIV B
- I
1 I
LTR I
. O

The O
constitutively O
active O
type O
of O
the O
CN B
A I
subunit I
, O
which O
lacks O
the O
auto B
- I
inhibitory I
and O
calmodulin B
- I
binding I
domains I
, O
acts O
in O
synergy O
with O
PMA O
to O
activate O
transcription O
from O
the O
GM B
- I
CSF I
promoter I
. O

The O
constitutively O
active O
type O
of O
the O
CN B
A I
subunit I
, O
which O
lacks O
the O
auto B
- I
inhibitory I
and O
calmodulin B
- I
binding I
domains I
, O
acts O
in O
synergy O
with O
PMA O
to O
activate O
transcription O
from O
the O
GM B
- I
CSF I
promoter I
. O

Several O
forms O
of O
EGR B
- I
1 I
protein I
are O
found O
within O
the O
different O
groups O
of O
cell O
lines O
, O
and O
the O
binding O
activity O
to O
DNA B
consensus I
sequences I
was O
investigated O
. O

E3 B
, O
a O
hematopoietic B
- I
specific I
transcript I
directly O
regulated O
by O
the O
retinoic B
acid I
receptor I
alpha I
. O

E3 B
, O
a O
hematopoietic B
- I
specific I
transcript I
directly O
regulated O
by O
the O
retinoic B
acid I
receptor I
alpha I
. O

These O
results O
indicate O
that O
E3 B
is O
a O
hematopoietic B
- I
specific I
gene I
that O
is O
an O
immediate O
target O
for O
the O
activated O
RAR B
alpha I
during O
myelopoiesis O
. O

To O
examine O
whether O
an O
active O
negative O
regulatory O
process O
occurs O
, O
we O
created O
a O
reporter B
construct I
containing O
as O
an O
enhancer B
four O
copies O
of O
the O
NF B
- I
AT I
site I
and O
one O
copy O
of O
the O
octamer B
site I
( O
4X B
NF I
- I
AT I
- I
Oct I
) O
. O

The O
simplest O
model O
to O
explain O
these O
results O
is O
that O
anergy O
is O
mediated O
by O
a O
complex O
of O
multiple O
transcription B
factors I
that O
exert O
a O
cis O
- O
acting O
dominant O
negative O
regulatory O
effect O
on O
the O
trans O
- O
activation O
of O
the O
IL B
- I
2 I
gene I
. O

Deletion O
of O
the O
EBNA2 B
- I
dependent I
enhancer I
located O
upstream O
of O
Cp B
resulted O
in O
a O
ca O
. O
two O
- O
to O
fivefold O
reduction O
in O
Cp B
activity O
in O
the O
LCLs O
assayed O
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

Expression O
of O
interleukin B
1beta I
and O
other O
cytokines B
, O
such O
as O
interleukin B
6 I
and O
tumor B
necrosis I
factor I
alpha I
, O
has O
been O
shown O
to O
be O
dependent O
on O
the O
activation O
of O
the O
transcription B
factor I
, O
NFkappaB B
. O

Nuclear O
translocation O
of O
NF B
- I
kappaB I
subunits I
may O
ultimately O
increase O
the O
intracellular O
pool O
of O
NF B
- I
kappaB I
/ I
IkappaBalpha I
by O
an O
autoregulatory O
mechanism O
. O

Soluble B
factors I
secreted O
by O
activated O
T O
- O
lymphocytes O
modulate O
the O
transcription O
of O
the O
immunosuppressive B
cytokine I
TGF B
- I
beta I
2 I
in O
glial O
cells O
. O

These O
data O
along O
with O
previous O
observations O
demonstrating O
the O
potent O
immunosuppressive O
activity O
of O
TGF B
- I
beta I
2 I
, O
support O
a O
model O
for O
a O
feedback O
mechanism O
between O
the O
activated O
T O
- O
lymphocytes O
and O
astrocytes O
via O
TGF B
- I
beta I
2 I
to O
regulate O
the O
immune O
response O
. O

These O
data O
along O
with O
previous O
observations O
demonstrating O
the O
potent O
immunosuppressive O
activity O
of O
TGF B
- I
beta I
2 I
, O
support O
a O
model O
for O
a O
feedback O
mechanism O
between O
the O
activated O
T O
- O
lymphocytes O
and O
astrocytes O
via O
TGF B
- I
beta I
2 I
to O
regulate O
the O
immune O
response O
. O

ALF1 B
transactivated O
transcription O
of O
Akv O
MLV O
through O
the O
two O
E B
( I
gre I
) I
motifs I
equally O
, O
whereas O
E2A B
protein I
required O
the O
promoter O
- O
proximal O
E B
( I
gre I
) I
motif O
. O

Moreover O
, O
ectopic B
Id1 I
repressed O
E B
( I
gre I
) I
- O
directed O
but O
not O
EA B
/ I
S I
- O
directed O
MLV O
transcription O
in O
lymphoid O
cell O
lines O
. O

In O
conclusion O
, O
E B
( I
gre I
) I
motifs O
and O
interacting O
basic B
helix I
- I
loop I
- I
helix I
proteins I
are O
important O
determinants O
for O
MLV O
transcriptional O
activity O
in O
lymphocytic O
cell O
lines O
. O

Although O
NGFI B
- I
B I
/ I
nur77 I
is O
essential O
for O
TCR O
- O
mediated O
apoptosis O
in O
T B
- I
cell I
hybridomas I
, O
the O
reports O
on O
nur77 O
knock O
- O
out O
mice O
and O
nur77 O
dominant O
negative O
transgenic O
mice O
suggest O
that O
there O
is O
a O
functional O
redundancy O
among O
NGFI B
- I
B I
/ I
nur77 I
family I
. O

However O
, O
NFATc B
. I
beta I
neither O
bound O
to O
the O
kappa3 B
element I
( O
an O
NFAT B
- I
binding I
site I
) O
in O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
nor O
activated O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
in O
cotransfection O
assays O
. O

Both O
are O
located O
in O
the O
particulate O
fraction O
following O
platelet O
activation O
and O
are O
also O
able O
to O
bind O
to O
a O
GST B
- I
construct I
containing O
the O
SH2 B
and I
SH3 I
domains I
of O
phospholipase B
C I
gamma I
1 I
. O

Both O
are O
located O
in O
the O
particulate O
fraction O
following O
platelet O
activation O
and O
are O
also O
able O
to O
bind O
to O
a O
GST B
- I
construct I
containing O
the O
SH2 B
and I
SH3 I
domains I
of O
phospholipase B
C I
gamma I
1 I
. O

Lymphocytes O
from O
CML O
patients O
lack O
a O
47 B
kDa I
factor I
having O
affinity O
for O
a O
genomic B
sterol I
regulatory I
sequence I
. O

Tyloxapol O
inhibits O
NF B
- I
kappa I
B I
and O
cytokine B
release O
, O
scavenges O
HOCI B
, O
and O
reduces O
viscosity O
of O
cystic O
fibrosis O
sputum O
. O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

In O
this O
study O
, O
we O
examined O
the O
molecular O
mechanism O
by O
which O
agents O
that O
elevate O
intracellular O
cAMP O
inhibit O
the O
expression O
of O
the O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
, O
tissue B
factor I
, O
endothelial B
leukocyte I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
genes I
. O

In O
transient O
transfectin O
experiments O
, O
BCL6 B
can O
repress O
transcription O
from O
promoters B
linked O
to O
its O
DNA B
target I
sequence I
and O
this O
activity O
is O
dependent O
upon O
specific O
DNA O
- O
binding O
and O
the O
presence O
of O
an O
intact O
N B
- I
terminal I
half I
of O
the O
protein O
. O

As O
the O
NF B
- I
kappa I
B I
transcription I
factor I
has O
a O
central O
role O
in O
the O
control O
of O
transcription O
of O
several O
genes B
involved O
in O
immune O
and O
inflammatory O
responses O
, O
the O
authors O
have O
analysed O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
human O
umbilical O
cord O
T O
lymphocytes O
. O

Altogether O
, O
these O
results O
suggest O
that O
ATRA O
/ O
9 O
- O
cis O
RA O
may O
play O
a O
key O
role O
in O
FL O
hematopoiesis O
via O
a O
dual O
effect O
hypothetically O
mediated O
by O
interaction O
with O
the O
RAR B
/ I
RXR I
heterodimer I
, O
ie O
, O
inhibition O
of O
HSC O
/ O
primitive O
HPC O
proliferation O
and O
induction O
of O
CFU O
- O
GEMM O
/ O
BFU O
- O
E O
/ O
CFU O
- O
M O
shift O
from O
the O
multipotent O
/ O
erythroid O
/ O
monocytic O
to O
the O
granulocytic O
- O
neutrophilic O
differentiation O
program O
. O

Analysis O
of O
the O
ligand B
- I
binding I
domain I
of O
human B
retinoic I
acid I
receptor I
alpha I
by O
site O
- O
directed O
mutagenesis O
. O

From O
these O
results O
, O
we O
can O
conclude O
that O
electrostatic O
interactions O
of O
retinoids O
with O
the O
RAR B
alpha I
- I
LBD I
play O
a O
significant O
role O
in O
ligand O
binding O
. O

Our O
findings O
support O
the O
recently O
determined O
calcineurin B
X O
- O
ray O
crystal O
structure O
, O
provide O
evidence O
that O
calcineurin B
is O
the O
only O
CsA B
- I
sensitive I
component I
limiting O
signaling O
from O
the O
T B
cell I
receptor I
to O
the O
nucleus O
, O
and O
suggest O
a O
means O
to O
render O
cells O
and O
tissues O
resistant O
to O
the O
toxic O
side O
effects O
of O
CsA O
and O
FK506 O
. O

The O
extent O
to O
which O
peptides O
containing O
chemically O
and O
post O
- O
translationally O
modified O
amino B
acid I
side I
chains I
are O
recognized O
by O
primed O
CTL O
has O
not O
been O
clearly O
defined O
. O

A O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase I
defect O
in O
repair B
/ I
transcription I
factor I
TFIIH B
of O
xeroderma O
pigmentosum O
group O
B O
affects O
both O
DNA O
repair O
and O
transcription O
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

Chloramphenicol B
acetyltransferase I
( O
CAT B
) O
activities O
directed O
by O
5 B
' I
upstream I
promoter I
were O
detected O
preferentially O
in O
perforin O
- O
expressing O
cell O
lines O
. O

The O
results O
suggest O
that O
a O
combination O
of O
the O
three O
proximal O
cis B
- I
acting I
elements I
may O
constitute O
a O
minimal O
region O
responsible O
for O
CTL O
- O
specific O
expression O
of O
perforin B
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- B
76 I
site I
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa B
3 I
site I
. O

Thus O
, O
through O
the O
differential O
use O
of O
the O
same O
promoter B
element I
, O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
, O
the O
TNF B
- I
alpha I
gene I
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
in O
response O
to O
the O
same O
extracellular O
signal O
. O

To O
address O
possible O
mechanisms O
that O
could O
explain O
this O
selective O
activity O
of O
c B
- I
ErbB I
, O
we O
analyzed O
the O
ability O
of O
these O
receptors O
to O
activate O
the O
different O
members O
of O
the O
Stat B
transcription I
factor I
family I
. O

The O
previously O
defined O
minimal B
enhancer I
containing O
the O
muA B
, I
muE3 I
, I
and I
muB I
sites I
is O
transactivated O
by O
a O
combination O
of O
the O
ETS B
- I
domain I
proteins I
PU B
. I
1 I
and O
Ets B
- I
1 I
in O
nonlymphoid O
cells O
. O

The O
core O
GGAAs O
of O
the O
muA B
and I
muB I
sites I
are O
separated O
by O
30 O
nucleotides O
, O
suggesting O
that O
ETS B
proteins I
bind O
to O
these O
sites O
from O
these O
same O
side O
of O
the O
DNA O
helix O
. O

Our O
results O
emphasize O
the O
multiple O
levels O
at O
which O
NFAT O
- O
dependent O
transactivation O
is O
regulated O
, O
and O
predict O
significant O
differences O
in O
the O
architecture O
of O
cooperative O
transcription B
complexes I
containing O
different O
NFAT B
- I
family I
proteins I
. O

This O
revealed O
that O
NF B
- I
kappaB I
generation O
was O
sensitive O
to O
chloroquine O
, O
an O
inhibitor O
of O
acidic B
sphingomyelinase I
, O
but O
not O
to O
the O
phosphatidylinositol B
3 I
- I
kinase I
inhibitor O
, O
wortmannin O
. O

The O
results O
suggest O
a O
new O
option O
for O
HIV O
gene O
therapy O
; O
bcl B
- I
2 I
muteins I
that O
have O
noncleavable B
alterations I
surrounding O
the O
HIV B
protease I
cleavage I
site I
. O

The O
results O
suggest O
a O
new O
option O
for O
HIV O
gene O
therapy O
; O
bcl B
- I
2 I
muteins I
that O
have O
noncleavable B
alterations I
surrounding O
the O
HIV B
protease I
cleavage I
site I
. O

The O
induction O
of O
T O
cell O
proliferation O
requires O
signals O
from O
the O
TCR B
and O
a O
co B
- I
receptor I
molecule I
, O
such O
as O
CD28 B
, O
that O
activate O
parallel O
and O
partially O
cross O
- O
reactive O
signaling O
pathways O
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

Increasing O
the O
levels O
of O
BCL B
- I
2 I
retarded O
the O
G0 O
- O
- O
> O
S O
transition O
, O
sustained O
the O
levels O
of O
cyclin B
- I
dependent I
kinase I
inhibitor O
p27Kip1 O
, O
and O
repressed O
postactivation O
death O
. O

GM B
- I
CSF I
gene I
activation O
in O
T O
cells O
is O
known O
to O
involve O
the O
transcription B
factors I
nuclear B
factor I
- I
kappa I
B I
, O
AP B
- I
1 I
, O
NFAT B
, O
and O
Sp1 O
. O

A O
2 B
- I
bp I
mutation I
within O
the O
CBF B
site O
resulted O
in O
a O
2 O
- O
3 O
- O
fold O
decrease O
in O
the O
activities O
of O
both O
a O
69 B
- I
bp I
proximal I
promoter I
fragment I
and O
a O
627 B
- I
bp I
full I
- I
length I
promoter I
fragment I
. O

The O
GM B
- I
CSF I
locus I
may O
represent O
one O
of O
several O
target O
genes B
that O
are O
dysregulated O
in O
acute O
myeloid O
leukemia O
. O

Furthermore O
, O
sublethal O
levels O
of O
H2O2 O
actively O
suppressed O
the O
transcriptional O
activation O
of O
NF B
- I
AT I
and O
IL B
- I
2 I
reporters I
as O
well O
as O
the O
expression O
of O
IL B
- I
2 I
mRNA I
in O
cells O
stimulated O
with O
PHA O
/ O
PMA O
. O

Furthermore O
, O
sublethal O
levels O
of O
H2O2 O
actively O
suppressed O
the O
transcriptional O
activation O
of O
NF B
- I
AT I
and O
IL B
- I
2 I
reporters I
as O
well O
as O
the O
expression O
of O
IL B
- I
2 I
mRNA I
in O
cells O
stimulated O
with O
PHA O
/ O
PMA O
. O

Many O
of O
Pb O
' O
s O
effects O
on O
the O
immune O
system O
could O
be O
explained O
through O
activation O
of O
the O
transcription B
factor I
, O
NF B
- I
kappa I
B I
. O

The O
effects O
of O
either O
catecholamine O
on O
IL B
- I
12 I
or O
IL B
- I
10 I
secretion O
were O
blocked O
completely O
by O
propranolol O
, O
a O
beta O
- O
adrenoreceptor O
antagonist O
, O
indicating O
that O
they O
were O
mediated O
by O
the O
beta B
- I
adrenergic I
receptor I
. O

Finally O
, O
the O
biological O
relevance O
of O
the O
observation O
that O
T B
. I
pallidum I
lipoproteins I
- O
lipopeptides O
induce O
both O
NF B
- I
kappa I
B I
and O
cytokine B
production O
in O
monocytes O
was O
supported O
by O
the O
ability O
of O
the O
synthetic O
analogs O
to O
promote O
human O
immunodeficiency O
virus O
replication O
in O
chronically O
infected O
U1 O
monocytoid O
cells O
; O
these O
observations O
also O
suggest O
a O
potential O
mechanism O
whereby O
a O
syphilitic O
chancre O
can O
serve O
as O
a O
cofactor O
for O
human O
immunodeficiency O
virus O
transmission O
. O

Finally O
, O
the O
biological O
relevance O
of O
the O
observation O
that O
T B
. I
pallidum I
lipoproteins I
- O
lipopeptides O
induce O
both O
NF B
- I
kappa I
B I
and O
cytokine B
production O
in O
monocytes O
was O
supported O
by O
the O
ability O
of O
the O
synthetic O
analogs O
to O
promote O
human O
immunodeficiency O
virus O
replication O
in O
chronically O
infected O
U1 O
monocytoid O
cells O
; O
these O
observations O
also O
suggest O
a O
potential O
mechanism O
whereby O
a O
syphilitic O
chancre O
can O
serve O
as O
a O
cofactor O
for O
human O
immunodeficiency O
virus O
transmission O
. O

The O
present O
study O
describes O
the O
cloning O
of O
a O
lymphoid B
- I
restricted I
gene I
, O
LYSP100 B
, O
that O
is O
homologous O
to O
another O
protein O
that O
localizes O
to O
PML O
NBs O
, O
SP100 B
. O

Freshly O
isolated O
monocytes O
expressed O
94 B
- I
kD I
STAT5A I
, O
92 O
- O
kD O
STAT5B B
, O
and O
an O
80 B
- I
kD I
STAT5A I
molecule I
. O

STAT5A B
- I
STAT5A I
homodimers I
and O
STAT5A B
- I
STAT5B I
heterodimers I
formed O
in O
response O
to O
GM B
- I
CSF I
. O

STAT5A B
- I
STAT5A I
homodimers I
and O
STAT5A B
- I
STAT5B I
heterodimers I
formed O
in O
response O
to O
GM B
- I
CSF I
. O

Latent B
membrane I
protein I
1 I
and O
, O
to O
a O
lesser O
extent O
, O
EBV B
nuclear I
antigen I
2 I
mediated O
the O
increase O
in O
p53 B
levels O
via O
activation O
of O
the O
NF B
- I
kappaB I
transcription B
factor I
. O

Latent B
membrane I
protein I
1 I
and O
, O
to O
a O
lesser O
extent O
, O
EBV B
nuclear I
antigen I
2 I
mediated O
the O
increase O
in O
p53 B
levels O
via O
activation O
of O
the O
NF B
- I
kappaB I
transcription B
factor I
. O

Tissue O
- O
specific O
expression O
of O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
mediated O
via O
cis B
- I
acting I
elements I
located O
within O
315 O
base O
pairs O
of O
the O
transcription B
start I
. O

IL B
- I
13 I
caused O
rapid O
phosphorylation O
of O
the O
three O
out O
of O
four O
members O
of O
the O
known O
Janus B
family I
of I
kinases I
( O
JAKs B
) O
. O

Furthermore O
, O
JAK2 B
associated O
with O
the O
IL B
- I
4R I
p140 I
before O
and O
after O
stimulation O
with O
IL B
- I
13 I
. O

Differential O
regulation O
of O
IL B
- I
6 I
gene I
transcription O
and O
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
in O
human O
monocytic O
cell O
lines O
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

In O
chloramphenicol B
acetyltransferase I
assays O
, O
utilizing O
the O
transient O
transfection O
of O
a O
chloramphenicol B
acetyltransferase I
reporter I
plasmid I
containing O
the O
IL B
- I
6 I
gene I
promoter I
, O
IL B
- I
4 I
, O
but O
not O
IL B
- I
10 I
, O
suppressed O
the O
transcriptional O
activity O
of O
the O
IL O
- O
6 O
gene O
promoter O
stimulated O
by O
PMA O
and O
LPS O
. O

On O
the O
other O
hand O
, O
IL B
- I
10 I
enhanced O
the O
degradation O
of O
IL B
- I
6 I
mRNA I
in O
a O
mRNA O
stability O
assay O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
inhibit O
the O
transcription O
of O
the O
IL B
- I
6 I
gene I
by O
affecting O
NF B
- I
kappaB I
binding O
activity O
, O
while O
IL B
- I
10 I
may O
inhibit O
the O
IL B
- I
6 I
mRNA I
levels O
post O
- O
transcriptionally O
, O
without O
suppressing O
promoter O
activity O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
inhibit O
the O
transcription O
of O
the O
IL B
- I
6 I
gene I
by O
affecting O
NF B
- I
kappaB I
binding O
activity O
, O
while O
IL B
- I
10 I
may O
inhibit O
the O
IL B
- I
6 I
mRNA I
levels O
post O
- O
transcriptionally O
, O
without O
suppressing O
promoter O
activity O
. O

Characterization O
and O
purification O
of O
a O
protein B
kinase I
C I
substrate I
in O
human O
B O
cells O
. O

These O
receptor O
functions O
required O
the O
presence O
of O
the O
box B
3 I
motifs I
, O
as O
shown O
by O
the O
analysis O
of O
the O
mouse O
IL B
- I
10R I
constructs O
containing O
progressively B
truncated I
cytoplasmic I
domains I
. O

These O
results O
suggest O
that O
both O
common O
mechanisms O
, O
such O
as O
the O
one O
mediated O
by O
the O
CIITA B
trans I
- I
activator I
, O
and O
distinct O
tissue O
- O
specific O
constraints O
contribute O
to O
the O
transcriptional O
control O
of O
constitutive O
and O
IFN B
- I
gamma I
- O
induced O
MHC B
class I
II I
gene I
expression O
. O

These O
results O
suggest O
that O
both O
common O
mechanisms O
, O
such O
as O
the O
one O
mediated O
by O
the O
CIITA B
trans I
- I
activator I
, O
and O
distinct O
tissue O
- O
specific O
constraints O
contribute O
to O
the O
transcriptional O
control O
of O
constitutive O
and O
IFN B
- I
gamma I
- O
induced O
MHC B
class I
II I
gene I
expression O
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa B
B I
- I
1 I
, O
kappa B
B I
- I
2 I
, O
kappa B
B I
- I
3 I
, O
kappa B
B I
- I
4 I
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa B
B I
- I
1 I
, O
kappa B
B I
- I
2 I
, O
kappa B
B I
- I
3 I
, O
kappa B
B I
- I
4 I
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa B
B I
- I
1 I
, O
kappa B
B I
- I
2 I
, O
kappa B
B I
- I
3 I
, O
kappa B
B I
- I
4 I
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa B
B I
- I
1 I
, O
kappa B
B I
- I
2 I
, O
kappa B
B I
- I
3 I
, O
kappa B
B I
- I
4 I
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

Structural O
and O
functional O
characterization O
of O
the O
human B
CD36 I
gene I
promoter I
: O
identification O
of O
a O
proximal O
PEBP2 B
/ I
CBF I
site I
. O

Structural O
and O
functional O
characterization O
of O
the O
human B
CD36 I
gene I
promoter I
: O
identification O
of O
a O
proximal O
PEBP2 B
/ I
CBF I
site I
. O

In O
these O
cells O
, O
CD36 B
is O
involved O
in O
phagocytosis O
of O
apoptotic O
cells O
, O
and O
foam O
cell O
formation O
by O
uptake O
of O
oxidized B
low I
density I
lipoprotein I
. O

Disruption O
of O
the O
PEBP2 B
/ I
CBF I
site I
markedly O
diminished O
the O
role O
of O
the O
PEBP2 B
/ I
CBF I
factors I
in O
the O
constitutive O
transcription O
of O
the O
CD36 B
gene I
. O

Disruption O
of O
the O
PEBP2 B
/ I
CBF I
site I
markedly O
diminished O
the O
role O
of O
the O
PEBP2 B
/ I
CBF I
factors I
in O
the O
constitutive O
transcription O
of O
the O
CD36 B
gene I
. O

The O
association O
of O
specific O
HLA B
- I
DQ I
alleles I
with O
autoimmunity O
is O
correlated O
with O
discrete O
polymorphisms O
in O
the O
HLA B
- I
DQ I
sequence I
that O
are O
localized O
within O
sites O
suitable O
for O
peptide O
recognition O
. O

The O
association O
of O
specific O
HLA B
- I
DQ I
alleles I
with O
autoimmunity O
is O
correlated O
with O
discrete O
polymorphisms O
in O
the O
HLA B
- I
DQ I
sequence I
that O
are O
localized O
within O
sites O
suitable O
for O
peptide O
recognition O
. O

Expression O
of O
the O
MAP B
kinase I
- I
specific I
phosphatase I
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

Triplex O
formation O
by O
GM3 O
blocked O
recombinant B
and I
nuclear I
NF I
- I
kappaB I
proteins I
binding O
to O
the O
GM B
- I
CSF I
element I
. O

Finally O
, O
GM3 O
greatly O
reduced O
the O
concentration O
of O
endogenous O
GM B
- I
CSF I
mRNA I
induced O
by O
different O
stimuli O
in O
Jurkat O
T O
cells O
but O
did O
not O
affect O
interleukin B
3 I
mRNA I
levels O
in O
the O
same O
cells O
. O

We O
conclude O
that O
the O
kappaB B
element I
in O
the O
GM B
- I
CSF I
promoter I
plays O
a O
central O
role O
in O
the O
transcriptional O
activation O
of O
the O
endogenous O
GM B
- I
CSF I
gene I
. O

We O
conclude O
that O
the O
kappaB B
element I
in O
the O
GM B
- I
CSF I
promoter I
plays O
a O
central O
role O
in O
the O
transcriptional O
activation O
of O
the O
endogenous O
GM B
- I
CSF I
gene I
. O

Colinear O
triplex O
formation O
acts O
as O
a O
selective O
transcriptional O
repressor O
of O
the O
GM B
- I
CSF I
gene I
and O
may O
have O
potential O
therapeutic O
application O
in O
cases O
of O
undesirable O
overexpression O
of O
this O
protein O
. O

Modulation O
of O
endogenous O
IL B
- I
1 I
beta I
and O
IL B
- I
1 I
receptor I
antagonist O
results O
in O
opposing O
effects O
on O
HIV O
expression O
in O
chronically O
infected O
monocytic O
cells O
. O

Modulation O
of O
endogenous O
IL B
- I
1 I
beta I
and O
IL B
- I
1 I
receptor I
antagonist O
results O
in O
opposing O
effects O
on O
HIV O
expression O
in O
chronically O
infected O
monocytic O
cells O
. O

Costimulation O
of O
U1 O
cells O
with O
LPS O
plus O
GM B
- I
CSF I
resulted O
in O
the O
accumulation O
of O
steady O
- O
state O
levels O
of O
HIV B
RNA I
; O
however O
, O
only O
a O
weak O
induction O
of O
HIV B
long I
terminal I
repeat I
- O
driven O
transcription O
, O
which O
was O
not O
associated O
with O
the O
activation O
of O
the O
cellular B
transcription I
factor I
nuclear B
factor I
- I
kappa I
B I
, O
was O
noted O
. O

These O
mechanisms O
include O
the O
assembly O
of O
higher B
order I
nucleoprotein I
complexes I
and O
other O
protein O
- O
protein O
interactions O
that O
enhance O
the O
functional O
specificity O
of O
transcriptional B
regulators I
in O
lymphocytes O
. O

However O
, O
no O
cytoplasmic B
p62c I
- I
fos I
was O
detected O
in O
unstimulated O
PBL O
, O
although O
in O
some O
cases O
cytoplasmic B
p39c I
- I
jun I
was O
detected O
, O
suggesting O
that O
subcellular O
compartmentalization O
of O
these O
proteins B
may O
occur O
under O
certain O
circumstances O
. O

However O
, O
no O
cytoplasmic B
p62c I
- I
fos I
was O
detected O
in O
unstimulated O
PBL O
, O
although O
in O
some O
cases O
cytoplasmic B
p39c I
- I
jun I
was O
detected O
, O
suggesting O
that O
subcellular O
compartmentalization O
of O
these O
proteins B
may O
occur O
under O
certain O
circumstances O
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

Expression O
of O
Retinoid B
X I
Receptor I
alpha I
is O
increased O
upon O
monocytic O
cell O
differentiation O
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
unstimulated O
monocytes O
predominantly O
expressed O
p50 B
NF B
- I
kappa I
B I
. O

The O
effects O
of O
IFN B
- I
gamma I
on O
the O
transcription B
factors I
were O
specific O
, O
since O
no O
change O
was O
observed O
in O
the O
expression O
of O
NF B
- I
IL I
- I
6 I
or O
I B
kappa I
B I
alpha I
, O
the O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

The O
effects O
of O
IFN B
- I
gamma I
on O
the O
transcription B
factors I
were O
specific O
, O
since O
no O
change O
was O
observed O
in O
the O
expression O
of O
NF B
- I
IL I
- I
6 I
or O
I B
kappa I
B I
alpha I
, O
the O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
the O
effects O
of O
IFN B
- I
gamma I
on O
the O
expression O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
may O
be O
important O
for O
the O
modulatory O
effects O
of O
IFN B
- I
gamma I
on O
the O
cytokine B
expression O
in O
activated O
human O
monocytes O
. O

The O
expression O
of O
MIP B
- I
1 I
alpha I
is O
induced O
during O
cellular O
activation O
of O
CD4 O
+ O
T O
- O
cells O
and O
monocytes O
. O

We O
have O
previously O
identified O
a O
new O
transcription B
factor I
family I
( O
the O
MNP B
family I
) O
whose O
expression O
is O
crucial O
for O
the O
induction O
of O
MIP B
- I
1 I
alpha I
transcription O
during O
cellular O
activation O
and O
in O
transformed O
B O
cells O
. O

In O
this O
report O
we O
show O
induction O
of O
MNP B
- I
1 I
in O
Jurkat O
T O
- O
cells O
expressing O
HIV B
- I
1 I
tat I
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 B
- I
bp I
region I
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 B
- I
bp I
region I
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

IL B
- I
10 I
markedly O
reduces O
nuclear O
factor O
( B
NF I
) I
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
induced O
in O
PBMC O
by O
stimulation O
with O
the O
anti B
- I
CD3 I
mAb I
OKT3 B
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF B
- I
kappa I
B I
/ I
Rel I
protein I
family I
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF B
- I
kappa I
B I
/ I
Rel I
protein I
family I
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

Here O
we O
provide O
evidence O
that O
this O
transformation O
is O
the O
result O
of O
double O
infection O
of O
a O
cell O
with O
two O
virions O
, O
the O
P3HR1 B
virus I
genome I
and O
a O
mini B
- I
EBV I
plasmid I
carrying O
the O
chimeric O
EBNA2 B
gene I
. O

These O
results O
indicate O
that O
, O
as O
already O
reported O
for O
the O
IL2Rbeta B
promoter I
, O
GA B
- I
binding I
protein I
is O
an O
essential O
component O
of O
gammac O
basal O
promoter O
activity O
. O

Detection O
of O
intracellular B
signal I
transduction I
molecules I
in O
PBMC O
from O
rhesus O
macaques O
and O
sooty O
mangabeys O
. O

We O
conclude O
that O
a O
VDRE B
- I
binding I
protein I
( O
s O
) O
, O
distinct O
from O
IDBP B
and O
present O
in O
nuclear O
extract O
of O
cells O
from O
a O
prototypical O
vitamin O
D O
- O
resistant O
NWP O
, O
is O
capable O
of O
inhibiting O
normal O
VDR B
- I
RXR I
heterodimer O
binding O
to O
the O
VDRE B
. O

Like O
IkappaBalpha B
, O
Tax B
- O
mediated O
breakdown O
of O
IkappaBbeta B
in O
transfected O
T O
lymphocytes O
is O
blocked O
either O
by O
cell O
- O
permeable O
proteasome O
inhibitors O
or O
by O
mutation O
Of O
IkappaBbeta B
at O
two O
serine O
residues O
present O
within O
its O
N B
- I
terminal I
region I
. O

Here O
, O
we O
describe O
the O
effect O
of O
383 B
- I
bp I
( I
delta383 I
) I
and I
99 I
- I
bp I
( I
delta99 I
) I
sequences I
containing O
the O
PYBF B
- I
binding I
site I
on O
transcription O
from O
various O
globin O
and O
non O
- O
globin O
promoters O
, O
using O
a O
transient O
assay O
with O
the O
cat B
reporter I
gene I
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
, O
a O
cell O
line O
with O
abundant O
PYBF B
activity O
. O

Campomelic O
dysplasia O
( O
CMPD1 O
) O
and O
autosomal O
XY O
sex O
reversal O
( O
SRA1 O
) O
are O
caused O
by O
mutations O
in O
the O
SRY B
- I
related I
gene I
SOX9 B
on O
17q B
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

In O
this O
study O
we O
present O
a O
deletion O
analysis O
of O
the O
N B
- I
terminal I
region I
of O
Oct B
- I
2a I
to O
determine O
the O
minimal B
repression I
domain I
. O

The O
first O
was O
to O
abruptly O
terminate O
tumor O
necrosis O
factor O
- O
induced O
NF B
- I
kappaB I
binding O
to O
the O
enhancer O
sequences O
in O
U1 O
monocytic O
cells O
, O
using O
a O
short O
pulse O
of O
exogenous B
tumor I
necrosis I
factor I
. O

In O
an O
attempt O
to O
identify O
changes O
in O
gene O
expression O
that O
accompany O
the O
T O
- O
cell O
stimulation O
defects O
associated O
with O
the O
loss O
of O
Rel B
, O
we O
have O
examined O
the O
expression O
of O
cell B
surface I
activation I
markers I
and O
cytokine O
production O
in O
mitogen O
- O
stimulated O
Rel O
- O
/ O
- O
T O
cells O
. O

Nuclear O
appearance O
of O
a O
factor O
that O
binds O
the O
CD28 B
response I
element I
within O
the O
interleukin B
- I
2 I
enhancer I
correlates O
with O
interleukin B
- I
2 I
production O
. O

Severe O
skewing O
of O
X O
inactivation O
resulting O
in O
inactivity O
of O
the O
intact O
X B
was O
found O
in O
blood O
and O
cultures O
of O
both O
types O
of O
skin O
, O
but O
analysis O
of O
DNA O
prepared O
directly O
from O
hypopigmented O
skin O
showed O
significant O
inactivation O
of O
the O
translocated O
X B
, O
inconsistent O
with O
the O
usual O
mechanism O
of O
phenotypic O
expression O
in O
X B
; I
autosome I
translocations I
. O

Large O
amounts O
of O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
and O
significant O
quantities O
of O
NF B
- I
AT I
were O
induced O
in O
SEA O
- O
activated O
CD4 O
+ O
spleen O
T O
cells O
, O
whereas O
Oct O
- O
1 O
and O
Oct O
- O
2 O
DNA O
binding O
activity O
was O
similar O
in O
both O
resting O
and O
activated O
T O
cells O
. O

These O
data O
indicate O
that O
, O
in O
contrast O
to O
most O
LPS O
effects O
, O
AP B
- I
1 I
, O
but O
not O
nuclear B
factor I
- I
kappaB I
, O
mediates O
LPS O
induction O
of O
collagenase B
transcription O
in O
macrophagelike O
cells O
. O

LPS O
treatment O
of O
RAW O
264 O
. O
7 O
cells O
, O
murine O
bone O
marrow O
- O
derived O
macrophages O
, O
and O
the O
human O
monocyte O
cell O
line O
THP O
- O
1 O
resulted O
in O
rapid O
activation O
of O
the O
p46 B
and I
p54 I
isoforms I
of O
JNK B
. O

This O
183 B
- I
bp I
region I
was O
both O
cell O
type O
specific O
and O
responsive O
to O
two O
distinct O
stimuli O
, O
lipopolysaccharide O
and O
dibutyryl O
cAMP O
, O
known O
to O
regulate O
B7 B
. I
1 I
expression O
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

Moreover O
, O
gp120 B
induces O
tyrosine O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT B
- I
1 I
alpha I
) O
as O
well O
as O
the O
Janus B
kinase I
( O
JAK2 B
) O
in O
glial O
cells O
. O

Northern O
blot O
analysis O
as O
well O
as O
Ab O
blocking O
and O
cytokine B
secretion O
studies O
indicated O
that O
the O
induction O
of O
either O
endogenous B
TNF I
- I
alpha I
or O
IL B
- I
10 I
was O
not O
involved O
in O
the O
cooperativity O
, O
nor O
was O
an O
up O
- O
regulation O
of O
TNF B
- I
alpha I
receptors I
. O

Northern O
blot O
analysis O
as O
well O
as O
Ab O
blocking O
and O
cytokine B
secretion O
studies O
indicated O
that O
the O
induction O
of O
either O
endogenous B
TNF I
- I
alpha I
or O
IL B
- I
10 I
was O
not O
involved O
in O
the O
cooperativity O
, O
nor O
was O
an O
up O
- O
regulation O
of O
TNF B
- I
alpha I
receptors I
. O

Interaction O
of O
HTLV B
- I
I I
Tax I
with O
the O
human B
proteasome I
: O
implications O
for O
NF B
- I
kappa I
B I
induction O
. O

Interaction O
of O
HTLV B
- I
I I
Tax I
with O
the O
human B
proteasome I
: O
implications O
for O
NF B
- I
kappa I
B I
induction O
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 B
proteasome I
subunit I
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic B
NF I
- I
kappa I
B I
/ I
Rel I
complexes I
to O
the O
proteasome B
for O
processing O
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 B
proteasome I
subunit I
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic B
NF I
- I
kappa I
B I
/ I
Rel I
complexes I
to O
the O
proteasome B
for O
processing O
. O

IL B
- I
11 I
mRNA I
and O
protein O
were O
both O
up O
- O
regulated O
during O
the O
course O
of O
this O
inflammatory O
response O
. O

The O
importance O
of O
NF B
- I
kappaB I
sites I
was O
confirmed O
by O
using O
vectors O
containing O
wild B
- I
type I
or I
mutant I
kappaB I
sites I
in O
a O
heterologous B
promoter I
. O

Evidence O
for O
lowered O
induction O
of O
nuclear B
factor I
kappa I
B I
in O
activated O
human O
T O
lymphocytes O
during O
aging O
. O

Here O
, O
we O
report O
a O
model O
of O
CD28 B
costimulation O
using O
PMA O
plus O
the O
natural B
ligand I
CD80 I
that O
resulted O
in O
very O
limited O
stimulation O
of O
IL B
- I
2 I
, O
as O
evidenced O
by O
both O
cytokine B
production O
and O
IL B
- I
2 I
promoter I
stimulation O
. O

In O
transient O
- O
transfection O
assays O
, O
a O
Qp B
- I
CAT I
reporter I
was O
activated O
by O
cotransfected O
JAK B
- I
1 I
and O
by O
treatment O
of O
cells O
with O
the O
cytokine B
IL B
- I
6 I
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
mitogenic O
activation O
, O
mediated O
primarily O
through O
the O
NF B
kappa I
B I
enhancer I
, O
is O
susceptible O
to O
CD8 B
- O
mediated O
inhibition O
, O
however O
, O
inhibition O
of O
Tat B
- O
mediated O
activation O
may O
rely O
upon O
a O
different O
pathway O
that O
is O
NFAT B
- I
1 I
dependent O
. O

Transient O
- O
transfection O
assays O
showed O
that O
bcl B
- I
x I
promoter I
was O
transactivated O
by O
wild B
- I
type I
Tax I
. O

Transient O
- O
transfection O
assays O
showed O
that O
bcl B
- I
x I
promoter I
was O
transactivated O
by O
wild B
- I
type I
Tax I
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA B
boxes I
of O
the O
beta B
- I
globin I
promoter I
. O

Based O
on O
these O
results O
, O
we O
present O
a O
model O
that O
illustrates O
how O
EKLF B
may O
be O
recruited O
to O
the O
beta B
- I
globin I
locus I
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

Previously O
, O
the O
action O
of O
MC903 O
and O
KH1060 O
was O
presumed O
to O
be O
mediated O
by O
the O
nuclear B
vitamin I
D I
receptor I
( O
VDRnuc B
) O
. O

Induced O
MIP B
- I
1alpha I
expression O
and O
secretion O
in O
PMA O
/ O
PHA O
stimulated O
tax O
transfected O
cells O
correlate O
with O
the O
noninduction O
of O
MNP B
- I
1 I
transcription B
factor I
, O
which O
is O
intimately O
involved O
in O
downmodulating O
the O
MIP B
- I
1alpha I
gene I
. O

An O
inhibitory O
, O
` O
` O
dominant O
- O
negative O
, O
' O
' O
form O
of O
the O
calcineurin B
catalytic I
( I
A I
) I
subunit I
was O
prepared O
, O
which O
lacks O
the O
calmodulin B
- I
binding I
domain I
, O
autoinhibitory B
domain I
and O
most O
of O
its O
catalytic O
core O
but O
possesses O
the O
regulatory B
( I
B I
) I
subunit I
binding O
domain O
. O

Immunoprecipitation O
of O
epitope B
- I
labeled I
BKO I
demonstrated O
for O
the O
formation O
of O
a O
tight O
complex O
with O
endogenous B
B I
subunit I
in O
Jurkat O
cells O
, O
consistent O
with O
an O
inhibitory O
mechanism O
that O
involves O
the O
sequestration O
of O
the O
B B
subunit I
. O

B O
cells O
were O
purified O
from O
buffy O
coat O
preparations O
of O
healthy O
blood O
donors O
by O
positive O
selection O
using O
an O
anti B
CD20 I
monoclonal I
antibody I
and O
a O
MiniMACS O
separation O
unit O
. O

Expression O
of O
wild B
- I
type I
SHP1 I
had O
a O
very O
small O
effect O
on O
the O
TCR O
- O
induced O
tyrosine O
phosphorylation O
of O
ZAP B
- I
70 I
and O
Syk B
, O
even O
when O
SHP1 B
was O
overexpressed O
20 O
- O
100 O
- O
fold O
over O
endogenous B
SHP1 I
. O

In O
the O
cell O
line O
HT93A O
, O
which O
is O
capable O
of O
differentiating O
towards O
both O
the O
eosinophil O
and O
neutrophil O
lineages O
in O
response O
to O
retinoic O
acid O
( O
RA O
) O
, O
C B
/ I
EBPalpha I
mRNA I
expression O
decreased O
significantly O
concomitant O
with O
eosinophilic O
and O
neutrophilic O
differentiation O
, O
whereas O
C B
/ I
EBPbeta I
expression O
was O
markedly O
increased O
. O

Furthermore O
, O
we O
have O
demonstrated O
that O
both O
C B
/ I
EBPbeta I
and O
GATA B
- I
1 I
can O
bind O
simultaneously O
to O
the O
C O
/ O
EBP O
- O
and O
GATA B
- I
binding I
sites I
in O
the O
MBP B
promoter I
. O

Role O
of O
the O
camp B
response I
element I
site I
in O
mediating O
repression O
by O
the O
upstream B
regulatory I
region I
. O

These O
foci O
, O
which O
were O
preferentially O
found O
adjacent O
to O
nucleoli O
or O
at O
the O
nuclear O
periphery O
, O
did O
not O
represent O
sites O
of O
active O
transcription O
or O
binding O
of O
GATA B
- I
1 I
to O
consensus B
sites I
in O
the O
beta B
- I
globin I
loci I
. O

Putative B
steroid I
binding I
domain I
of O
the O
human B
mineralocorticoid I
receptor I
, O
expressed O
in O
E O
. O
coli O
in O
the O
presence O
of O
heat B
shock I
proteins I
shows O
typical O
native O
receptor O
characteristics O
. O

Renal O
cell O
carcinoma O
- O
derived O
gangliosides O
suppress O
nuclear B
factor I
- I
kappaB I
activation O
in O
T O
cells O
. O

We O
also O
demonstrate O
that O
the O
IKK B
complex I
, O
but O
not O
p90 B
( I
rsk I
) I
, O
is O
responsible O
for O
the O
in O
vivo O
phosphorylation O
of O
IkappaBalpha B
mediated O
by O
the O
co O
- O
activation O
of O
PKC B
and O
calcineurin B
. O

A O
novel O
immunosuppressive B
factor I
in O
bovine O
colostrum O
blocks O
activation O
of O
the O
interleukin B
2 I
gene I
enhancer I
at O
the O
NFAT B
site I
. O

VASP O
is O
not O
involved O
in O
Shigella O
movement O
, O
and O
the O
function O
of O
profilin B
does O
not O
require O
its O
binding O
to O
proline B
- I
rich I
regions I
. O

Elevated O
levels O
of O
c B
- I
Maf I
protein I
led O
to O
marked O
increases O
in O
Myb B
: I
Maf I
complexes I
and O
the O
accumulation O
of O
monocyte O
/ O
macrophage O
cells O
, O
followed O
by O
eventual O
programmed O
cell O
death O
. O

Elevated O
levels O
of O
c B
- I
Maf I
protein I
led O
to O
marked O
increases O
in O
Myb B
: I
Maf I
complexes I
and O
the O
accumulation O
of O
monocyte O
/ O
macrophage O
cells O
, O
followed O
by O
eventual O
programmed O
cell O
death O
. O

Analysis O
of O
targets O
that O
could O
mediate O
these O
phenotypic O
changes O
indicated O
that O
c B
- I
Maf I
likely O
plays O
a O
key O
role O
in O
myeloid O
cell O
development O
through O
dual O
mechanisms O
; O
inhibition O
of O
a O
select O
set O
of O
c B
- I
Myb I
regulated O
targets O
, O
such O
as O
Bcl B
- I
2 I
and O
CD13 B
/ I
APN I
, O
coupled O
with O
the O
activation O
of O
as O
yet O
undefined O
differentiation B
- I
promoting I
genes I
. O

We O
have O
examined O
the O
effect O
of O
Rb B
expression O
on O
the O
activation O
of O
the O
promoter O
for O
HLA B
- I
DRA I
, O
the O
prototype B
class I
II I
gene I
. O

Activation O
of O
NF B
- I
kappa I
B I
is O
induced O
by O
prooxidants O
and O
several O
stimuli O
eliciting O
oxidative O
stress O
, O
such O
as O
cytokines B
, O
lipopolysaccharide O
, O
UV O
irradiation O
and O
other O
mediators O
. O

The O
total O
protein O
content O
of O
NF B
- I
kappaB I
subunit I
( O
P65 B
) O
in O
MNC O
lysates O
also O
showed O
a O
decrease O
following O
hydrocortisone O
injection O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
ability O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
, O
a O
proinflammatory B
cytokine I
) O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
an O
anti B
- I
inflammatory I
cytokine I
) O
to O
differentially O
regulate O
the O
sensitivity O
of O
human O
monocytes O
/ O
macrophages O
to O
glucocorticoids O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
ability O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
, O
a O
proinflammatory B
cytokine I
) O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
an O
anti B
- I
inflammatory I
cytokine I
) O
to O
differentially O
regulate O
the O
sensitivity O
of O
human O
monocytes O
/ O
macrophages O
to O
glucocorticoids O
. O

Because O
NF B
- I
kappa I
B I
contributes O
to O
the O
transcription O
of O
numerous O
inflammatory B
genes I
and O
has O
been O
shown O
to O
be O
a O
molecular O
target O
of O
antiinflammatory O
drugs O
, O
we O
sought O
to O
characterize O
the O
functional O
role O
of O
the O
NF B
- I
kappa I
B I
protein I
complex I
in O
lupus O
T O
cells O
. O

Also O
, O
NF B
- I
kappa I
B I
activity O
remained O
absent O
in O
follow O
- O
up O
studies O
. O

Two O
- O
color O
immunohistochemistry O
demonstrated O
that O
both O
macrophages O
and O
fibroblast O
- O
like O
synoviocytes O
were O
positive O
for O
nuclear O
C B
/ I
EBP I
beta I
. O

We O
find O
that O
PU B
. I
1 I
interacts O
directly O
with O
GATA B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
required O
for O
erythroid O
differentiation O
. O

This O
remodeling O
of O
promoter O
chromatin O
structure O
resulted O
in O
3 O
- O
fold O
increases O
in O
beta B
- I
globin I
gene I
transcription O
and O
induction O
, O
and O
inhibited O
long O
- O
term O
beta B
- I
globin I
gene I
silencing O
. O

This O
remodeling O
of O
promoter O
chromatin O
structure O
resulted O
in O
3 O
- O
fold O
increases O
in O
beta B
- I
globin I
gene I
transcription O
and O
induction O
, O
and O
inhibited O
long O
- O
term O
beta B
- I
globin I
gene I
silencing O
. O

Here O
we O
investigate O
the O
hypothesis O
that O
low O
shear O
- O
induced O
activation O
of O
NF B
- I
kappaB I
is O
responsible O
for O
enhanced O
expression O
of O
vascular B
cell I
adhesion I
molecule I
( O
VCAM B
- I
1 I
) O
resulting O
in O
augmented O
endothelial O
cell O
- O
monocyte O
( O
EC O
- O
Mn O
) O
adhesion O
and O
that O
this O
activation O
is O
dependent O
on O
intracellular O
oxidant O
activity O
. O

Nuclear B
factor I
- I
90 I
of O
activated O
T O
- O
cells O
: O
A O
double B
- I
stranded I
RNA I
- O
binding O
protein O
and O
substrate O
for O
the O
double B
- I
stranded I
RNA I
- I
dependent I
protein I
kinase I
, O
PKR B
. O

Nuclear B
factor I
- I
90 I
of O
activated O
T O
- O
cells O
: O
A O
double B
- I
stranded I
RNA I
- O
binding O
protein O
and O
substrate O
for O
the O
double B
- I
stranded I
RNA I
- I
dependent I
protein I
kinase I
, O
PKR B
. O

Using O
in O
vitro O
translated O
polypeptides O
, O
we O
have O
demonstrated O
that O
NF90 B
specifically O
binds O
to O
double B
- I
stranded I
RNA I
. O

C5a O
- O
induced O
reporter B
gene I
expression O
was O
abolished O
by O
introducing O
mutations O
into O
the O
kappaB B
sites I
and O
by O
coexpression O
of O
a O
dominant B
negative I
IkappaBalpha I
construct I
resistant O
to O
agonist O
- O
induced O
phosphorylation O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Potent O
and O
stable O
attenuation O
of O
live O
- O
HIV O
- O
1 O
by O
gain O
of O
a O
proteolysis B
- I
resistant I
inhibitor I
of O
NF B
- I
kappaB I
( O
IkappaB B
- I
alphaS32 I
/ I
36A I
) O
and O
the O
implications O
for O
vaccine O
development O
. O

Multiple O
NF B
- I
ATc I
isoforms I
with O
individual O
transcriptional O
properties O
are O
synthesized O
in O
T O
lymphocytes O
. O

Inhibition O
of O
NF B
- I
kappa I
B I
resulted O
in O
the O
externalization O
of O
phosphatidylserine O
, O
induction O
of O
DNA O
breaks O
, O
and O
morphological O
changes O
consistent O
with O
apoptosis O
. O

Functional O
analysis O
indicates O
that O
the O
BRs B
are O
involved O
in O
control O
of O
hIL B
- I
5 I
promoter I
activity O
. O

PNU156804 O
action O
is O
restricted O
to O
some O
signaling O
pathways O
; O
it O
does O
not O
affect O
NF B
- I
kappa I
B I
activation O
by O
PMA O
in O
T O
cells O
but O
blocks O
that O
induced O
by O
CD40 B
cross O
- O
linking O
in O
B O
lymphocytes O
. O

METHODS O
: O
Allergen O
- O
specific O
T O
- O
cell O
clones O
and O
T O
- O
cell O
hybridomas O
were O
established O
from O
the O
peripheral O
blood O
lymphocytes O
of O
patients O
with O
asthma O
, O
and O
the O
transcriptional O
regulation O
of O
the O
IL B
- I
5 I
gene I
was O
investigated O
with O
transient O
transfection O
and O
electrophoretic O
mobility O
shift O
analysis O
. O

Surprisingly O
, O
we O
find O
also O
that O
the O
interaction O
between O
SLP B
- I
76 I
and O
Vav B
is O
not O
required O
for O
their O
cooperation O
in O
augmenting O
IL B
- I
2 I
promoter I
activity O
, O
as O
the O
two O
molecules O
appear O
to O
function O
in O
different O
signaling O
pathways O
upstream O
of O
IL B
- I
2 I
gene I
expression O
. O

Surprisingly O
, O
we O
find O
also O
that O
the O
interaction O
between O
SLP B
- I
76 I
and O
Vav B
is O
not O
required O
for O
their O
cooperation O
in O
augmenting O
IL B
- I
2 I
promoter I
activity O
, O
as O
the O
two O
molecules O
appear O
to O
function O
in O
different O
signaling O
pathways O
upstream O
of O
IL B
- I
2 I
gene I
expression O
. O

Additionally O
, O
overexpression O
of O
Vav B
, O
but O
not O
SLP B
- I
76 I
, O
augments O
CD28 O
- O
induced O
IL B
- I
2 I
promoter I
activity O
. O

This O
correlated O
with O
the O
initiation O
of O
signaling O
downstream O
of O
Notch O
, O
as O
evidenced O
by O
increased O
levels O
of O
HES B
- I
1 I
transcripts I
in O
co O
- O
cultivated O
T O
cells O
and O
of O
CD23 B
transcripts I
in O
co O
- O
cultivated O
B O
cells O
. O

Signaling O
through O
the O
lymphotoxin B
- I
beta I
receptor I
stimulates O
HIV O
- O
1 O
replication O
alone O
and O
in O
cooperation O
with O
soluble O
or O
membrane B
- I
bound I
TNF I
- I
alpha I
. O

All O
tissues O
and O
cells O
studied O
were O
homozygous O
for O
the O
wild B
- I
type I
gene I
, O
and O
were O
heterozygous O
as O
well O
as O
homozygous O
for O
the O
codon B
- I
10 I
- I
variant I
type I
. O

USF B
/ I
c I
- I
Myc I
enhances O
, O
while O
Yin B
- I
Yang I
1 I
suppresses O
, O
the O
promoter O
activity O
of O
CXCR4 B
, O
a O
coreceptor B
for O
HIV O
- O
1 O
entry O
. O

Different O
sequence O
requirements O
for O
expression O
in O
erythroid O
and O
megakaryocytic O
cells O
within O
a O
regulatory B
element I
upstream O
of O
the O
GATA B
- I
1 I
gene I
. O

This O
core O
contains O
a O
GATA B
site I
separated O
by O
10 O
base O
pairs O
from O
an O
E B
- I
box I
motif I
. O

Fibroblast B
growth I
factors I
( O
FGFs B
) O
are O
heparin B
- I
binding I
proteins I
crucial O
to O
embryogenesis O
, O
angiogenesis O
, O
and O
wound O
healing O
. O

Here O
, O
we O
investigate O
the O
role O
of O
Rho B
in O
regulating O
the O
distribution O
of O
the O
monocyte B
- I
binding I
receptors I
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
in O
human O
endothelial O
cells O
. O

C3 O
transferase O
and O
cytochalasin O
D O
did O
not O
alter O
the O
expression O
levels O
of O
monocyte B
- I
binding I
receptors I
on O
endothelial O
cells O
, O
but O
did O
inhibit O
clustering O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
on O
the O
cell O
surface O
induced O
by O
monocyte O
adhesion O
or O
cross B
- I
linking I
antibodies I
. O

C3 O
transferase O
and O
cytochalasin O
D O
did O
not O
alter O
the O
expression O
levels O
of O
monocyte B
- I
binding I
receptors I
on O
endothelial O
cells O
, O
but O
did O
inhibit O
clustering O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
on O
the O
cell O
surface O
induced O
by O
monocyte O
adhesion O
or O
cross B
- I
linking I
antibodies I
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

CTLA B
- I
4 I
ligation O
inhibited O
CD3 O
/ O
CD28 B
- O
induced O
IL B
- I
2 I
mRNA I
accumulation O
by O
inhibiting O
IL B
- I
2 I
transcription O
, O
which O
appears O
to O
be O
mediated O
in O
part O
through O
decreasing O
NF B
- I
AT I
accumulation O
in O
the O
nuclei O
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Here O
we O
report O
that O
in O
erythroid O
cells O
, O
GATA B
- I
1 I
strongly O
induces O
the O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
bcl B
- I
xL I
, O
but O
not O
the O
related O
proteins O
bcl B
- I
2 I
and O
mcl B
- I
1 I
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic B
cytokine I
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic B
cytokine I
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

PI B
3 I
- I
kinase I
also O
regulates O
the O
activity O
of O
p70 B
( I
s6k I
) I
, O
the O
40S B
ribosomal I
protein I
S6 I
kinase I
, O
a O
response O
that O
is O
abrogated O
by O
the O
macrolide O
rapamycin O
. O

PI B
3 I
- I
kinase I
also O
regulates O
the O
activity O
of O
p70 B
( I
s6k I
) I
, O
the O
40S B
ribosomal I
protein I
S6 I
kinase I
, O
a O
response O
that O
is O
abrogated O
by O
the O
macrolide O
rapamycin O
. O

Moreover O
, O
the O
effects O
of O
rapamycin O
on O
, O
and O
the O
role O
of O
p70 B
( I
s6k I
) I
in O
, O
IL B
- I
2 I
and O
PI B
3 I
- I
kinase I
activation O
of O
E2Fs B
have O
not O
been O
characterized O
. O

Moreover O
, O
the O
effects O
of O
rapamycin O
on O
, O
and O
the O
role O
of O
p70 B
( I
s6k I
) I
in O
, O
IL B
- I
2 I
and O
PI B
3 I
- I
kinase I
activation O
of O
E2Fs B
have O
not O
been O
characterized O
. O

Our O
present O
results O
show O
that O
IL B
- I
2 I
- O
and O
PI B
3 I
- I
kinase I
- O
induced O
pathways O
for O
the O
regulation O
of O
E2F B
transcriptional O
activity O
include O
both O
rapamycin O
- O
resistant O
and O
rapamycin O
- O
sensitive O
components O
. O

Thus O
, O
the O
rapamycin O
- O
controlled O
processes O
involved O
in O
E2F B
regulation O
appear O
to O
be O
mediated O
by O
p70 B
( I
s6k I
) I
. O

Since O
1988 O
, O
several O
families O
of O
functionally O
important O
T B
cell I
transcription I
factors I
have O
been O
identified O
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
319 I
and I
- I
219 I
bp I
upstream I
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription B
factor I
expression I
plasmids I
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

The O
effects O
of O
GDSP O
on O
pancreatic O
weight O
, O
serum B
amylase I
and I
lipase I
, O
morphologic O
changes O
in O
the O
pancreas O
, O
neutrophil O
infiltration O
, O
and O
nuclear B
factor I
KB I
( O
NF B
- I
KB I
) O
activation O
were O
measured O
in O
rats O
infused O
with O
supramaximal O
dose O
of O
cerulein O
( O
5 O
( O
g O
/ O
kg O
/ O
h O
) O
for O
6 O
h O
. O

Our O
previous O
studies O
pertaining O
to O
macrophage O
response O
to O
LPS O
identified O
a O
novel O
DNA B
- I
binding I
domain I
located O
from O
- O
550 O
to O
- O
487 O
in O
the O
human B
TNF I
- I
alpha I
promoter I
that O
contains O
transcriptional O
activity O
, O
but O
lacks O
any O
known O
NF B
- I
kappaB I
- B
binding I
sites I
. O

Transfection O
of O
Jurkat O
cells O
with O
the O
NF B
- I
kappaB I
subunits I
p50 B
and O
p65 B
confers O
resistance O
against O
Fas O
- O
mediated O
apoptosis O
. O

Activation O
of O
T O
lymphocytes O
to O
produce O
cytokines B
is O
regulated O
by O
the O
counterbalance O
of O
protein B
- I
tyrosine I
kinases I
and O
protein O
- O
tyrosine O
phosphatases O
, O
many O
of O
which O
have O
a O
high O
degree O
of O
substrate O
specificity O
because O
of O
physical O
association O
with O
their O
targets O
. O

In O
this O
study O
, O
the O
influence O
of O
the O
sequences O
located O
between B
- I
3134 I
and I
- I
2987 I
on O
the O
transcriptional O
activity O
of O
the O
proIL B
- I
1beta I
gene I
in O
LPS O
- O
stimulated O
Raw O
264 O
. O
7 O
cells O
was O
examined O
in O
detail O
. O

These O
data O
indicated O
that O
two O
NF B
- I
kappaB I
- I
binding I
sites I
, O
which O
are O
located O
between O
- B
3134 I
and I
- I
3059 I
, O
are O
critical O
for O
the O
activation O
of O
proIL B
- I
1beta I
gene I
transcription O
. O

Gel O
supershift O
assays O
demonstrated O
that O
thrombin B
induced O
binding O
of O
NF B
- I
kappa I
Bp65 I
( O
Rel B
A I
) O
to O
downstream O
NF B
- I
kappa I
B I
site I
of O
the O
ICAM B
- I
1 I
promoter I
. O

Gel O
supershift O
assays O
demonstrated O
that O
thrombin B
induced O
binding O
of O
NF B
- I
kappa I
Bp65 I
( O
Rel B
A I
) O
to O
downstream O
NF B
- I
kappa I
B I
site I
of O
the O
ICAM B
- I
1 I
promoter I
. O

These O
data O
indicate O
that O
thrombin B
activates O
endothelial O
ICAM B
- I
1 I
expression O
and O
polymorphonuclear O
leukocyte O
adhesion O
by O
NF B
- I
kappa I
Bp65 I
binding O
to O
the O
downstream O
NF B
- I
kappa I
B I
site I
of O
ICAM B
- I
1 I
promoter I
after O
proteolytically O
activated O
receptor O
- O
1 O
activation O
. O

These O
data O
indicate O
that O
thrombin B
activates O
endothelial O
ICAM B
- I
1 I
expression O
and O
polymorphonuclear O
leukocyte O
adhesion O
by O
NF B
- I
kappa I
Bp65 I
binding O
to O
the O
downstream O
NF B
- I
kappa I
B I
site I
of O
ICAM B
- I
1 I
promoter I
after O
proteolytically O
activated O
receptor O
- O
1 O
activation O
. O

HLA B
class I
I I
Ags I
have O
been O
implicated O
to O
play O
a O
major O
role O
in O
this O
process O
, O
since O
signaling O
via O
HLA B
class I
I I
molecules I
can O
induce O
the O
proliferation O
of O
aortic O
endothelial O
as O
well O
as O
smooth O
muscle O
cells O
. O

HLA B
class I
I I
Ags I
have O
been O
implicated O
to O
play O
a O
major O
role O
in O
this O
process O
, O
since O
signaling O
via O
HLA B
class I
I I
molecules I
can O
induce O
the O
proliferation O
of O
aortic O
endothelial O
as O
well O
as O
smooth O
muscle O
cells O
. O

PG490 O
also O
inhibits O
PMA O
- O
stimulated O
activation O
of O
a O
chimeric B
transcription I
factor I
in O
which O
the O
C B
- I
terminal I
TA1 I
transactivation I
domain I
of O
NF B
- I
kappaB I
p65 I
is O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL4 B
. O

Unexpected O
and O
coordinated O
expression O
of O
Spi B
- I
1 I
, O
Fli B
- I
1 I
, O
and O
megakaryocytic B
genes I
in O
four O
Epo O
- O
dependent O
cell O
lines O
established O
from O
transgenic O
mice O
displaying O
erythroid O
- O
specific O
expression O
of O
a O
thermosensitive B
SV40 I
T I
antigen I
. O

Most O
erythroleukemic O
cell O
lines O
established O
in O
vitro O
coexpress O
erythrocytic B
and I
megakaryocytic I
markers I
that O
often O
are O
associated O
with O
expression O
of O
Spi B
- I
1 I
and O
/ O
or O
Fli B
- I
1 I
transcription I
factors I
known O
as O
transactivators B
of I
megakaryocyte I
- I
specific I
promoters I
. O

STAT1 B
, O
which O
is O
activated O
in O
response O
to O
many O
lymphocyte B
- I
activating I
cytokines I
including O
the O
interferons B
, O
is O
essential O
for O
cell O
- O
mediated O
immunity O
, O
as O
the O
absence O
of O
this O
protein O
is O
associated O
with O
prominent O
defects O
in O
the O
ability O
to O
control O
viral O
infections O
. O

Spi B
- I
C I
interacted O
with O
DNA O
similarly O
to O
PU B
. I
1 I
as O
judged O
by O
methylation O
interference O
, O
band O
- O
shift O
and O
site O
selection O
analysis O
, O
and O
activated O
transcription O
of O
a O
kappaY B
element I
reporter I
gene I
upon O
co O
- O
transfection O
of O
HeLa O
cells O
. O

Spi B
- I
C I
RNA I
was O
expressed O
in O
mature O
B O
lymphocytes O
and O
at O
lower O
levels O
in O
macrophages O
. O

However O
, O
the O
HTLV B
- I
I I
genes I
including O
Tax B
are O
not O
expressed O
significantly O
in O
primary O
leukemic O
cells O
from O
ATL O
patients O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major B
I I
gamma I
3 I
transcription I
initiation I
site I
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human B
I I
gamma I
1 I
, O
I B
gamma I
2 I
, O
and O
I B
gamma I
4 I
regions O
. O

CIITA B
- O
induced O
occupation O
of O
MHC B
class I
II I
promoters I
is O
independent O
of O
the O
cooperative O
stabilization O
of O
the O
promoter B
- I
bound I
multi I
- I
protein I
complexes I
. O

Activation O
of O
MHC B
class I
II I
promoters I
requires O
binding O
of O
at O
least O
three O
distinct O
multi B
- I
protein I
complexes I
( O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
) O
. O

Activation O
of O
MHC B
class I
II I
promoters I
requires O
binding O
of O
at O
least O
three O
distinct O
multi B
- I
protein I
complexes I
( O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
) O
. O

Finally O
, O
we O
conclude O
that O
this O
effect O
of O
CIITA B
is O
cell O
- O
type O
specific O
, O
since O
expression O
of O
CIITA B
is O
not O
required O
for O
normal O
occupation O
of O
MHC B
class I
II I
promoters I
in O
B O
lymphocytes O
. O

SH2 B
domain I
- I
containing I
protein I
76 I
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear B
factor I
of I
activated I
cells I
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

This O
fusion O
protein O
contains O
the O
DNA B
- I
binding I
domain I
of O
the O
transcription B
factor I
AML1 B
fused O
in O
- O
frame O
to O
the O
entire O
MDS1 B
/ I
EVI1 I
with O
the O
exclusion O
of O
its O
first O
12 O
amino O
acids O
. O

Beta O
- O
catenin O
is O
the O
vertebrate O
homolog O
of O
the O
Drosophila B
segment I
polarity I
gene I
Armadillo B
and O
plays O
roles O
in O
both O
cell O
- O
cell O
adhesion O
and O
transduction O
of O
the O
Wnt O
signaling O
cascade O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Interestingly O
, O
the O
combination O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
and O
RA O
markedly O
enhanced O
the O
levels O
of O
p27 B
( I
KIP1 I
) I
transcript O
and O
protein O
as O
compared O
with O
levels O
induced O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
alone O
. O

Previous O
studies O
have O
implicated O
a O
role O
for O
intracellular O
thiols O
in O
the O
activation O
of O
nuclear B
factor I
- I
kappaB I
and O
transcriptional O
regulation O
of O
endothelial B
cell I
adhesion I
molecules I
. O

Previous O
studies O
have O
implicated O
a O
role O
for O
intracellular O
thiols O
in O
the O
activation O
of O
nuclear B
factor I
- I
kappaB I
and O
transcriptional O
regulation O
of O
endothelial B
cell I
adhesion I
molecules I
. O

This O
study O
demonstrates O
that O
changes O
in O
endothelial O
cell O
GSSG O
/ O
GSH O
cause O
transcription O
- O
independent O
and O
transcription O
- O
dependent O
surface O
expression O
of O
different O
endothelial B
cell I
adhesion I
molecules I
, O
which O
leads O
to O
a O
2 O
- O
phase O
neutrophil O
- O
endothelial O
adhesion O
response O
. O

Angiotensin B
II I
activates O
the O
proinflammatory B
transcription I
factor I
nuclear B
factor I
- I
kappaB I
in O
human O
monocytes O
. O

Consequently O
, O
cytosolic O
activation O
, O
nuclear O
translocation O
and O
DNA O
- O
binding O
of O
nuclear B
factor I
- I
kappaB I
were O
decreased O
. O

Because O
these O
induced O
gene O
products O
have O
NF B
- I
kappaB I
sites I
in O
their O
promoter B
regions I
, O
we O
next O
examined O
whether O
there O
was O
an O
up O
- O
regulation O
of O
nuclear O
NF B
- I
kappaB I
levels O
. O

These O
results O
suggest O
that O
Fli B
- I
1 I
is O
likely O
to O
regulate O
lineage B
- I
specific I
genes I
during O
megakaryocytopoiesis O
. O

This O
RXR B
agonist O
activity O
is O
blocked O
by O
RAR B
- O
specific O
antagonists O
, O
suggesting O
extensive O
cross O
- O
talk O
between O
the O
partners O
of O
the O
RXR B
- I
RARalpha403 I
heterodimer I
. O

In O
several O
cell O
types O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
/ O
or O
activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
has O
been O
demonstrated O
to O
be O
extremely O
important O
in O
blocking O
apoptosis O
. O

In O
several O
cell O
types O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
/ O
or O
activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
has O
been O
demonstrated O
to O
be O
extremely O
important O
in O
blocking O
apoptosis O
. O

The O
phosphorylation O
appears O
to O
be O
related O
to O
the O
signaling O
events O
that O
are O
activated O
by O
TRAF2 B
under O
these O
circumstances O
, O
since O
two O
nonfunctional O
mutants O
were O
found O
to O
be O
phosphorylated O
significantly O
less O
than O
the O
wild B
- I
type I
protein I
. O

Though O
the O
levels O
of O
DP1 B
and I
- I
2 I
increase O
when O
cells O
progress O
from O
G0 O
to O
S O
, O
the O
proportion O
of O
DP1 B
to O
DP2 B
remains O
relatively O
constant O
during O
the O
cell O
cycle O
. O

In O
addition O
, O
DNA O
- O
binding O
activities O
of O
Jun B
- I
Fos I
heterodimers I
were O
observed O
by O
electrophoretic O
mobility O
shift O
assays O
during O
the O
course O
of O
natural O
cytotoxicity O
. O

The O
CD34 O
+ O
myelomonocytic O
cell O
line O
KG1 O
differentiates O
into O
dendritic O
- O
like O
cells O
in O
response O
to O
granulocyte B
- I
macrophage I
CSF I
plus O
TNF B
- I
alpha I
, O
or O
PMA O
( O
with O
or O
without O
the O
calcium O
ionophore O
ionomycin O
, O
or O
TNF B
- I
alpha I
) O
, O
with O
different O
stimuli O
mediating O
different O
aspects O
of O
the O
process O
. O

RFLAT B
- I
1 I
: O
a O
new O
zinc B
finger I
transcription I
factor I
that O
activates O
RANTES B
gene I
expression O
in O
T O
lymphocytes O
. O

Several O
intracellular O
signaling B
proteins I
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

In O
addition O
, O
the O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
and O
enhanced O
tyrosine O
phosphorylation O
of O
phospholipase O
Cgamma O
were O
seen O
after O
anti O
- O
CD28 O
mAb O
and O
CHO O
- O
CD80 O
stimulation O
but O
to O
a O
much O
lesser O
extent O
after O
CHO B
- I
CD86 I
stimulation O
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 B
- I
type I
lymphokines I
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

FasL B
- I
dependent I
reporter I
constructs I
in O
MRL O
- O
lpr O
/ O
lpr O
and O
C3H O
- O
gld O
/ O
gld O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
were O
constitutively O
active O
, O
and O
this O
activity O
was O
largely O
prevented O
by O
mutation O
of O
the O
critical O
Egr B
family I
binding I
element I
. O

The O
activity O
of O
the O
CCAAT B
- I
box I
binding I
factor I
NF I
- I
Y I
is O
modulated O
through O
the O
regulated O
expression O
of O
its O
A B
subunit I
during O
monocyte O
to O
macrophage O
differentiation O
: O
regulation O
of O
tissue B
- I
specific I
genes I
through O
a O
ubiquitous O
transcription B
factor I
. O

Differential O
induction O
of O
DNA B
- I
binding I
activities I
following O
CD19 B
cross O
- O
linking O
in O
human O
B O
lineage O
cells O
. O

The O
protein O
has O
no O
known O
DNA B
- I
binding I
domain I
but O
does O
contain O
three O
ankyrin O
repeats O
that O
are O
likely O
to O
be O
important O
in O
protein O
- O
protein O
interactions O
. O

Members O
of O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
binding I
( I
CREB I
) I
/ I
activating I
transcription I
factor I
1 I
( I
ATF I
- I
1 I
) I
family I
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

Delta O
- O
opioid O
receptors O
expressed O
by O
Jurkat O
T O
cells O
enhance O
IL B
- I
2 I
secretion O
by O
increasing O
AP B
- I
1 I
complexes I
and O
activity O
of O
the O
NF B
- I
AT I
/ I
AP I
- I
1 I
- I
binding I
promoter I
element I
. O

Reporter O
gene O
constructs O
were O
used O
to O
map O
this O
effect O
of O
deltorphin O
to O
the O
AP B
- I
1 I
- I
and I
NF I
- I
AT I
/ I
AP I
- I
1 I
- I
binding I
sites I
of O
the O
IL B
- I
2 I
promoter I
. O

HS B
I I
- I
III I
, O
located O
5 O
' O
from O
the O
transcriptional B
initiation I
site I
, O
were O
found O
in O
hematopoietic O
and O
non O
- O
hematopoietic O
cells O
, O
whereas O
HS B
IV I
- I
VII I
, O
located O
3 O
' O
from O
the O
transcriptional B
start I
site I
, O
were O
exclusively O
observed O
in O
T O
- O
cells O
. O

HS B
I I
- I
III I
, O
located O
5 O
' O
from O
the O
transcriptional B
initiation I
site I
, O
were O
found O
in O
hematopoietic O
and O
non O
- O
hematopoietic O
cells O
, O
whereas O
HS B
IV I
- I
VII I
, O
located O
3 O
' O
from O
the O
transcriptional B
start I
site I
, O
were O
exclusively O
observed O
in O
T O
- O
cells O
. O

Among O
these O
hypersensitive B
sites I
, O
two O
transcriptional B
control I
elements I
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA B
- I
3 I
gene I
and O
the O
other O
between B
8 I
. I
3 I
and I
5 I
. I
9 I
kilobases I
5 O
' O
from O
the O
GATA B
- I
3 I
transcriptional I
initiation I
site I
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

The O
present O
study O
was O
designed O
to O
analyze O
the O
roles O
of O
the O
two O
GR B
isoforms I
on O
glucocorticoid O
- O
mediated O
transrepression O
of O
the O
IL B
- I
2 I
gene I
. O

Furthermore O
, O
GRbeta B
did O
not O
antagonize O
the O
repressive O
effects O
of O
GRalpha B
on O
IL B
- I
2 I
promoter I
activity O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal B
binding I
element I
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal B
binding I
element I
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

In O
a O
series O
of O
electrophoretic O
mobility O
shift O
assays O
with O
protein O
extracts O
of O
highly O
polarized O
Th2 O
clones O
from O
atopics O
and O
Th1 O
clones O
from O
controls O
we O
compared O
DNA O
- O
binding O
activities O
at O
the O
two O
NFAT B
- I
binding I
elements I
P0 B
and O
P1 B
of O
the O
crucial O
proximal O
human O
IL B
- I
4 I
promoter I
. O

In O
a O
series O
of O
electrophoretic O
mobility O
shift O
assays O
with O
protein O
extracts O
of O
highly O
polarized O
Th2 O
clones O
from O
atopics O
and O
Th1 O
clones O
from O
controls O
we O
compared O
DNA O
- O
binding O
activities O
at O
the O
two O
NFAT B
- I
binding I
elements I
P0 B
and O
P1 B
of O
the O
crucial O
proximal O
human O
IL B
- I
4 I
promoter I
. O

The O
prevalent O
complex O
is O
the O
heterodimer B
p50 I
- I
p65 I
. O

Tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
- O
induced O
HIV O
- O
1 O
replication O
in O
OM10 O
. O
1 O
or O
Ach2 O
cells O
was O
significantly O
inhibited O
by O
non O
- O
cytotoxic O
doses O
of O
AuTG O
( O
> O
10 O
microM O
in O
OM10 O
. O
1 O
cells O
and O
> O
25 O
F O
. O
M O
in O
Ach2 O
cells O
) O
, O
while O
25 O
microM O
of O
the O
counter B
- I
anion I
thioglucose I
( O
TG B
) O
or O
gold O
compound O
containing O
divalent O
gold O
ion O
, O
HAuCl3 O
, O
had O
no O
effect O
. O

Indeed O
, O
the O
availability O
of O
selective O
and O
orally O
active O
proteasome O
inhibitors O
should O
prove O
useful O
in O
delineating O
the O
roles O
of O
the O
proteasome O
and O
NF B
- I
kappa I
B I
in O
other O
pathophysiological O
conditions O
such O
as O
cancer O
and O
heart O
disease O
. O

Transcriptional O
regulation O
of O
the O
alpha2 B
integrin I
gene I
in O
cells O
undergoing O
megakaryocytic O
differentiation O
requires O
a O
core B
promoter I
between O
bp O
- O
30 O
and O
- O
92 O
, O
a O
silencer B
between O
bp O
- O
92 O
and O
- O
351 O
, O
and O
megakaryocytic B
enhancers I
in O
the O
distal B
5 I
' I
flank I
. O

In O
contrast O
, O
activation O
in O
THP B
- I
1 I
cells I
occurred O
in O
the O
absence O
of O
vanadate O
and O
was O
unaffected O
by O
catalase B
. O

These O
findings O
suggest O
the O
presence O
in O
vaginal O
fluid O
of O
agent O
( O
s O
) O
derived O
from O
indigenous O
bacteria O
that O
can O
activate O
the O
HIV B
- I
1 I
LTR I
, O
cytokine B
production O
, O
and O
NF B
- I
kappaB I
in O
cells O
of O
macrophage O
lineage O
, O
with O
possible O
influence O
on O
vaginal O
physiology O
and O
host O
defense O
. O

AR B
can O
be O
visualized O
with O
the O
anti B
- I
AR I
antibodies I
in O
the O
cytoplasm O
of O
permeabilized O
T O
cells O
by O
using O
CLSM O
, O
though O
AR B
are O
not O
detectable O
in O
cytosol O
fractions O
when O
using O
the O
charcoal O
binding O
assay O
with O
3H O
- O
R1881 O
as O
ligand O
. O

IL B
- I
10 I
preincubation O
resulted O
in O
the O
inhibition O
of O
gene O
expression O
for O
several O
IFN B
- I
induced I
genes I
, O
such O
as O
IP B
- I
10 I
, O
ISG54 B
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

The O
endothelial O
expression O
of O
vascular B
cell I
adhesion I
molecule I
- I
1 I
( O
VCAM B
- I
1 I
) O
, O
E B
- I
selectin I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
monitored O
by O
cell O
surface O
enzyme O
immunoassays O
or O
flow O
cytometry O
, O
and O
steady O
- O
state O
levels O
of O
VCAM B
- I
1 I
mRNA I
were O
assessed O
by O
Northern O
blot O
analysis O
. O

In O
this O
study O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
gene O
expression O
and O
protein O
secretion O
of O
IL B
- I
6 I
in O
human O
PBMCs O
, O
either O
alone O
or O
in O
combination O
with O
LPS O
or O
IL B
- I
1beta I
. O

Furthermore O
, O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
induction O
of O
NF B
- I
kappaB I
and O
activating B
protein I
- I
1 I
binding O
. O

Furthermore O
, O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
induction O
of O
NF B
- I
kappaB I
and O
activating B
protein I
- I
1 I
binding O
. O

These O
results O
demonstrate O
the O
capacity O
of O
intact O
C3a B
and O
its O
circulating O
des B
- I
Arg I
form I
to O
exert O
immunmodulatory O
effects O
in O
vitro O
. O

The O
suggested O
roles O
of O
the O
downstream B
3 I
' I
regions I
acting O
as O
a O
Locus B
Control I
Region I
( O
LCR B
) O
, O
have O
allowed O
comparisons O
to O
be O
made O
between O
the O
regulation O
of O
the O
IgH B
locus I
with O
other O
model O
systems O
whose O
gene O
expression O
is O
governed O
by O
LCR B
activity O
. O

MATERIALS O
AND O
METHODS O
: O
Peptides O
derived O
from O
oncogenic B
proteins I
were O
screened O
for O
the O
presence O
of O
HLA B
binding I
motifs I
; O
actual O
binding O
were O
evaluated O
by O
HLA O
stabilization O
experiments O
using O
transfectants O
and O
specific O
anti B
- I
HLA I
antibodies I
. O

Phosphatidylinositol B
3 I
- I
kinase I
couples O
the O
interleukin B
- I
2 I
receptor I
to O
the O
cell B
cycle I
regulator I
E2F B
. O

Phosphatidylinositol B
3 I
- I
kinase I
couples O
the O
interleukin B
- I
2 I
receptor I
to O
the O
cell B
cycle I
regulator I
E2F B
. O

TRADD B
was O
the O
only O
protein O
that O
interacted O
with O
wild B
- I
type I
TES2 I
and O
not O
with O
isoleucine B
- I
mutated I
TES2 I
. O

TRADD B
was O
the O
only O
protein O
that O
interacted O
with O
wild B
- I
type I
TES2 I
and O
not O
with O
isoleucine B
- I
mutated I
TES2 I
. O

Core B
- I
specific I
mAb I
inhibited O
mCD14 B
- O
mediated O
uptake O
of O
homologous O
and O
heterologous O
LPS O
, O
while O
producing O
less O
concurrent O
enhancement O
of O
non O
- O
mCD14 B
- O
mediated O
LPS O
uptake O
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

From O
these O
observations O
we O
conclude O
that O
free O
thiols O
in O
the O
IL B
- I
1RI I
complex I
are O
essential O
for O
the O
activation O
of O
the O
IL B
- I
1RI I
- I
associated I
protein I
kinase I
and O
that O
this O
process O
is O
mandatory O
for O
IL B
- I
1 I
signaling O
leading O
to O
NF B
- I
kappa I
B I
activation O
. O

From O
these O
observations O
we O
conclude O
that O
free O
thiols O
in O
the O
IL B
- I
1RI I
complex I
are O
essential O
for O
the O
activation O
of O
the O
IL B
- I
1RI I
- I
associated I
protein I
kinase I
and O
that O
this O
process O
is O
mandatory O
for O
IL B
- I
1 I
signaling O
leading O
to O
NF B
- I
kappa I
B I
activation O
. O

Expression O
of O
bcl B
- I
6 I
protein I
in O
normal O
skin O
and O
epidermal O
neoplasms O
. O

The O
estrogen B
receptor I
( O
ER B
) O
repressed O
erythroid O
differentiation O
and O
erythroid B
- I
specific I
gene I
expression O
. O

Furthermore O
, O
compared O
with O
wild B
- I
type I
Id3 I
, O
an O
Id3 B
Asp5 I
mutant I
( O
mimicking O
phosphorylation O
) O
is O
unable O
to O
promote O
cell O
cycle O
S O
phase O
entry O
in O
transfected O
fibroblasts O
, O
whereas O
an O
Id3 B
Ala5 I
mutant I
( O
ablating O
phosphorylation O
) O
displays O
an O
activity O
significantly O
greater O
than O
that O
of O
wild B
- I
type I
Id3 I
protein I
. O

Cooperation O
of O
binding B
sites I
for O
STAT6 B
and O
NF B
kappa I
B I
/ I
rel I
in O
the O
IL B
- I
4 I
- O
induced O
up O
- O
regulation O
of O
the O
human B
IgE I
germline I
promoter I
. O

In O
contrast O
, O
lipopolysaccharide O
stimulation O
primarily O
induced O
the O
p65 B
/ I
p50 I
heterodimer I
that O
has O
been O
shown O
to O
result O
in O
gene O
activation O
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

Our O
finding O
that O
Vpr B
can O
regulate O
NF B
- I
kappa I
B I
supports O
the O
hypothesis O
that O
some O
aspects O
of O
viral O
pathogenesis O
are O
the O
consequence O
of O
cell O
dysregulation O
by O
Vpr B
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
induces O
tyrosine O
phosphorylation O
of O
STATs B
3 I
and I
5 I
( O
signal O
transducer O
and O
activator O
of O
transcription O
) O
. O

In O
addition O
, O
both O
RelA B
and O
c B
- I
Rel I
, O
but O
not O
NF B
- I
kappa I
B1 I
, O
were O
shown O
to O
transactivate O
an O
ICAM B
- I
1 I
kappa I
B I
- I
reporter I
construct I
. O

Control O
of O
NF B
- I
kappa I
B I
activity O
by O
the O
I B
kappa I
B I
beta I
inhibitor I
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
maintained O
in O
an O
inactive O
cytoplasmic O
state O
by O
I B
kappa I
B I
inhibitors I
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
maintained O
in O
an O
inactive O
cytoplasmic O
state O
by O
I B
kappa I
B I
inhibitors I
. O

G28 B
- I
5 I
sFv I
was O
a O
more O
potent O
agonist O
than O
G28 B
- I
5 I
IgG I
and O
was O
able O
to O
stimulate O
CD40 B
responses O
by O
B O
cells O
and O
monocytes O
. O

G28 B
- I
5 I
sFv I
was O
a O
more O
potent O
agonist O
than O
G28 B
- I
5 I
IgG I
and O
was O
able O
to O
stimulate O
CD40 B
responses O
by O
B O
cells O
and O
monocytes O
. O

Increased O
CRH B
promoter O
activity O
following O
phorbol O
ester O
treatment O
was O
inhibited O
by O
a O
dominant O
negative O
NF B
- I
IL6 I
mutant I
, O
showing O
that O
the O
effects O
of O
phorbol O
ester O
were O
principally O
mediated O
by O
C B
/ I
EBP I
. O

A O
similar O
spectrum O
of O
transcript O
deletions O
has O
previously O
been O
described O
in O
the O
putative B
tumour I
suppressor I
gene I
FHIT B
. O

Interleukin B
- I
7 I
upregulates O
the O
interleukin B
- I
2 I
- I
gene I
expression O
in O
activated O
human O
T O
lymphocytes O
at O
the O
transcriptional O
level O
by O
enhancing O
the O
DNA O
binding O
activities O
of O
both O
nuclear O
factor O
of O
activated O
T O
cells O
and O
activator B
protein I
- I
1 I
. O

The O
visualization O
of O
heavy B
and I
light I
chain I
genes I
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa B
genes I
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma B
and I
lambda I
genes I
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda B
genes I
being O
more O
interior O
when O
compared O
with O
the O
gamma B
genes I
. O

Transcription B
factor I
NF B
- I
kappa I
B I
must O
be O
released O
from O
cytoplasmic B
inhibitory I
molecules I
( O
I B
kappa I
Bs I
) O
in O
order O
to O
move O
to O
the O
nucleus O
and O
to O
activate O
its O
target B
genes I
. O

Many O
of O
these O
events O
are O
dependent O
upon O
the O
ability O
of O
CD40 B
to O
activate O
the O
transcription O
factor O
NF B
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

Many O
of O
these O
events O
are O
dependent O
upon O
the O
ability O
of O
CD40 B
to O
activate O
the O
transcription O
factor O
NF B
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

To O
define O
the O
CD40 B
signaling O
components O
upstream O
of O
NF B
- I
kappa I
B I
activation O
and O
the O
functional O
consequences O
downstream O
of O
NF B
- I
kappa I
B I
activation O
, O
we O
examined O
mouse O
B O
cell O
transfectants O
expressing O
wild B
- I
type I
or I
mutant I
human I
CD40 I
. O

To O
define O
the O
CD40 B
signaling O
components O
upstream O
of O
NF B
- I
kappa I
B I
activation O
and O
the O
functional O
consequences O
downstream O
of O
NF B
- I
kappa I
B I
activation O
, O
we O
examined O
mouse O
B O
cell O
transfectants O
expressing O
wild B
- I
type I
or I
mutant I
human I
CD40 I
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

NF B
- I
kappa I
B I
activation O
was O
independent O
of O
the O
transmembrane B
domain I
of O
CD40 B
, O
suggesting O
that O
it O
is O
independent O
of O
p23 B
, O
a O
molecule O
that O
associates O
with O
CD40 B
in O
a O
region O
other O
than O
the O
cytoplasmic B
domain I
. O

NF B
- I
kappa I
B I
activation O
correlated O
with O
the O
ability O
of O
CD40 B
to O
induce O
Ab O
secretion O
and O
the O
up O
- O
regulation O
of O
ICAM B
- I
1 I
and O
LFA B
- I
1 I
. O

The O
M B
- I
CSF I
receptor I
was O
first O
detectable O
in O
the O
myeloid O
- O
committed O
CD34 O
+ O
Thy O
- O
l O
- O
CD45RA O
+ O
subset O
. O

Further O
, O
M O
. O
tuberculosis O
and O
its O
tuberculin B
, O
purified B
protein I
derivative I
, O
induced O
the O
degradation O
of O
I B
kappa I
B I
- I
alpha I
and O
the O
expression O
of O
I B
kappa I
B I
- I
alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
monocytes O
. O

They O
also O
suggest O
that O
the O
function O
of O
Spi B
- I
1 I
/ I
PU I
. I
1 I
in O
the O
late O
phase O
of O
Friend O
leukemia O
requires O
specific O
signaling O
from O
the O
gp55 B
- I
modified I
EpoR I
generated O
during O
the O
early O
phase O
of O
the O
disease O
. O

The O
POU B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
regulate O
the O
activity O
of O
octamer B
- I
dependent I
promoters I
, O
including O
those O
that O
direct O
transcription O
from O
rearranged O
immunoglobulin B
genes I
. O

The O
class B
II I
trans I
- I
activator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multi I
- I
functional I
domain I
protein I
which O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Transient O
transfection O
of O
a O
B O
lymphoma O
line O
resulted O
in O
up O
to O
89 O
% O
reduction O
of O
constitutive O
MHC B
class I
II I
expression O
within O
5 O
days O
and O
suppression O
of O
HLA B
- I
DRA I
mRNA I
synthesis O
. O

The O
tax B
protein I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
mediates O
the O
transactivation O
of O
the O
c B
- I
sis I
/ I
platelet I
- I
derived I
growth I
factor I
- I
B I
promoter I
through O
interactions O
with O
the O
zinc B
finger I
transcription I
factors I
Sp1 B
and O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

One O
ATF B
/ I
CRE I
motif I
is O
located O
in O
the O
distal B
promoter I
at O
the O
nuclear B
matrix I
- I
associated I
Site I
IV I
, O
and O
the O
second O
motif O
is O
present O
in O
the O
proximal B
promoter I
at O
Site B
I I
. O

Thus O
, O
our O
data O
establish O
that O
ATF B
/ I
CREB I
factors I
functionally O
modulate O
histone B
H4 I
gene I
transcription O
at O
distal B
and I
proximal I
promoter I
elements I
. O

Indeed O
, O
addition O
of O
inhibitors O
of O
NF B
- I
kappa I
B I
activation O
pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
, O
to O
the O
lymphocytes O
of O
the O
chemically O
- O
exposed O
group O
was O
capable O
of O
inhibiting O
programmed O
cell O
death O
by O
40 O
% O
. O

This O
reversal O
of O
apoptosis O
almost O
to O
the O
control O
level O
by O
inhibitor O
of O
NF B
- I
kappa I
B I
activation O
may O
indicate O
involvement O
of O
this O
signaling B
molecule I
in O
MTBE O
and O
benzene O
induction O
of O
programmed O
cell O
death O
. O

Purified B
SR I
- I
BP I
retained O
its O
binding O
properties O
and O
migrated O
on O
SDS O
- O
polyacrylamide O
gel O
as O
a O
Mr B
28 I
, I
000 I
protein I
. O

Here O
we O
report O
the O
induction O
of O
the O
synthesis O
and O
of O
the O
hydrolytic O
activity O
of O
phospholipase B
C I
gamma I
1 I
( O
PLC B
gamma I
1 I
) O
in O
human O
T O
lymphocytes O
by O
IFN B
- I
beta I
. O

Interestingly O
, O
we O
consistently O
observed O
30 O
% O
less O
RT B
- I
PCR I
product I
derived O
from O
the O
small B
t I
allele I
mRNA I
in O
steady O
state O
, O
a O
finding O
which O
also O
speaks O
against O
a O
higher O
stability O
of O
the O
small B
t I
allele I
mRNA I
. O

Interestingly O
, O
we O
consistently O
observed O
30 O
% O
less O
RT B
- I
PCR I
product I
derived O
from O
the O
small B
t I
allele I
mRNA I
in O
steady O
state O
, O
a O
finding O
which O
also O
speaks O
against O
a O
higher O
stability O
of O
the O
small B
t I
allele I
mRNA I
. O

Interestingly O
, O
we O
consistently O
observed O
30 O
% O
less O
RT B
- I
PCR I
product I
derived O
from O
the O
small B
t I
allele I
mRNA I
in O
steady O
state O
, O
a O
finding O
which O
also O
speaks O
against O
a O
higher O
stability O
of O
the O
small B
t I
allele I
mRNA I
. O

Moreover O
, O
anti B
- I
TNF I
- I
alpha I
inhibited O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
- O
driven O
transcription O
of O
a O
reporter B
gene I
in O
primary O
T O
cells O
in O
response O
to O
activation O
, O
either O
in O
the O
presence O
or O
the O
absence O
of O
HIV B
- I
1 I
Tat I
. O

Our O
results O
support O
an O
important O
role O
for O
autocrine O
TNF B
- I
alpha I
secretion O
in O
controlling O
HIV O
replication O
in O
primary O
T O
cells O
because O
of O
its O
ability O
to O
maintain O
NF B
- I
kappa I
B I
elevated O
in O
the O
nucleus O
of O
T O
cells O
. O

Intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
is O
an O
important O
molecule O
in O
promotion O
of O
polymorphonuclear O
neutrophil O
transendothelial O
migration O
during O
inflammation O
. O

Nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
/ I
Rel I
transcription I
factors I
may O
be O
involved O
in O
atherosclerosis O
, O
as O
is O
suggested O
by O
the O
presence O
of O
activated O
NF B
- I
kappa I
B I
in O
human O
atherosclerotic O
lesions O
. O

This O
activation O
of O
NF B
- I
kappa I
B I
was O
inhibited O
by O
the O
antioxidant O
and O
H2O2 O
scavenger O
pyrrolidine O
dithiocarbamate O
and O
the O
proteasome B
inhibitor O
PSI O
. O

The O
oxLDL B
- O
induced O
NF B
- I
kappa I
B I
activation O
was O
accompanied O
by O
an O
initial O
depletion O
of O
I B
kappa I
B I
- I
alpha I
followed O
by O
a O
slight O
transient O
increase O
in O
the O
level O
of O
this O
inhibitor O
protein O
. O

PURPOSE O
: O
To O
demonstrate O
that O
leukocyte O
adhesion O
to O
cultured O
corneal O
endothelial O
cells O
is O
mediated O
by O
the O
CD18 B
antigen I
, O
and O
to O
determine O
whether O
dexamethasone O
directly O
suppresses O
adhesion O
by O
inhibiting O
activation O
of O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
. O

Restriction O
analysis O
revealed O
that O
neutrophils O
express O
the O
GH B
- I
N I
gene I
but O
not O
the O
GH B
- I
V I
gene I
. O

Restriction O
analysis O
revealed O
that O
neutrophils O
express O
the O
GH B
- I
N I
gene I
but O
not O
the O
GH B
- I
V I
gene I
. O

The O
pp52 B
promoter I
contains O
an O
initiator O
specifying O
the O
unique O
5 B
' I
terminus I
of O
pp52 B
mRNA I
, O
tandem O
pairs O
of O
Ets B
and I
SP1 I
motifs I
, O
and O
a O
lone B
C I
/ I
EBP I
motif I
. O

Like O
the O
class B
II I
genes I
, O
the O
HLA B
- I
DM I
genes I
contain O
upstream O
regulatory O
sequences O
similar O
to O
the O
S B
- I
X I
- I
Y I
regulatory I
region I
as O
well O
as O
additional O
putative O
regulatory O
sites O
. O

In O
addition O
, O
in O
vivo O
footprint O
analysis O
showed O
the O
putative O
X B
and I
Y I
boxes I
to O
be O
occupied O
by O
transcription B
factors I
in O
wild O
- O
type O
B O
cells O
, O
but O
not O
in O
RFX O
- O
deficient O
B O
cells O
. O

In O
a O
previous O
study O
, O
we O
demonstrated O
that O
bufalin O
, O
which O
is O
an O
active O
principle O
of O
Chinese O
medicine O
, O
chan O
' O
su O
, O
caused O
apoptosis O
in O
human O
leukemia O
U937 O
cells O
by O
anomalous O
activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
via O
the O
signaling O
pathway O
of O
Ras B
, O
Raf B
- I
1 I
, O
and O
MAPK B
kinase I
- I
1 I
. O

Decreased O
transcriptional O
activation O
by O
N B
- I
terminal I
deletions I
of O
CIITA B
is O
correlated O
directly O
with O
their O
reduced O
binding O
to O
TAFII32 B
. O

Ligand O
binding O
and O
activation O
of O
the O
IL B
- I
10 I
receptor I
expressed O
on O
B O
- O
CLL O
cells O
results O
in O
the O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
and O
STAT3 B
proteins O
. O

In O
THP O
- O
1 O
cells O
transfected O
with O
HIV B
plasmid I
constructs I
, O
both O
organisms O
induced O
transcription O
from O
the O
HIV B
long I
terminal I
repeat I
that O
was O
dependent O
on O
intact O
NF B
- I
kappaB I
binding I
sequences I
. O

In O
this O
report O
we O
present O
the O
characterisation O
of O
NF B
- I
kappaB I
subunits I
engaged O
in O
complexes O
binding O
to O
the O
HIV B
- I
1 I
NF I
- I
kappaB I
site I
in O
human O
8e51 O
T O
- O
cells O
, O
that O
harbour O
a O
defective O
HIV O
- O
1 O
. O

In O
fact O
, O
mAb B
L243 I
but O
not O
the O
staphylococcal B
superantigens I
, O
staphylococcal B
exotoxin I
toxic I
shock I
syndrome I
toxin I
- I
I I
or O
staphylococcal B
enterotoxin I
B I
, O
regulate O
the O
NF B
- I
kappa I
B I
binding O
activity O
. O

Moreover O
, O
electrophoretic O
mobility O
shift O
assays O
demonstrated O
that O
CMV O
induced O
the O
formation O
of O
NF B
- I
kappaB I
and O
AP B
- I
1 I
complexes I
. O

This O
presents O
several O
problems O
in O
vectors O
, O
particularly O
those O
in O
which O
additional O
genes O
, O
either O
a O
co B
- I
stimulatory I
gene I
or O
a O
selectable O
marker O
, O
are O
inserted O
. O

Activation O
and O
regulation O
of O
NF B
- I
kappa I
B I
are O
tightly O
controlled O
by O
a O
group O
of O
inhibitory B
proteins I
( O
I B
kappa I
B I
) O
that O
sequester O
NF B
- I
kappa I
B I
in O
the O
cytoplasm O
of O
immune O
/ O
inflammatory O
effector O
cells O
. O

Activation O
and O
regulation O
of O
NF B
- I
kappa I
B I
are O
tightly O
controlled O
by O
a O
group O
of O
inhibitory B
proteins I
( O
I B
kappa I
B I
) O
that O
sequester O
NF B
- I
kappa I
B I
in O
the O
cytoplasm O
of O
immune O
/ O
inflammatory O
effector O
cells O
. O

Liberated O
NF B
- I
kappa I
B I
migrates O
to O
the O
nucleus O
, O
where O
it O
binds O
to O
specific B
promoter I
sites I
and O
activates O
gene O
transcription O
. O

C B
/ I
EBPepsilon I
mRNA I
was O
greatly O
induced O
during O
in O
vitro O
granulocytic O
differentiation O
of O
human O
primary O
CD34 O
( O
+ O
) O
cells O
. O

One O
of O
them O
, O
hT86 O
, O
encoding O
a O
putative B
zinc I
finger I
protein I
was O
found O
to O
derepress O
beta B
- I
galactosidase I
activity O
in O
the O
Oct B
- I
2 I
- O
harboring O
tester O
strain O
at O
the O
transcriptional O
level O
. O

Functional O
analysis O
of O
monocytic O
THP O
- O
1 O
cells O
transfected O
with O
plasmids B
containing O
various O
lengths O
of O
TNF B
- I
alpha I
promoter I
localized O
enhancer B
elements I
in O
a O
region O
( O
- B
182 I
to I
- I
37 I
base I
pairs I
( O
bp O
) O
) O
that O
were O
required O
for O
optimal O
transcription O
of O
the O
TNF B
- I
alpha I
gene I
in O
response O
to O
LPS O
. O

Functional O
analysis O
of O
monocytic O
THP O
- O
1 O
cells O
transfected O
with O
plasmids B
containing O
various O
lengths O
of O
TNF B
- I
alpha I
promoter I
localized O
enhancer B
elements I
in O
a O
region O
( O
- B
182 I
to I
- I
37 I
base I
pairs I
( O
bp O
) O
) O
that O
were O
required O
for O
optimal O
transcription O
of O
the O
TNF B
- I
alpha I
gene I
in O
response O
to O
LPS O
. O

In O
unstimulated O
THP O
- O
1 O
, O
CRE B
- I
binding I
protein I
and O
, O
to O
a O
lesser O
extent O
, O
c B
- I
Jun I
complexes I
were O
found O
to O
bind O
to O
the O
CRE B
site I
. O

In O
unstimulated O
THP O
- O
1 O
, O
CRE B
- I
binding I
protein I
and O
, O
to O
a O
lesser O
extent O
, O
c B
- I
Jun I
complexes I
were O
found O
to O
bind O
to O
the O
CRE B
site I
. O

The O
CRE B
and I
kappaB3 I
sites I
in O
region B
II I
together O
conferred O
strong O
LPS O
responsiveness O
to O
a O
heterologous B
promoter I
, O
whereas O
individually O
they O
failed O
to O
provide O
transcriptional O
activation O
. O

Furthermore O
, O
increasing O
the O
spacing O
between O
the O
CRE B
and I
the I
kappaB3 I
sites I
completely O
abolished O
LPS O
induction O
, O
suggesting O
a O
cooperative O
interaction O
between O
c B
- I
Jun I
complexes I
and O
p50 B
/ I
p65 I
. O

The O
other O
, O
CIITA B
, O
encodes O
a O
large O
protein O
with O
a O
defined O
acidic B
transcriptional I
activation I
domain I
; O
this O
protein O
does O
not O
interact O
with O
DNA O
. O

Phosphatidylinositol B
3 I
- I
kinase I
( O
PI3 B
- I
K I
) O
has O
been O
implicated O
in O
the O
regulation O
of O
cell O
proliferation O
in O
many O
cell O
types O
. O

The O
resulting O
fusion B
genes I
encode O
the O
two O
structurally O
unique O
PML B
/ I
RARalpha I
and O
RARalpha B
/ I
PML I
fusion I
proteins I
as O
well O
as O
aberrant B
PML I
gene I
products I
, O
the O
respective O
pathogenetic O
roles O
of O
which O
have O
not O
been O
elucidated O
. O

This O
suggests O
that O
CHEMR1 B
may O
be O
a O
receptor O
for O
unidentified O
C B
- I
C I
chemokine I
or O
a O
low O
- O
affinity O
receptor O
for O
MIP B
- I
1alpha I
. O

Its O
N B
- I
terminal I
region I
is O
capable O
of O
activating O
transcription O
from O
a O
reporter O
gene O
when O
fused O
to O
a O
DNA B
binding I
domain I
. O

In O
this O
study O
, O
a O
combined O
pharmacologic O
and O
genetic O
strategy O
using O
two O
PKC B
( O
NF B
- I
kappa I
B I
) O
inhibitors O
, O
pentoxifylline O
( O
PTX O
) O
and O
Go O
- O
6976 O
, O
and O
a O
stably O
expressed O
anti B
- I
Tat I
single I
- I
chain I
intracellular I
antibody I
( O
sFv B
intrabody I
) O
was O
employed O
to O
obtain O
cooperative O
inhibition O
of O
both O
HIV O
- O
1 O
LTR B
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

Treatment O
of O
cells O
with O
PTX O
and O
Go O
- O
6976 O
resulted O
in O
cooperative O
inhibition O
of O
both O
HIV B
- I
1 I
LTR I
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

The O
combined O
treatment O
resulted O
in O
more O
durable O
inhibition O
of O
HIV O
- O
1 O
replication O
than O
was O
seen O
with O
the O
NF B
- I
kappa I
B I
inhibitors O
alone O
or O
the O
anti O
- O
Tat B
sFv I
intrabodies I
alone O
. O

Also O
in O
the O
current O
study O
, O
binding O
activity O
to O
the O
CD28RE B
/ I
AP I
- I
1 I
sequence I
of O
the O
IL B
- I
2 I
promoter I
is O
evaluated O
. O

These O
data O
indicate O
that O
functional O
complexes O
encompassing O
both O
the O
CD28RE B
and O
the O
AP B
- I
1 I
- I
binding I
sites I
influence O
IL B
- I
2 I
promoter I
activity O
in O
CD28 B
- O
costimulated O
T O
cells O
. O

Patients O
with O
one O
type O
of O
major B
histocompatibility I
complex I
class I
II I
combined O
immunodeficiency O
have O
mutations O
in O
a O
gene O
termed O
class B
II I
transactivator I
( O
CIITA B
) O
, O
which O
coordinately O
controls O
the O
transcription O
of O
the O
three O
major O
human B
class I
II I
genes I
, O
HLA B
- I
DR I
, I
- I
DQ I
, I
and I
- I
DP I
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

After O
4 O
hours O
, O
IL B
- I
1 I
beta I
and O
IL B
- I
8 I
concentration O
of O
the O
cell O
- O
free O
supernatant O
had O
increased O
by O
268 O
+ O
/ O
- O
36 O
% O
and O
210 O
+ O
/ O
- O
7 O
% O
, O
respectively O
, O
and O
cellular O
MCP B
- I
1 I
content O
had O
increased O
by O
170 O
+ O
/ O
- O
8 O
% O
. O

Triggering O
of O
HLA B
class I
II I
antigens I
by O
the O
anti B
- I
HLA I
- I
DR I
monoclonal I
antibody I
( I
mAb I
) I
L243 I
significantly O
( O
P O
< O
0 O
. O
05 O
) O
and O
differentially O
enhanced O
the O
release O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
by O
the O
non O
- O
Hodgkin O
' O
s O
lymphoma O
cells O
Ri O
- O
I O
, O
Ci O
- O
I O
, O
and O
Sc O
- O
I O
, O
which O
are O
at O
a O
distinct O
stage O
of O
B O
- O
cell O
differentiation O
, O
and O
by O
the O
more O
mature O
Burkitt O
lymphoma O
cell O
Raji O
; O
in O
contrast O
, O
it O
did O
not O
induce O
TNF B
- I

Triggering O
of O
HLA B
class I
II I
antigens I
by O
the O
anti B
- I
HLA I
- I
DR I
monoclonal I
antibody I
( I
mAb I
) I
L243 I
significantly O
( O
P O
< O
0 O
. O
05 O
) O
and O
differentially O
enhanced O
the O
release O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
by O
the O
non O
- O
Hodgkin O
' O
s O
lymphoma O
cells O
Ri O
- O
I O
, O
Ci O
- O
I O
, O
and O
Sc O
- O
I O
, O
which O
are O
at O
a O
distinct O
stage O
of O
B O
- O
cell O
differentiation O
, O
and O
by O
the O
more O
mature O
Burkitt O
lymphoma O
cell O
Raji O
; O
in O
contrast O
, O
it O
did O
not O
induce O
TNF B
- I

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

Cyclosporin O
A O
interferes O
with O
the O
inducible O
degradation O
of O
NF B
- I
kappa I
B I
inhibitors O
, O
but O
not O
with O
the O
processing O
of O
p105 O
/ O
NF B
- I
kappa I
B1 I
in O
T O
cells O
. O

Cyclosporin O
A O
interferes O
with O
the O
inducible O
degradation O
of O
NF B
- I
kappa I
B I
inhibitors O
, O
but O
not O
with O
the O
processing O
of O
p105 O
/ O
NF B
- I
kappa I
B1 I
in O
T O
cells O
. O

Accordingly O
, O
immunoblot O
experiments O
showed O
that O
amongst O
NF B
- I
kappa I
B I
/ B
Rel I
proteins I
, O
RelA B
and O
p50 B
are O
mobilized O
to O
the O
nucleus O
following O
microglial O
cell O
stimulation O
with O
A O
beta O
( O
25 O
- O
35 O
) O
plus O
IFN B
gamma I
. O

Higher O
concentrations O
of O
A O
beta O
( O
25 O
- O
35 O
) O
were O
effective O
by O
themselves O
in O
inducing O
NF B
- I
kappa I
B I
activation O
, O
both O
in O
the O
N9 O
microglial O
cell O
line O
and O
in O
rat O
primary O
microglia O
, O
as O
well O
as O
in O
human O
monocytes O
. O

For O
purposes O
of O
comparison O
, O
microglia O
were O
also O
stimulated O
with O
bacterial O
LPS O
, O
a O
known O
NF B
- I
kappa I
B I
inducer O
. O

As O
expected O
, O
LPS O
strongly O
induced O
the O
formation O
of O
two O
NF B
- I
kappa I
B I
DNA O
- O
binding O
activities O
, O
one O
of O
which O
was O
identified O
as O
RelA B
/ I
p50 I
. O

Collectively O
, O
these O
findings O
indicate O
that O
NF B
- I
kappa I
B I
activation O
might O
constitute O
one O
of O
the O
mechanisms O
underlying O
the O
inducible O
expression O
of O
kappa B
B I
- I
dependent I
genes I
in O
microglia O
stimulated O
by O
A O
beta O
peptides O
and O
IFN B
gamma I
, O
or O
by O
LPS O
. O

The O
serum O
also O
detected O
a O
170 B
- I
kD I
protein I
that O
seems O
to O
be O
a O
mouse O
homologue O
of O
human B
BAF170 I
. O

Chloramphenicol B
acetyltransferase I
expression I
constructs I
containing O
regions O
of O
the O
human B
collagenase I
- I
1 I
promoter I
were O
stably O
or O
transiently O
transfected O
into O
U937 O
cells O
, O
and O
reporter O
activity O
was O
assessed O
at O
various O
times O
after O
the O
onset O
of O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
- O
mediated O
differentiation O
. O

In O
support O
of O
this O
interpretation O
, O
mutation O
of O
putative O
nuclear B
localization I
sequences I
decreased O
nuclear O
localization O
and O
increased O
transcriptional O
activation O
by O
membrane B
- I
bound I
DeltaE I
. O

EMS O
analyses O
utilizing O
a O
series O
of O
mutated B
pp I
repeat I
elements I
demonstrate O
that O
the O
nucleotide O
sequence O
requirements O
for O
U1 B
( O
U1A B
/ I
U1B I
) O
and O
U2 B
formation O
are O
separable O
from O
those O
required O
for O
C1 B
- I
C3 I
formation O
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

The O
two O
AP B
- I
1 I
sites I
bound O
c B
- I
Fos I
/ I
c I
- I
Jun I
heterodimers I
in O
both O
unstimulated O
and O
LPS O
- O
stimulated O
cells O
. O

Inhibitory O
effect O
of O
growth O
hormone O
on O
TNF B
- I
alpha I
secretion O
and O
nuclear B
factor I
- I
kappaB I
translocation O
in O
lipopolysaccharide O
- O
stimulated O
human O
monocytes O
. O

Immunoblot O
and O
flow O
cytometry O
analysis O
revealed O
a O
limited O
proteolysis O
of O
the O
carboxyl B
terminus I
of O
the O
alphaIIb B
subunit I
heavy I
chain I
( O
alphaIIbH B
) O
, O
as O
judged O
by O
the O
disappearance O
of O
the O
epitope O
for O
the O
monoclonal B
antibody I
PMI I
- I
1 I
. O

The O
suppression O
of O
productive O
LAI O
replication O
in O
naive O
T O
cells O
is O
not O
due O
to O
differential O
expression O
of O
viral B
coreceptors I
, O
nor O
is O
it O
due O
to O
inhibition O
of O
activation O
of O
the O
important O
HIV O
transcription B
factors I
, O
nuclear B
factor I
- I
kappaB I
and O
activator B
protein I
- I
1 I
. O

The O
suppression O
of O
productive O
LAI O
replication O
in O
naive O
T O
cells O
is O
not O
due O
to O
differential O
expression O
of O
viral B
coreceptors I
, O
nor O
is O
it O
due O
to O
inhibition O
of O
activation O
of O
the O
important O
HIV O
transcription B
factors I
, O
nuclear B
factor I
- I
kappaB I
and O
activator B
protein I
- I
1 I
. O

In O
earlier O
studies O
, O
we O
have O
identified O
the O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
as O
molecular O
targets O
for O
oxidative O
signalling O
processes O
during O
cell O
cycle O
entry O
, O
and O
have O
shown O
that O
oxidative O
signalling O
is O
involved O
in O
the O
regulation O
of O
early O
changes O
in O
gene O
expression O
during O
the O
G0 O
to O
G1 O
phase O
transition O
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

Through O
activation O
of O
this O
and O
other O
NF B
- I
Y I
driven O
promoters B
, O
the O
Tax1 B
- B
NF I
- I
Y I
interaction O
may O
play O
a O
critical O
role O
in O
causing O
cellular O
transformation O
and O
HTLV O
- O
1 O
pathogenesis O
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human B
G I
- I
CSFR I
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine B
G I
- I
CSFR I
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human B
G I
- I
CSFR I
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine B
G I
- I
CSFR I
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

Using O
a O
mitogenically B
incompetent I
human I
G I
- I
CSFR I
mutant I
in O
which O
Pro639 O
and O
Pro641 O
were O
substituted O
by O
alanine O
, O
the O
box B
1 I
PDP I
motif I
was O
found O
to O
be O
required O
for O
activation O
of O
Jak B
kinases I
, O
tyrosine O
phosphorylation O
of O
the O
G B
- I
CSFR I
, O
and O
recruitment O
of O
Stat B
proteins I
. O

CONCLUSION O
: O
These O
studies O
suggest O
that O
RA O
can O
augment O
IL B
- I
2 I
mRNA I
production O
by O
T O
cells O
with O
a O
possible O
paracrine O
effect O
on O
IL B
- I
2R I
- I
alpha I
expression O
. O

In O
MDMs O
, O
an O
upregulation O
of O
I B
kappa I
B I
alpha I
synthesis O
as O
well O
as O
the O
appearance O
of O
a O
novel O
M O
( O
r O
) O
40 O
, O
000 O
form O
of O
I B
kappa I
B I
alpha I
were O
also O
observed O
. O

In O
MDMs O
, O
an O
upregulation O
of O
I B
kappa I
B I
alpha I
synthesis O
as O
well O
as O
the O
appearance O
of O
a O
novel O
M O
( O
r O
) O
40 O
, O
000 O
form O
of O
I B
kappa I
B I
alpha I
were O
also O
observed O
. O

These O
observations O
suggest O
that O
p65 B
and I
c I
- I
Rel I
complexes I
play O
distinct O
roles O
in O
gene O
expression O
and O
that O
both O
forms O
of O
NF B
- I
kappa I
B I
play O
critical O
roles O
during O
late O
stages O
of O
the O
intrathymic O
maturation O
of O
T O
cells O
. O

The O
function O
of O
LEF B
- I
1 I
is O
dependent O
, O
in O
part O
, O
on O
the O
HMG B
domain I
that O
induces O
a O
sharp O
bend O
in O
the O
DNA O
helix O
, O
and O
on O
an O
activation B
domain I
that O
stimulates O
transcription O
only O
in O
a O
specific O
context O
of O
other O
enhancer B
- I
binding I
proteins I
. O

Overexpression O
of O
ALY B
stimulates O
the O
activity O
of O
the O
TCR B
alpha I
enhancer I
complex I
reconstituted O
in O
transfected O
nonlymphoid O
HeLa O
cells O
, O
whereas O
down O
- O
regulation O
of O
ALY B
by O
anti O
- O
sense O
oligonucleotides O
virtually O
eliminates O
TCR B
alpha I
enhancer I
activity O
in O
T O
cells O
. O

We O
overexpressed O
AML1a B
( O
without O
the O
transcription B
- I
activating I
domain I
) O
and O
AML1b B
( O
with O
the O
domain O
) O
proteins O
in O
K562 O
leukemia O
cells O
, O
which O
can O
be O
induced O
to O
differentiate O
into O
hemoglobin O
- O
producing O
cells O
and O
megakaryocytes O
. O

The O
influence O
of O
the O
anti O
- O
allergy O
agent O
azelastine O
hydrochloride O
( O
Azeptin O
) O
on O
NF B
- I
kappa I
B I
activation O
associated O
with O
the O
generation O
of O
cytokines B
and O
nitric O
oxide O
( O
NO O
) O
was O
investigated O
in O
various O
kinds O
of O
human O
and O
mouse O
cells O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Experimental O
expression O
in O
mice O
and O
spontaneous O
expression O
in O
human O
SLE O
of O
polyomavirus B
T I
- I
antigen I
. O

We O
have O
previously O
demonstrated O
that O
experimental O
expression O
of O
the O
polyomavirus B
transcription I
factor I
T I
- I
antigen I
has O
the O
potential O
to O
induce O
anti B
- I
DNA I
antibodies I
in O
mice O
. O

The O
results O
described O
here O
indicate O
that O
cognate O
interaction O
of O
B O
cells O
recognizing O
DNA O
or O
DNA B
- I
associated I
proteins I
and O
T O
cells O
recognizing O
T B
antigen I
had O
taken O
place O
as O
a O
consequence O
of O
complex O
formation O
between O
T B
ag I
and O
DNA O
in O
vivo O
in O
the O
context O
of O
polyomavirus O
reactivations O
. O

HIV B
- I
1 I
LTR I
transcription O
is O
controlled O
by O
a O
complex O
array O
of O
virus B
- I
encoded I
and I
cellular I
proteins I
. O

GC O
efficiently O
suppressed O
IL B
- I
5 I
synthesis O
of O
T O
- O
cell O
clones O
activated O
via O
either O
T B
- I
cell I
receptor I
( O
TCR B
) O
or O
IL B
- I
2 I
receptor I
( O
IL B
- I
2R I
) O
. O

GC O
efficiently O
suppressed O
IL B
- I
5 I
synthesis O
of O
T O
- O
cell O
clones O
activated O
via O
either O
T B
- I
cell I
receptor I
( O
TCR B
) O
or O
IL B
- I
2 I
receptor I
( O
IL B
- I
2R I
) O
. O

The O
LAZ3 B
/ I
BCL6 I
transcript I
was O
found O
in O
a O
variety O
of O
tissues O
, O
including O
skeletal O
muscle O
, O
peripheral O
blood O
leukocytes O
, O
and O
weakly O
in O
normal O
lymph O
nodes O
. O

Nuclear B
transcription I
factor I
kB I
( O
NF B
- I
kappa I
B I
) O
is O
a O
ubiquitous B
transcription I
factor I
and O
pleiotropic B
regulator I
of O
numerous O
genes O
involved O
in O
the O
immune O
and O
inflammatory O
responses O
. O

Nuclear B
transcription I
factor I
kB I
( O
NF B
- I
kappa I
B I
) O
is O
a O
ubiquitous B
transcription I
factor I
and O
pleiotropic B
regulator I
of O
numerous O
genes O
involved O
in O
the O
immune O
and O
inflammatory O
responses O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

Based O
upon O
work O
from O
our O
laboratory O
, O
we O
propose O
that O
inhibition O
of O
NF B
- I
kappa I
B I
activation O
produces O
significant O
anti O
inflammatory O
activity O
which O
may O
be O
mediated O
by O
the O
inhibition O
of O
transcription O
of O
certain O
pro B
- I
inflammatory I
mediators I
and O
adhesion B
molecules I
. O

Based O
upon O
work O
from O
our O
laboratory O
, O
we O
propose O
that O
inhibition O
of O
NF B
- I
kappa I
B I
activation O
produces O
significant O
anti O
inflammatory O
activity O
which O
may O
be O
mediated O
by O
the O
inhibition O
of O
transcription O
of O
certain O
pro B
- I
inflammatory I
mediators I
and O
adhesion B
molecules I
. O

NF B
- I
kappa I
B I
- O
independent O
suppression O
of O
HIV O
expression O
by O
ascorbic O
acid O
. O

Pretreatment O
of O
ACH O
- O
2 O
T O
cells O
by O
NAC O
followed O
by O
stimulation O
with O
PMA O
, O
TNF B
- I
alpha I
, O
or O
hydrogen O
peroxide O
( O
H2O2 O
) O
resulted O
in O
strong O
suppression O
of O
NF B
- I
kappa I
B I
activation O
. O

These O
results O
suggest O
that O
the O
molecular O
mechanism O
of O
HIV O
inhibition O
by O
ascorbate O
is O
not O
mediated O
via O
NF B
- I
kappa I
B I
inhibition O
, O
unlike O
that O
seen O
with O
other O
antioxidants O
. O

A O
T B
cell I
- I
specific I
enhancer I
in O
the O
interleukin B
- I
3 I
locus I
is O
activated O
cooperatively O
by O
Oct B
and I
NFAT I
elements I
within O
a O
DNase B
I I
- I
hypersensitive I
site I
. O

A O
T B
cell I
- I
specific I
enhancer I
in O
the O
interleukin B
- I
3 I
locus I
is O
activated O
cooperatively O
by O
Oct B
and I
NFAT I
elements I
within O
a O
DNase B
I I
- I
hypersensitive I
site I
. O

We O
suggest O
that O
the O
T O
cell O
- O
specific O
expression O
of O
the O
IL B
- I
3 I
gene I
is O
partly O
controlled O
through O
the O
enhancer O
by O
cooperation O
between O
Oct B
and I
NFAT I
family I
proteins I
. O

The O
adenovirus B
E1B I
19K I
gene I
plays O
an O
essential O
role O
in O
transformation O
of O
primary O
rodent O
cells O
in O
cooperation O
with O
E1A B
and O
in O
the O
inhibition O
of O
apoptosis O
during O
lytic O
infection O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

CONCLUSIONS O
: O
Our O
results O
establish O
that O
PI B
3 I
- I
kinase I
can O
both O
positively O
and O
negatively O
regulate O
T O
- O
cell O
function O
, O
and O
uncover O
a O
previously O
unrecognized O
function O
for O
PI B
3 I
- I
kinase I
in O
T O
cells O
as O
a O
selective O
negative O
regulator O
of O
TCR B
- O
signalling O
events O
and O
therefore O
as O
a O
determinant O
of O
T O
- O
cell O
homeostasis O
. O

CONCLUSIONS O
: O
Our O
results O
establish O
that O
PI B
3 I
- I
kinase I
can O
both O
positively O
and O
negatively O
regulate O
T O
- O
cell O
function O
, O
and O
uncover O
a O
previously O
unrecognized O
function O
for O
PI B
3 I
- I
kinase I
in O
T O
cells O
as O
a O
selective O
negative O
regulator O
of O
TCR B
- O
signalling O
events O
and O
therefore O
as O
a O
determinant O
of O
T O
- O
cell O
homeostasis O
. O

The O
two O
related O
protein B
- I
tyrosine I
kinases I
Syk B
and O
Zap B
are O
rapidly O
phosphorylated O
on O
tyrosine O
residues O
and O
enzymatically O
activated O
upon O
crosslinking O
of O
the O
T B
cell I
antigen I
receptor I
. O

The O
two O
related O
protein B
- I
tyrosine I
kinases I
Syk B
and O
Zap B
are O
rapidly O
phosphorylated O
on O
tyrosine O
residues O
and O
enzymatically O
activated O
upon O
crosslinking O
of O
the O
T B
cell I
antigen I
receptor I
. O

Expression O
of O
NFAT B
- I
family I
proteins I
in O
normal O
human O
T O
cells O
. O

Cotransfection O
experiments O
revealed O
that O
both O
hGATA B
- I
4 I
and O
PMA O
/ O
A23187 O
stimulation O
are O
necessary O
for O
the O
IL B
- I
5 I
promoter I
activation O
. O

The O
requirement O
of O
another O
regulatory B
element I
called O
CLE0 B
, O
which O
lies O
downstream O
of O
the O
- B
70 I
GATA I
site I
, O
was O
also O
demonstrated O
. O

The O
electrophoretic O
mobility O
shift O
assay O
with O
extracts O
of O
COS O
cells O
expressing O
GATA B
- I
binding I
proteins I
showed O
that O
GATA B
- I
4 I
has O
the O
highest O
binding O
affinity O
to O
the O
- B
70 I
GATA I
site I
among O
the O
three O
GATA B
- I
binding I
proteins I
. O

The O
electrophoretic O
mobility O
shift O
assay O
with O
extracts O
of O
COS O
cells O
expressing O
GATA B
- I
binding I
proteins I
showed O
that O
GATA B
- I
4 I
has O
the O
highest O
binding O
affinity O
to O
the O
- B
70 I
GATA I
site I
among O
the O
three O
GATA B
- I
binding I
proteins I
. O

The O
electrophoretic O
mobility O
shift O
assay O
with O
extracts O
of O
COS O
cells O
expressing O
GATA B
- I
binding I
proteins I
showed O
that O
GATA B
- I
4 I
has O
the O
highest O
binding O
affinity O
to O
the O
- B
70 I
GATA I
site I
among O
the O
three O
GATA B
- I
binding I
proteins I
. O

These O
results O
demonstrate O
the O
selective O
role O
of O
GATA B
- I
4 I
in O
the O
transcriptional O
regulation O
of O
the O
IL B
- I
5 I
gene I
in O
a O
circumstance O
where O
multiple O
members O
of O
the O
GATA B
- I
binding I
proteins I
are O
expressed O
. O

These O
results O
demonstrate O
the O
selective O
role O
of O
GATA B
- I
4 I
in O
the O
transcriptional O
regulation O
of O
the O
IL B
- I
5 I
gene I
in O
a O
circumstance O
where O
multiple O
members O
of O
the O
GATA B
- I
binding I
proteins I
are O
expressed O
. O

We O
found O
that O
NFATx1 B
DNA O
binding O
activity O
and O
interaction O
with O
AP O
- O
1 O
polypeptides O
were O
dependent O
on O
its O
central B
Rel I
similarity I
region I
and O
that O
transcriptional O
activation O
was O
reduced O
by O
deletions O
of O
either O
its O
N B
- I
terminal I
domain I
or O
its O
C B
- I
terminal I
domain I
, O
suggesting O
the O
presence O
of O
intrinsic B
transcriptional I
activation I
motifs I
in O
both O
regions O
. O

We O
found O
that O
NFATx1 B
DNA O
binding O
activity O
and O
interaction O
with O
AP O
- O
1 O
polypeptides O
were O
dependent O
on O
its O
central B
Rel I
similarity I
region I
and O
that O
transcriptional O
activation O
was O
reduced O
by O
deletions O
of O
either O
its O
N B
- I
terminal I
domain I
or O
its O
C B
- I
terminal I
domain I
, O
suggesting O
the O
presence O
of O
intrinsic B
transcriptional I
activation I
motifs I
in O
both O
regions O
. O

We O
found O
that O
NFATx1 B
DNA O
binding O
activity O
and O
interaction O
with O
AP O
- O
1 O
polypeptides O
were O
dependent O
on O
its O
central B
Rel I
similarity I
region I
and O
that O
transcriptional O
activation O
was O
reduced O
by O
deletions O
of O
either O
its O
N B
- I
terminal I
domain I
or O
its O
C B
- I
terminal I
domain I
, O
suggesting O
the O
presence O
of O
intrinsic B
transcriptional I
activation I
motifs I
in O
both O
regions O
. O

We O
found O
that O
NFATx1 B
DNA O
binding O
activity O
and O
interaction O
with O
AP O
- O
1 O
polypeptides O
were O
dependent O
on O
its O
central B
Rel I
similarity I
region I
and O
that O
transcriptional O
activation O
was O
reduced O
by O
deletions O
of O
either O
its O
N B
- I
terminal I
domain I
or O
its O
C B
- I
terminal I
domain I
, O
suggesting O
the O
presence O
of O
intrinsic B
transcriptional I
activation I
motifs I
in O
both O
regions O
. O

This O
cis B
element I
binds O
a O
protein O
complex O
referred O
to O
as O
HRF B
( O
heme B
- I
responsive I
factor I
) O
, O
which O
is O
greatly O
enhanced O
both O
in O
heme O
- O
treated O
FLCs O
and O
during O
monocyte O
- O
to O
- O
macrophage O
differentiation O
. O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig B
gene I
class I
switch O
recombination O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig B
gene I
class I
switch O
recombination O

Rap1 B
is O
a O
small O
, O
Ras B
- I
like I
GTPase I
whose O
function O
and O
regulation O
are O
still O
largely O
unknown O
. O

The O
E1A B
and I
hexon I
primers I
amplified O
DNA O
from O
representative O
adenoviral O
serotypes O
in O
all O
six O
adenoviral O
groups O
( O
A O
- O
F O
) O
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

The O
DNA B
- I
binding I
domain I
( O
amino B
acids I
421 I
- I
486 I
) O
is O
completely O
conserved O
among O
human B
, I
squirrel I
monkey I
, I
owl I
monkey I
, I
and I
cotton I
- I
top I
tamarin I
receptors I
. O

These O
observations O
suggest O
the O
functional O
importance O
of O
gamma B
( I
c I
) I
in O
the O
IL B
- I
7R I
complex I
. O

These O
observations O
suggest O
the O
functional O
importance O
of O
gamma B
( I
c I
) I
in O
the O
IL B
- I
7R I
complex I
. O

In O
this O
study O
we O
determined O
the O
effects O
of O
SAC O
on O
NF B
- I
kappa I
B I
activation O
in O
human O
T O
lymphocytes O
( O
Jurkat O
cells O
) O
induced O
by O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
and O
H2O2 O
. O

In O
this O
study O
we O
determined O
the O
effects O
of O
SAC O
on O
NF B
- I
kappa I
B I
activation O
in O
human O
T O
lymphocytes O
( O
Jurkat O
cells O
) O
induced O
by O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
and O
H2O2 O
. O

By O
screening O
a O
T O
cell O
cDNA B
library I
, O
we O
identified O
a O
novel B
ets I
transcription I
factor I
that O
binds O
RBTN B
- I
2 I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
and O
AP B
- I
1 I
are O
insufficient O
for O
IL B
- I
2 I
promoter I
activation O
: O
requirement O
for O
CD28 B
up O
- O
regulation O
of O
RE B
/ I
AP I
. O

Deregulated O
TCR B
- O
mediated O
responses O
and O
the O
fast O
kinetics O
of O
tumor O
development O
in O
these O
mutant O
thymocytes O
implicate O
Ikaros O
as O
a O
central B
tumor I
suppressor I
gene I
for O
the O
T O
cell O
lineage O
. O

In O
particular O
, O
TRAF6 B
interacted O
with O
membrane B
- I
proximal I
determinants I
distinct O
from O
those O
binding O
TRAFs B
1 I
, I
2 I
, I
3 I
, I
and I
5 I
. O

The O
molecular O
mechanisms O
by O
which O
IL B
- I
4 I
induces O
expression O
of O
the O
IL B
- I
4 I
gene I
are O
not O
known O
, O
although O
the O
IL B
- I
4 I
- I
activated I
transcription I
factor I
signal I
transducer I
and I
activator I
of I
transcription I
6 I
( O
Stat6 B
) O
is O
required O
for O
this O
effect O
. O

A O
novel O
transcription B
factor I
regulates O
expression O
of O
the O
vacuolar B
H I
+ I
- I
ATPase I
B2 I
subunit I
through O
AP B
- I
2 I
sites I
during O
monocytic O
differentiation O
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP B
- I
2 I
response I
elements I
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP B
- I
2 I
antibodies I
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

Time O
- O
course O
experiments O
showed O
that O
nuclear O
levels O
of O
GATA B
- I
1 I
and O
p45 B
NF I
- I
E2 I
proteins O
increased O
during O
BA O
treatment O
. O

NLS B
peptide O
- O
mediated O
disruption O
of O
the O
nuclear O
import O
of O
these O
transcription B
factors I
results O
in O
inhibition O
of O
I O
kappa O
B O
alpha O
and O
IL O
- O
2 O
gene O
expression O
, O
processes O
dependent O
on O
NF B
- I
kappa I
B I
or O
the O
combination O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
and O
NFAT B
. O

NLS B
peptide O
- O
mediated O
disruption O
of O
the O
nuclear O
import O
of O
these O
transcription B
factors I
results O
in O
inhibition O
of O
I O
kappa O
B O
alpha O
and O
IL O
- O
2 O
gene O
expression O
, O
processes O
dependent O
on O
NF B
- I
kappa I
B I
or O
the O
combination O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
and O
NFAT B
. O

Further O
, O
we O
show O
that O
inhibitory O
NLS B
peptide O
interacts O
in O
vitro O
with O
a O
cytoplasmic B
NLS I
receptor I
complex I
comprised O
of O
the O
Rch1 B
/ I
importin I
( I
karyopherin I
) I
- I
beta I
heterodimer I
expressed O
in O
Jurkat O
T O
cells O
. O

Quantitative O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
showed O
an O
increase O
in O
steady O
- O
state O
TNF B
- I
alpha I
mRNA I
after O
3 O
to O
4 O
hours O
of O
cross O
- O
linking O
. O

In O
the O
present O
report O
we O
show O
that O
in O
various O
transiently O
or O
stably O
transfected O
cell O
lines O
, O
X O
- O
ray O
irradiation O
up O
- O
regulates O
HIV B
- I
1 I
LTR I
transcription O
through O
the O
kappaB B
regulatory I
elements I
. O

In O
addition O
, O
X O
- O
ray O
activation O
of O
HIV B
- I
1 I
LTR I
in O
transiently O
or O
stably O
transfected O
cell O
lines O
is O
inhibited O
by O
a O
potent O
antioxidant O
drug O
, O
pyrrolidine O
dithiocarbamate O
and O
by O
another O
drug O
, O
known O
for O
its O
role O
in O
the O
trapping O
of O
growth B
factors I
, O
suramin O
. O

Nuclear B
factor I
- I
kappaB I
was O
found O
to O
be O
activated O
in O
ventilated O
macrophages O
. O

Evidence O
suggests O
that O
IL B
- I
10 I
may O
inhibit O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
through O
an O
unknown O
mechanism O
. O

Therefore O
in O
this O
study O
, O
we O
have O
examined O
the O
role O
of O
glucocorticoid B
receptor I
/ I
s I
( O
GR B
) O
characteristics O
in O
the O
developing O
of O
these O
abnormalities O
in O
patients O
with O
PCOS O
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

In O
order O
to O
investigate O
the O
factors O
that O
influence O
the O
induction O
of O
ICAM B
- I
1 I
molecules O
, O
Northern O
blot O
analysis O
to O
measure O
the O
expression O
level O
of O
ICAM B
- I
1 I
mRNAs I
and O
Southern O
blot O
hybridization O
to O
analyze O
the O
integration O
of O
human O
T O
- O
cell O
- O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
provirus O
were O
done O
. O

Furthermore O
, O
analysis O
with O
cloned O
CD8 O
+ O
T O
cells O
indicated O
that O
G75 O
and O
G76 O
were O
not O
cross O
- O
reactive O
specificities O
, O
suggesting O
a O
key O
role O
for O
the O
N B
- I
terminal I
residues I
of O
the O
variant O
peptide O
in O
dictating O
specificities O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
and O
transforming B
growth I
factor I
beta I
( O
TGF B
- I
beta I
) O
are O
inhibitory O
for O
B O
and O
T O
cells O
, O
IgE B
production O
, O
and O
mast O
cell O
proliferation O
, O
and O
they O
induce O
apoptosis O
in O
eosinophils O
. O

The O
IL B
- I
10 I
gene O
polymorphism O
was O
a O
C O
- O
to O
- O
A O
exchange O
571 B
base I
pairs I
upstream I
from O
the O
translation B
start I
site I
and O
was O
present O
between O
consensus B
binding I
sequences I
for O
Sp1 B
and O
elevated O
total O
serum O
. O

However O
, O
it O
was O
only O
the O
IL B
- I
2 I
promoter I
whose O
activation O
by O
Tpl B
- I
2 I
was O
fully O
blocked O
by O
the O
dominant B
negative I
mutant I
MEK1S218 I
/ I
222A I
and O
the O
MEK1 O
/ O
MEK2 O
inhibitor O
PD098059 O
. O

We O
investigated O
the O
function O
of O
the O
evolutionary O
conserved O
X2 B
box I
in O
the O
promoter B
of O
the O
HLA B
- I
DRA I
gene I
from O
the O
human B
major I
histocompatibility I
complex I
( O
MHC B
) O
in O
resting O
and O
activated O
B O
cells O
. O

We O
investigated O
the O
function O
of O
the O
evolutionary O
conserved O
X2 B
box I
in O
the O
promoter B
of O
the O
HLA B
- I
DRA I
gene I
from O
the O
human B
major I
histocompatibility I
complex I
( O
MHC B
) O
in O
resting O
and O
activated O
B O
cells O
. O

Effect O
of O
environmental O
estrogens O
on O
IL B
- I
1beta I
promoter I
activity O
in O
a O
macrophage O
cell O
line O
. O

17beta O
- O
estradiol O
( O
E2 O
) O
markedly O
enhanced O
lipopolysaccharide O
- O
( O
LPS O
) O
induced O
IL B
- I
1beta I
promoter I
- O
driven O
CAT B
activity O
in O
a O
dose O
- O
dependent O
manner O
. O

Unlike O
the O
mycoestrogens O
, O
none O
of O
the O
compounds O
, O
with O
the O
exception O
of O
genistein O
, O
synergized O
with O
LPS O
to O
enhance O
IL B
- I
1beta I
promoter I
activity O
. O

In O
non O
- O
rheumatoid O
arthritis O
, O
binding O
of O
NF B
- I
kappa I
B I
in O
synovial O
T O
cells O
was O
exclusively O
mediated O
by O
p50 B
/ I
p50 I
homodimers I
. O

In O
non O
- O
rheumatoid O
arthritis O
, O
binding O
of O
NF B
- I
kappa I
B I
in O
synovial O
T O
cells O
was O
exclusively O
mediated O
by O
p50 B
/ I
p50 I
homodimers I
. O

Since O
one O
of O
the O
two O
X B
chromosomes I
is O
randomly O
inactivated O
at O
an O
early O
stage O
of O
female O
embryonic O
development O
, O
X B
- I
linked I
markers I
have O
been O
used O
to O
study O
the O
origin O
and O
development O
of O
various O
neoplastic O
disorders O
in O
affected O
heterozygous O
women O
; O
clonality O
assays O
have O
provided O
a O
useful O
tool O
to O
the O
understanding O
of O
the O
mechanisms O
underlying O
the O
development O
of O
neoplasia O
. O

Further O
characterization O
of O
FKHRL1 B
and O
its O
related O
family O
members O
should O
shed O
light O
on O
the O
transcriptional O
mechanisms O
of O
this O
fork B
head I
gene I
subfamily I
and O
their O
role O
in O
T O
helper O
cell O
differentiation O
and O
regulation O
of O
cell O
growth O
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
the O
- O
300 O
region O
of O
the O
IL B
- I
1beta I
promoter O
, O
which O
contains O
a O
nuclear B
factor I
- I
kappaB I
( I
NF I
- I
kappaB I
) I
binding I
site I
, O
contained O
a O
functional B
RBP I
binding I
site I
. O

Recent O
studies O
, O
however O
, O
demonstrate O
that O
the O
transcribed O
5 B
' I
- I
untranslated I
leader I
region I
( O
5 B
' I
- I
UTR I
) O
also O
contains O
important O
transcriptional B
elements I
. O

In O
contrast O
, O
the O
expression O
pattern O
of O
LOX B
- I
1 I
is O
different O
from O
that O
of O
the O
natural B
killer I
cell I
receptors I
; O
LOX B
- I
1 I
is O
expressed O
in O
vascular O
- O
rich O
organs O
, O
but O
not O
in O
lymphocytes O
. O

These O
results O
demonstrate O
that O
the O
human B
LOX I
- I
1 I
gene I
is O
a O
new O
member O
of O
the O
natural B
killer I
gene I
complex I
with O
a O
unique O
expression O
profile O
. O

In O
this O
report O
, O
we O
describe O
the O
transcriptional O
regulation O
of O
the O
beta B
- I
casein I
gene I
by O
cytokines B
in O
T O
cells O
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 B
. I
3 I
and O
charybdotoxin B
- I
resistant I
components I
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned B
KV I
channels I
expressed O
in O
cell O
lines O
. O

Dexamethasone O
treatment O
completely O
blocked O
12 O
- O
O O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
induction O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
activity O
and O
elicited O
an O
increase O
in O
the O
amount O
of O
immunoreactive B
IkappaB I
alpha I
in O
sensitive O
6TG1 O
. O
1 O
cells O
but O
not O
in O
resistant O
ICR27TK O
. O
3 O
cells O
. O

Intestinal O
epithelial O
cells O
can O
express O
HLA B
class I
II I
antigens I
and O
may O
function O
as O
antigen O
- O
presenting O
cells O
to O
CD4 O
( O
+ O
) O
T O
cells O
within O
the O
intestinal O
mucosa O
. O

As O
NF B
- I
kappa I
B I
is O
a O
critical O
transcription B
factor I
in O
the O
control O
of O
IL B
- I
2 I
expression O
, O
we O
next O
analysed O
its O
nuclear O
translocation O
in O
neonatal O
and O
adult O
T O
cells O
using O
the O
electrophoretic O
mobility O
shift O
assay O
and O
, O
because O
induction O
of O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
is O
required O
for O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
we O
also O
analysed O
levels O
of O
intracellular O
ROI O
in O
these O
cells O
using O
the O
ROI O
- O
reactive O
fluorochrome O
DCFH O
- O
DA O
and O
flow O
cytometry O
. O

As O
NF B
- I
kappa I
B I
is O
a O
critical O
transcription B
factor I
in O
the O
control O
of O
IL B
- I
2 I
expression O
, O
we O
next O
analysed O
its O
nuclear O
translocation O
in O
neonatal O
and O
adult O
T O
cells O
using O
the O
electrophoretic O
mobility O
shift O
assay O
and O
, O
because O
induction O
of O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
is O
required O
for O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
we O
also O
analysed O
levels O
of O
intracellular O
ROI O
in O
these O
cells O
using O
the O
ROI O
- O
reactive O
fluorochrome O
DCFH O
- O
DA O
and O
flow O
cytometry O
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

Electrophoretic O
mobility O
shift O
assay O
of O
protein O
extracts O
from O
shock O
lungs O
exhibited O
an O
increase O
in O
Stat3 B
activation O
with O
kinetics O
similar O
to O
IL B
- I
6 I
mRNA I
. O

The O
MHC B
class I
II I
transactivator I
( O
CIITA B
) O
requires O
conserved O
leucine B
charged I
domains I
for O
interactions O
with O
the O
conserved O
W B
box I
promoter I
element I
. O

The O
MHC B
class I
II I
transactivator I
( O
CIITA B
) O
requires O
conserved O
leucine B
charged I
domains I
for O
interactions O
with O
the O
conserved O
W B
box I
promoter I
element I
. O

Correlations O
of O
TCRzeta B
or O
p56 B
( I
lck I
) I
levels O
with O
response O
or O
disease O
variables O
, O
except O
for O
lower O
TCRzeta B
levels O
( O
P O
< O
0 O
. O
001 O
) O
in O
the O
presence O
of O
bone O
metastases O
, O
were O
not O
found O
. O

In O
the O
majority O
of O
patients O
with O
advanced O
RCC O
, O
peripheral O
blood O
T O
cells O
express O
TCRzeta B
and O
p56 B
( I
lck I
) I
, O
and O
in O
a O
subset O
, O
reduced O
levels O
of O
these O
TCRzeta B
associated I
molecules I
are O
seen O
that O
may O
increase O
during O
cytokine B
- O
based O
therapy O
. O

In O
addition O
, O
Tax B
also O
stimulates O
the O
transcription O
of O
the O
E2F B
- I
1 I
gene I
itself O
. O

Moreover O
, O
neither O
TCR B
or O
Ras B
activation O
of O
AP B
- I
1 I
is O
dependent O
on O
PtdIns B
3 I
- I
kinase I
. O

The O
present O
data O
thus O
highlight O
that O
PtdIns B
3 I
- I
kinase I
and O
Akt B
/ I
PKB I
are O
not O
universal O
Ras B
effector I
molecules I
. O

The O
Fy O
( O
a O
- O
b O
- O
) O
phenotype O
has O
been O
associated O
with O
a O
mutation O
in O
the O
FY B
* I
B I
promoter I
at O
the O
GATA B
box I
that O
abolishes O
the O
expression O
of O
erythrocyte B
Duffy I
protein I
. O

Expression O
of O
the O
IL B
- I
2 I
gene I
requires O
activation O
of O
T O
cells O
through O
stimulation O
of O
the O
TCR B
and O
costimulation O
through O
accessory B
receptors I
. O

In O
this O
study O
, O
we O
analyzed O
whether O
activities O
of O
these O
phosphatases O
are O
necessary O
for O
the O
expression O
of O
the O
IL B
- I
2 I
gene I
. O

The O
transcription B
factors I
active O
at O
the O
IL B
- I
2 I
promoter I
were O
differentially O
influenced O
: O
upon O
down O
- O
modulation O
of O
okadaic B
acid I
- I
sensitive I
phosphatases I
, O
transactivation O
by O
octamer O
, O
NF B
- I
kappa I
B I
, O
and O
NF B
of I
activated I
T I
cells I
proteins I
was O
abrogated O
, O
while O
transactivation O
by O
AP B
- I
1 I
proteins I
was I
even I
enhanced I
. I

The O
transcription B
factors I
active O
at O
the O
IL B
- I
2 I
promoter I
were O
differentially O
influenced O
: O
upon O
down O
- O
modulation O
of O
okadaic B
acid I
- I
sensitive I
phosphatases I
, O
transactivation O
by O
octamer O
, O
NF B
- I
kappa I
B I
, O
and O
NF B
of I
activated I
T I
cells I
proteins I
was O
abrogated O
, O
while O
transactivation O
by O
AP B
- I
1 I
proteins I
was I
even I
enhanced I
. I

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
bis O
[ O
4 O
- O
[ O
2 O
, O
4 O
- O
dioxo O
- O
5 O
- O
thiazolidinyl O
) O
methyl O
] O
phenyl O
] O
methane O
( O
YM O
- O
268 O
) O
, O
a O
thiazolidinedione O
derivative O
, O
on O
glucose O
uptake O
, O
adipocyte O
differentiation O
through O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
and O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
activity O
in O
cultured O
cells O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
bis O
[ O
4 O
- O
[ O
2 O
, O
4 O
- O
dioxo O
- O
5 O
- O
thiazolidinyl O
) O
methyl O
] O
phenyl O
] O
methane O
( O
YM O
- O
268 O
) O
, O
a O
thiazolidinedione O
derivative O
, O
on O
glucose O
uptake O
, O
adipocyte O
differentiation O
through O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
and O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
activity O
in O
cultured O
cells O
. O

Although O
common O
members O
of O
the O
apoptotic O
cascade O
are O
shared O
between O
different O
cell O
types O
, O
it O
appears O
that O
cell B
- I
specific I
factors I
can O
influence O
the O
response O
to O
a O
given O
apoptotic O
stimuli O
. O

alpha B
- I
IFN I
causes O
dephosphorylation O
of O
pRb B
and O
loss O
of O
p130 B
phosphorylated I
Form I
3 I
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

Northern O
blot O
analysis O
of O
L132 O
cells O
transfected O
with O
the O
C B
/ I
EBP I
alpha I
expression O
vector O
demonstrate O
that O
C B
/ I
EBP I
alpha I
is O
sufficient O
to O
enhance O
MRP14 B
expression O
in O
the O
context O
of O
the O
whole O
genome O
. O

Northern O
blot O
analysis O
of O
L132 O
cells O
transfected O
with O
the O
C B
/ I
EBP I
alpha I
expression O
vector O
demonstrate O
that O
C B
/ I
EBP I
alpha I
is O
sufficient O
to O
enhance O
MRP14 B
expression O
in O
the O
context O
of O
the O
whole O
genome O
. O

This O
pathway O
resulted O
in O
the O
induction O
of O
the O
transcription B
factors I
NF B
- I
kappa I
B I
, O
NF B
- I
AT I
, O
and O
proteins O
binding O
to O
the O
CD28 B
response O
element O
of O
the O
IL B
- I
2 I
promoter I
. O

This O
pathway O
resulted O
in O
the O
induction O
of O
the O
transcription B
factors I
NF B
- I
kappa I
B I
, O
NF B
- I
AT I
, O
and O
proteins O
binding O
to O
the O
CD28 B
response O
element O
of O
the O
IL B
- I
2 I
promoter I
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 B
. I
3 I
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 B
. I
3 I
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

IL B
- I
12 I
is O
a O
75 B
- I
kDa I
heterodimeric I
cytokine I
composed O
of O
two O
covalently O
linked O
p35 B
and I
p40 I
chains I
. O

This O
was O
associated O
with O
the O
down O
- O
regulation O
of O
IL B
- I
12p40 I
mRNA I
expression O
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated B
beta I
gene I
promoter I
, O
indicating O
the O
presence O
of O
a O
positive B
transcriptional I
element I
( O
s O
) O
in O
the O
upstream B
delta I
globin I
regulatory I
region I
. O

Expression O
of O
either O
BZLF1 B
or O
BRLF1 B
triggers O
expression O
of O
the O
other O
immediate B
- I
early I
factor I
, O
and O
together O
these O
activators O
act O
individually O
or O
in O
synergy O
on O
downstream B
targets I
to O
activate O
the O
viral O
lytic O
cycle O
. O

We O
first O
demonstrate O
, O
in O
human O
and O
mouse O
intraspecies O
hybrids O
, O
the O
coordinate O
suppression O
of O
MHC B
class I
II I
, O
Ii B
( O
invariant B
chain I
) O
and O
HLA B
- I
DM I
gene I
transcription O
, O
and O
the O
release O
of O
the O
silencing O
by O
the O
addition O
of O
interferon B
gamma I
. O

Since O
the O
inhibition O
of O
Ca2 O
+ O
redistribution O
by O
an O
inhibitor O
of O
intracellular O
Ca2 O
+ O
mobilization O
, O
8 O
- O
( O
diethylamino O
) O
- O
octyl O
- O
3 O
, O
4 O
, O
5 O
- O
trimethoxybenzoate O
hydrochloride O
, O
inhibited O
TCR B
- I
induced I
FasL I
but O
not O
Fas B
, O
the O
expression O
of O
Fas B
appears O
to O
be O
independent O
of O
Ca2 O
+ O
mobilization O
. O

Administration O
of O
the O
cytokine B
interleukin I
- I
2 I
( O
IL B
- I
2 I
) O
can O
result O
in O
therapeutic O
benefits O
for O
individuals O
with O
renal O
cell O
carcinoma O
and O
melanoma O
. O

RXR B
, O
RAR B
, O
and O
c B
- I
erbA I
/ I
TR I
- O
specific O
ligands O
were O
found O
to O
induce O
erythroid B
- I
specific I
gene I
expression O
and O
to O
accelerate O
erythroid O
differentiation O
in O
culture O
, O
with O
T3 O
being O
most O
effective O
. O

This O
observation O
was O
made O
despite O
normal O
cytoplasmic O
levels O
of O
the O
Rel B
- I
A I
protein I
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

The O
activation O
of O
NF B
- I
kappaB I
has O
been O
recognized O
to O
regulate O
a O
number O
of O
genes O
necessary O
for O
normal O
T O
cell O
responses O
including O
IL B
- I
2 I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
and O
several O
T B
cell I
surface I
receptors I
. O

SLP B
- I
76 I
was O
not O
required O
for O
TCR B
- O
induced O
tyrosine O
phosphorylation O
of O
most O
proteins O
, O
but O
was O
required O
for O
optimal O
tyrosine O
phosphorylation O
and O
activation O
of O
phospholipase B
C I
- I
gamma1 I
( O
PLC B
- I
gamma1 I
) O
, O
as O
well O
as O
Ras B
pathway O
activation O
. O

Thus O
, O
coupling O
of O
TCR B
- I
regulated I
PTKs I
to O
downstream O
signaling O
pathways O
requires O
SLP B
- I
76 I
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated B
Stat I
- I
3 I
protein I
associates O
with O
the O
human B
serum I
- I
inducible I
element I
( I
hSIE I
) I
DNA I
- I
probe I
derived O
from O
the O
interferon B
- I
gamma I
activated I
site I
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

We O
further O
demonstrate O
that O
0 O
. O
1 O
- O
0 O
. O
5 O
microM O
DMDTC O
inhibits O
intracellular O
IL B
- I
2 I
production O
and O
decreases O
surface O
expression O
of O
CD25 B
( O
the O
alpha B
subunit I
of O
the O
IL B
- I
2 I
receptor I
) O
in O
T O
cells O
stimulated O
with O
phorbol O
ester O
. O

To O
determine O
whether O
the O
acquisition O
of O
antitumor O
function O
during O
ex O
vivo O
activation O
is O
associated O
with O
modifications O
in O
signal O
transduction O
capacity O
, O
the O
protein O
tyrosine B
kinases I
p56lck B
and O
p59fyn B
and O
proteins O
of O
the O
NF B
- I
kappaB I
family I
were O
analyzed O
in O
tumor O
- O
draining O
LN O
T O
cells O
. O

In O
contrast O
, O
the O
cytoplasmic O
levels O
of O
c B
- I
Rel I
and O
Rel B
A I
were O
normal O
in O
freshly O
isolated O
tumor O
- O
draining O
LN O
, O
as O
was O
nuclear O
kappaB B
DNA O
- O
binding O
activity O
induced O
by O
anti B
- I
CD3 I
mAb I
or O
phorbol O
myristate O
acetate O
. O

BACKGROUND O
: O
The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multifunctional I
domain I
protein I
that O
acts O
as O
a O
transcriptional B
activator I
and O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

IL B
- I
3 I
, O
IL B
- I
4 I
, O
and O
IL B
- I
5 I
independently O
up O
- O
regulated O
TGF B
- I
beta1 I
mRNA I
and O
product O
expression O
by O
eosinophils O
in O
all O
donors O
. O

A O
recent O
study O
showed O
a O
MLL B
/ I
AF10 I
fusion I
in O
all O
cases O
of O
AML O
with O
t B
( I
10 I
; I
11 I
) I
and O
various O
breakpoints O
on O
chromosome B
11 I
ranging O
from O
q13 B
to O
q23 B
. O

We O
conclude O
that O
the O
t B
( I
10 I
; I
11 I
) I
( I
p13 I
; I
q14 I
) I
indicates O
CALM B
and I
MLL I
rearrangements I
in O
morphologically O
distinct O
subsets O
of O
acute O
leukemia O
and O
may O
be O
associated O
with O
a O
poor O
prognosis O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
MyD88 B
is O
a O
critical O
component O
in O
the O
signaling O
cascade O
that O
is O
mediated O
by O
IL B
- I
1 I
receptor I
as O
well O
as O
IL B
- I
18 I
receptor I
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
MyD88 B
is O
a O
critical O
component O
in O
the O
signaling O
cascade O
that O
is O
mediated O
by O
IL B
- I
1 I
receptor I
as O
well O
as O
IL B
- I
18 I
receptor I
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
located O
on O
the O
X B
chromosome I
, O
which O
is O
randomly O
inactivated O
in O
every O
cell O
, O
heterozygous O
females O
can O
bear O
either O
an O
active O
wild O
- O
type O
or O
mutant O
( O
referred O
to O
as O
GATA B
- I
1 I
. I
05 I
) O
GATA B
- I
1 I
allele O
, O
consequently O
leading O
to O
variable O
anemic O
severity O
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

To O
correlate O
changes O
in O
nuclear O
factor O
binding O
in O
vitro O
with O
transcriptional O
activity O
in O
vivo O
and O
define O
the O
structural O
requirements O
for O
IL B
- I
2 I
promoter I
repression O
, O
we O
used O
transient O
DNA O
transfections O
. O

Jurkat O
cells O
were O
transfected O
with O
plasmids B
containing O
either O
the O
intact O
IL B
- I
2 I
promoter I
or O
its O
AP B
- I
1 I
, I
NF I
- I
AT I
, I
and I
NF I
- I
kB I
motifs I
. O

Other O
bacterial O
toxins O
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
T B
cell I
mitogens I
, O
UV O
light O
, O
gamma O
rays O
and O
oxidative O
stress O
were O
reported O
to O
induce O
NF B
- I
kappa I
B I
. O

Antisera O
to O
Fos B
inhibits O
NF B
- I
AT I
DNA O
binding O
as O
does O
an O
oligonucleotide O
containing O
a O
binding B
site I
for I
AP1 I
. O

Activation O
of O
the O
HIV O
- O
1 O
provirus O
correlated O
with O
the O
activation O
of O
binding O
of O
55 B
- I
and I
85 I
- I
kDa I
proteins I
to O
the O
kappa B
B I
enhancer I
and O
binding O
of O
the O
50 B
- I
kDa I
HLP I
- I
1 I
protein I
to O
the O
LBP B
- I
1 I
sequences I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
. O

Surprisingly O
, O
the O
NF B
- I
kappa I
B I
and O
HLP O
- O
1 O
binding O
activities O
were O
substantially O
inhibited O
in O
acyclovir O
- O
treated O
cells O
. O

Transcriptional O
activation O
of O
the O
macrophage B
colony I
- I
stimulating I
factor I
gene I
by O
IL B
- I
2 I
is O
associated O
with O
secretion O
of O
bioactive O
macrophage B
colony I
- I
stimulating I
factor I
protein I
by O
monocytes O
and O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
. O

Transcriptional O
activation O
of O
the O
M B
- I
CSF I
gene I
by O
IL B
- I
2 I
is O
preceded O
by O
enhanced O
binding O
activity O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
to O
its O
recognition O
sequence O
in O
the O
5 O
' O
regulatory O
enhancer O
region O
of O
the O
M B
- I
CSF I
gene I
. O

Transcriptional O
activation O
of O
the O
M B
- I
CSF I
gene I
by O
IL B
- I
2 I
is O
preceded O
by O
enhanced O
binding O
activity O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
to O
its O
recognition O
sequence O
in O
the O
5 O
' O
regulatory O
enhancer O
region O
of O
the O
M B
- I
CSF I
gene I
. O

Transcriptional O
activation O
of O
the O
M B
- I
CSF I
gene I
by O
IL B
- I
2 I
is O
preceded O
by O
enhanced O
binding O
activity O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
to O
its O
recognition O
sequence O
in O
the O
5 O
' O
regulatory O
enhancer O
region O
of O
the O
M B
- I
CSF I
gene I
. O

A O
serum B
response I
element I
and O
a O
binding B
site I
for I
NF I
- I
Y I
mediate O
the O
serum O
response O
of O
the O
human B
thrombospondin I
1 I
gene I
. O

Oxidoreductive O
regulation O
of O
nuclear B
factor I
kappa I
B I
. O

The O
promoter O
activity O
from O
HIV B
long I
terminal I
repeat I
was O
greatly O
augmented O
by O
co O
- O
transfecting O
the O
Trx B
- I
expressing I
plasmid I
, O
whose O
effect O
was O
dependent O
on O
the O
NF B
kappa I
B I
- O
binding O
sites O
. O

The O
promoter O
activity O
from O
HIV B
long I
terminal I
repeat I
was O
greatly O
augmented O
by O
co O
- O
transfecting O
the O
Trx B
- I
expressing I
plasmid I
, O
whose O
effect O
was O
dependent O
on O
the O
NF B
kappa I
B I
- O
binding O
sites O
. O

We O
have O
demonstrated O
earlier O
that O
the O
crosslinkage O
of O
the O
CD3 B
/ I
TCR I
complex I
with O
the O
CD2 B
antigen I
results O
in O
the O
proliferation O
of O
normal O
human O
T O
cells O
. O

Activation O
of O
primary O
human O
T O
- O
lymphocytes O
through O
CD2 B
plus I
CD28 I
adhesion I
molecules I
induces O
long O
- O
term O
nuclear O
expression O
of O
NF B
- I
kappa I
B I
. O

Resting O
T O
- O
cell O
nuclear O
extracts O
contained O
KBF1 B
/ I
p50 I
homodimer I
. O

To O
determine O
whether O
the O
defect O
in O
the O
patient O
' O
s O
T O
lymphocytes O
involved O
a O
trans B
- I
acting I
factor I
common O
to O
the O
affected O
lymphokine B
genes I
, O
we O
examined O
the O
ability O
of O
nuclear B
factors I
from O
the O
patient O
' O
s O
T O
lymphocytes O
to O
bind O
response O
elements O
present O
in O
the O
regulatory B
region I
of O
IL2 B
. O

p105 B
and O
p98 B
precursor B
proteins I
play O
an O
active O
role O
in O
NF B
- I
kappa I
B I
- O
mediated O
signal O
transduction O
. O

The O
eukaryotic O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
participates O
in O
many O
parts O
of O
the O
genetic O
program O
mediating O
T O
lymphocyte O
activation O
and O
growth O
. O

Transfection O
studies O
indicate O
that O
the O
I B
kappa I
B I
alpha I
gene I
is O
specifically O
induced O
by O
the O
65 B
- I
kilodalton I
transactivating I
subunit I
of O
NF B
- I
kappa I
B I
. O

Together O
, O
these O
results O
show O
that O
NF B
- I
kappa I
B I
controls O
the O
expression O
of O
I B
kappa I
B I
alpha O
by O
means O
of O
an O
inducible O
autoregulatory O
pathway O
. O

Few O
known O
genes B
( O
IL B
- I
2 I
, O
members O
of O
the O
IL B
- I
8 I
family I
, O
interferon B
- I
gamma I
) O
are O
induced O
in O
T O
cells O
only O
through O
the O
combined O
effect O
of O
phorbol O
myristic O
acetate O
( O
PMA O
) O
and O
a O
Ca O
( O
2 O
+ O
) O
- O
ionophore O
, O
and O
expression O
of O
only O
these O
genes B
can O
be O
fully O
suppressed O
by O
Cyclosporin O
A O
( O
CyA O
) O
. O

NF B
- I
kappa I
B I
is O
a O
pleiotropic B
regulator I
of O
a O
variety O
of O
genes O
implicated O
in O
the O
cellular O
response O
to O
injury O
. O

These O
findings O
indicate O
that O
antisense O
oligomers O
to O
p65 B
can O
be O
used O
to O
define O
the O
role O
of O
NF B
- I
kappa I
B I
in O
the O
activation O
pathways O
of O
neutrophils O
. O

Overexpression O
of O
p65 B
increases O
endogenous O
I B
kappa I
B I
protein O
in O
both O
carcinoma O
and O
lymphoid O
cells O
by O
two O
mechanisms O
: O
protein O
stabilization O
and O
increased O
transcription O
of O
I B
kappa I
B I
mRNA I
. O

When O
the O
wild B
- I
type I
hGR I
and O
hGR B
- I
Ile I
729 I
were O
expressed O
in O
COS O
- O
1 O
cells O
and O
assayed O
for O
[ O
3H O
] O
- O
Dexamethasone O
binding O
, O
the O
dissociation O
constants O
were O
0 O
. O
799 O
+ O
/ O
- O
0 O
. O
068 O
and O
1 O
. O
54 O
+ O
/ O
- O
0 O
. O
06 O
nM O
( O
mean O
+ O
/ O
- O
SEM O
) O
( O
P O
< O
0 O
. O
01 O
) O
, O
respectively O
. O

When O
the O
wild B
- I
type I
hGR I
and O
hGR B
- I
Ile I
729 I
were O
expressed O
in O
COS O
- O
1 O
cells O
and O
assayed O
for O
[ O
3H O
] O
- O
Dexamethasone O
binding O
, O
the O
dissociation O
constants O
were O
0 O
. O
799 O
+ O
/ O
- O
0 O
. O
068 O
and O
1 O
. O
54 O
+ O
/ O
- O
0 O
. O
06 O
nM O
( O
mean O
+ O
/ O
- O
SEM O
) O
( O
P O
< O
0 O
. O
01 O
) O
, O
respectively O
. O

Dimerization O
of O
NF B
- I
KB2 I
with O
RelA B
( I
p65 I
) I
regulates O
DNA O
binding O
, O
transcriptional O
activation O
, O
and O
inhibition O
by O
an O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

We O
have O
previously O
found O
that O
NFKB2 B
( I
p49 I
/ I
p52 I
) I
acts O
in O
concert O
with O
RelA B
( I
p65 I
) I
to O
stimulate O
the O
HIV B
enhancer I
in O
Jurkat O
T O
- O
leukemia O
cells O
. O

The O
c B
- I
rel I
protooncogene I
product I
represses O
NF B
- I
kappa I
B I
p65 B
- O
mediated O
transcriptional O
activation O
of O
the O
long O
terminal O
repeat O
of O
type O
1 O
human O
immunodeficiency O
virus O
. O

This O
intracellular O
signaling O
complex O
potently O
stimulates O
kappa O
B O
- O
directed O
transcription O
from O
either O
the O
HIV B
- I
1 I
LTR I
or O
the O
IL B
- I
2R I
alpha I
promoter I
via O
the O
strong O
transactivation O
domain O
present O
in O
p65 B
. O

We O
now O
demonstrate O
that O
nuclear O
expression O
of O
human O
c B
- I
Rel I
, O
which O
is O
induced O
by O
either O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
with O
delayed O
kinetics O
relative O
to O
p65 B
, O
markedly O
represses O
p65 B
- O
mediated O
activation O
of O
these O
transcription O
units O
. O

Competition O
with O
an O
AP B
- I
1 I
motif I
or O
with O
anti B
- I
Jun I
and O
anti B
- I
Fos I
antibodies I
abolished O
binding O
to O
the O
NFAT B
motif I
in O
both O
T O
and O
B O
cells O
, O
indicating O
that O
Jun O
and O
Fos O
are O
critical O
for O
NFAT B
complex I
formation O
in O
both O
cell O
types O
. O

However O
, O
when O
combined O
with O
unstimulated O
B O
or O
T O
cell O
extracts O
, O
full O
- O
length O
, O
but O
not O
truncated O
, O
Jun O
/ O
Fos O
heterodimers O
were O
able O
to O
form O
an O
NFAT B
complex I
, O
indicating O
the O
presence O
of O
a O
constitutively B
expressed I
nuclear I
factor I
( O
s O
) O
in O
B O
and O
T O
cells O
necessary O
for O
the O
formation O
of O
the O
NFAT B
complex I
in O
both O
cell O
types O
. O

We O
find O
that O
a O
short O
enhancer O
element O
containing O
the O
NF B
- I
kappa I
B I
binding I
site I
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
gene I
( O
IL B
- I
2R I
alpha I
) O
is O
preferentially O
activated O
in O
T O
cells O
. O

Serum B
response I
factor I
( O
SRF B
) O
binds O
to O
a O
site O
adjacent O
to O
the O
NF B
- I
kappa I
B I
site I
in O
the O
IL B
- I
2R I
enhancer I
, O
and O
both O
sites O
together O
have O
strong O
transcriptional O
activity O
specifically O
in O
T O
cells O
. O

Mutual O
regulation O
of O
the O
transcriptional B
activator I
NF B
- I
kappa I
B I
and O
its O
inhibitor O
, O
I B
kappa I
B I
- I
alpha I
. O

Groups O
1 O
and O
2 O
have O
a O
serine B
- I
rich I
region I
and O
an O
` O
` O
arginine B
element I
` O
` O
( O
RRLPIF B
) O
at O
the O
carboxyl B
terminus I
. O

All O
groups O
contain O
cysteine B
- I
and I
histidine I
- I
rich I
putative I
zinc I
finger I
domains I
and O
a O
serine B
- I
phenylalanine I
` I
` I
SFS I
' I
' I
domain I
similar O
to O
part O
of O
the O
large O
subunit O
of O
eukaryotic B
RNA I
polymerase I
II I
. O

One O
enigmatic O
aspect O
of O
GATA B
factor I
expression O
is O
that O
several O
GATA B
proteins I
, O
which O
ostensibly O
share O
the O
same O
DNA B
- I
binding I
site I
specificity O
, O
are O
coexpressed O
in O
erythroid O
cells O
. O

PBL O
constitutively O
express O
c B
- I
jun I
transcripts I
, O
and O
the O
level O
of O
c B
- I
jun I
mRNA I
is O
not O
altered O
by O
PHA B
activation O
in O
the O
absence O
or O
presence O
of O
EC O
. O

PBL O
constitutively O
express O
c B
- I
jun I
transcripts I
, O
and O
the O
level O
of O
c B
- I
jun I
mRNA I
is O
not O
altered O
by O
PHA B
activation O
in O
the O
absence O
or O
presence O
of O
EC O
. O

In O
contrast O
, O
c B
- I
fos I
mRNA I
is O
absent O
from O
resting O
T O
cells O
and O
is O
induced O
on O
PHA B
activation O
. O

Site O
- O
directed O
mutagenesis O
demonstrated O
that O
this O
HS B
- I
40 I
enhancer O
- O
zeta B
2 I
globin I
promoter I
interaction O
is O
mediated O
by O
the O
two O
GATA O
- O
1 O
factor O
binding O
motifs O
located O
at O
- O
230 O
and O
- O
104 O
, O
respectively O
. O

We O
report O
the O
characterization O
of O
the O
cis B
- I
and I
trans I
- I
acting I
elements I
involved O
in O
the O
tissue O
- O
specific O
activity O
of O
the O
L B
gene I
erythroid I
promoter I
. O

To O
determine O
whether O
these O
different O
X1 O
box O
activities O
represented O
distinct O
DNA B
binding I
proteins I
or O
multimeric O
forms O
of O
the O
same O
factor O
( O
s O
) O
, O
protease B
treatment O
of O
the O
crude O
nuclear O
extracts O
followed O
by O
DNA O
- O
binding O
assays O
were O
carried O
out O
and O
demonstrated O
that O
B O
cell O
extracts O
contain O
at O
least O
two O
X1 B
- I
specific I
factors I
. O

Human O
immunodeficiency O
viruses O
containing O
heterologous B
enhancer I
/ I
promoters I
are O
replication O
competent O
and O
exhibit O
different O
lymphocyte O
tropisms O
. O

The O
E1A B
and I
hexon I
primers I
amplified O
DNA O
from O
representative O
adenoviral O
serotypes O
in O
all O
six O
adenoviral O
groups O
( O
A O
- O
F O
) O
. O

RESULTS O
: O
In O
the O
OM O
- O
10 O
. O
1 O
promyelocytic O
model O
of O
chronic O
infection O
, O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
also O
resulted O
in O
a O
substantial O
increase O
in O
75 B
kd I
TNF I
receptor I
( O
TR75 B
) O
expression O
although O
55 B
kD I
TNF I
receptor I
( O
TR55 B
) O
levels O
were O
not O
dramatically O
altered O
. O

RESULTS O
: O
In O
the O
OM O
- O
10 O
. O
1 O
promyelocytic O
model O
of O
chronic O
infection O
, O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
also O
resulted O
in O
a O
substantial O
increase O
in O
75 B
kd I
TNF I
receptor I
( O
TR75 B
) O
expression O
although O
55 B
kD I
TNF I
receptor I
( O
TR55 B
) O
levels O
were O
not O
dramatically O
altered O
. O

Anti B
- I
TR55 I
antibody I
cross O
- O
linking O
in O
chronically O
infected O
U1 O
promonocytic O
cultures O
could O
only O
partially O
substitute O
for O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
. O

UT B
- I
7 I
Epo I
and O
UT O
- O
7 O
expressed O
similar O
levels O
of O
GATA B
- I
1 I
mRNA I
and O
binding O
activity O
. O

UT B
- I
7 I
Epo I
and O
UT O
- O
7 O
expressed O
similar O
levels O
of O
GATA B
- I
1 I
mRNA I
and O
binding O
activity O
. O

Globin B
chains I
( O
alpha B
, O
beta B
and O
gamma B
) O
were O
clearly O
detectable O
by O
affinity O
chromatography O
in O
UT B
- I
7 I
Epo I
but O
not O
in O
UT O
- O
7 O
cells O
. O

Okadaic O
acid O
increased O
the O
synthesis O
of O
the O
interleukin B
- I
1 I
beta I
precursor O
and O
mature O
forms O
and O
their O
secretion O
. O

Expression O
of O
tal B
- I
1 I
and O
GATA B
- I
binding I
proteins I
during O
human O
hematopoiesis O
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
known O
to O
transactivate O
several O
genes O
specific O
for O
the O
erythroid O
, O
megakaryocytic O
, O
and O
mastocytic O
/ O
basophilic O
lineages O
, O
we O
studied O
GATA B
- I
1 I
expression O
in O
these O
purified O
hematopoietic O
cells O
. O

Different O
modes O
, O
like O
chemical O
induction O
, O
lytic O
superinfection O
with O
EBV O
and O
single O
gene O
trans O
- O
activation O
converted O
the O
recombinant B
ori I
Lyt I
element I
in O
R7 O
- O
57 O
reporter O
cells O
. O

The O
observation O
that O
a O
mutated B
LT I
- I
kappa I
B I
construct I
( O
M1 B
- I
CAT I
) O
was O
inactive O
in O
C81 O
- O
66 O
- O
45 O
, O
confirmed O
the O
importance O
of O
NF B
- I
kappa I
B I
in O
LT B
gene O
expression O
. O

This O
paper O
describes O
how O
the O
expression O
of O
the O
monocyte B
- I
macrophage I
Ag I
, O
CD14 B
, O
and O
the O
low O
affinity B
Fc I
receptor I
for O
IgE B
, O
CD23 B
, O
were O
inversely O
regulated O
during O
VitD3 O
- O
and O
RA O
- O
induced O
monocytic O
differentiation O
of O
human O
U O
- O
937 O
monoblasts O
. O

Cell O
- O
specific O
bifunctional O
role O
of O
Jun B
oncogene I
family I
members I
on O
glucocorticoid B
receptor I
- O
dependent O
transcription O
. O

Cross O
competition O
experiments O
with O
an O
octamer O
sequence O
from O
the O
Ig O
heavy O
chain O
promoter O
, O
the O
BAT B
box I
, O
and O
a O
TA O
- O
rich O
sequence O
present O
in O
the O
CD21 B
promoter I
revealed O
that O
all O
three O
sequences O
bound O
the O
same O
nuclear B
proteins I
suggesting O
that O
the O
BAT B
box I
binding I
proteins I
were O
Oct B
- I
1 I
and O
Oct B
- I
2 I
. O

One O
cDNA B
clone I
of O
a O
primary O
response O
gene O
, O
expressed O
upon O
macrophage O
differentiation O
, O
encoded O
for O
Egr B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
. O

HL O
- O
60 O
cells O
constitutively O
expressing O
an O
Egr B
- I
1 I
transgene I
( O
HL B
- I
60Egr I
- I
1 I
) O
could O
be O
induced O
for O
macrophage O
, O
but O
not O
granulocyte O
, O
differentiation O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
three O
specific O
protein B
- I
DNA I
complexes I
formed O
with O
sequences O
of O
the O
EBNA2 B
responsive I
element I
. O

Cotransfection O
of O
an O
hGATA B
- I
3 I
expression I
plasmid I
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

Early B
B I
- I
cell I
factor I
( O
EBF B
) O
was O
identified O
previously O
as O
a O
tissue O
- O
specific O
and O
differentiation O
stage O
- O
specific O
DNA B
- I
binding I
protein I
that O
participates O
in O
the O
regulation O
of O
the O
pre B
- I
B I
and I
B I
lymphocyte I
- I
specific I
mb I
- I
1 I
gene I
. O

Induction O
by O
hemin O
increases O
, O
while O
induction O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
represses O
, O
erythroid B
- I
specific I
gene I
expression O
in O
the O
human O
cell O
line O
K562 O
. O

These O
involve O
activation O
of O
the O
sodium B
/ I
proton I
exchanger I
of O
the O
cell O
membrane O
at O
very O
low O
, O
physiological O
concentrations O
of O
aldosterone O
with O
an O
acute O
onset O
within O
1 O
- O
2 O
min O
. O

Human B
immunodeficiency I
virus I
type I
1 I
Nef I
protein I
inhibits O
NF B
- I
kappa I
B I
induction O
in O
human O
T O
cells O
. O

These O
results O
indicate O
that O
defective O
recruitment O
of O
NF B
- I
kappa I
B I
may O
underlie O
Nef B
' O
s O
negative O
transcriptional O
effects O
on O
the O
HIV B
- I
1 I
and I
interleukin I
2 I
promoters I
. O

This O
high B
- I
affinity I
site I
has O
been O
conserved O
in O
the O
promoters B
of O
both O
human B
and I
mouse I
CD19 I
genes I
and O
was O
furthermore O
shown O
to O
confer O
B O
- O
cell O
specificity O
to O
a O
beta O
- O
globin O
reporter O
gene O
in O
transient O
transfection O
experiments O
. O

Regulation O
of O
replicative O
functions O
in O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
genome I
is O
mediated O
through O
activation O
of O
a O
virally B
encoded I
transcription I
factor I
, O
Z B
( O
BZLF1 B
) O
. O

The O
long B
terminal I
repeat I
( I
LTR I
) I
region I
of O
HIV B
proviral I
DNA I
contains O
binding O
sites O
for O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
and O
this O
transcriptional B
activator I
appears O
to O
regulate O
HIV O
activation O
. O

The O
long B
terminal I
repeat I
( I
LTR I
) I
region I
of O
HIV B
proviral I
DNA I
contains O
binding O
sites O
for O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
and O
this O
transcriptional B
activator I
appears O
to O
regulate O
HIV O
activation O
. O

Okadaic O
acid O
is O
a O
potent O
inducer O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
, O
and O
tumor B
necrosis I
factor I
- I
alpha I
in O
human O
B O
lymphocytes O
. O

Treatment O
of O
human O
B O
lymphocytes O
with O
an O
optimal O
concentration O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
phosphatases B
1 I
and I
2A I
, O
resulted O
in O
the O
induction O
of O
the O
transcription B
factor I
, O
AP B
- I
1 I
and O
a O
marked O
increase O
in O
NF B
- I
kappa I
B I
levels O
. O

Treatment O
of O
human O
B O
lymphocytes O
with O
an O
optimal O
concentration O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
phosphatases B
1 I
and I
2A I
, O
resulted O
in O
the O
induction O
of O
the O
transcription B
factor I
, O
AP B
- I
1 I
and O
a O
marked O
increase O
in O
NF B
- I
kappa I
B I
levels O
. O

Although O
okadaic O
acid O
provides O
a O
potent O
inductive O
signal O
for O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
it O
did O
not O
induce O
either O
B O
cell O
proliferation O
or O
immunoglobulin B
secretion O
. O

c B
- I
myc I
mRNA I
expression O
in O
minor O
salivary O
glands O
of O
patients O
with O
Sjogren O
' O
s O
syndrome O
. O

A O
novel B
T I
cell I
- I
specific I
negative I
regulatory I
element I
( O
NRE B
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL B
- I
4 I
gene I
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE B
- I
I I
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE B
- I
II I
) O
. O

We O
used O
phenolic O
, O
lipid O
- O
soluble O
, O
chain O
- O
breaking O
antioxidants O
( O
butylated O
hydroxyanisole O
( O
BHA O
) O
, O
nordihydroquairetic O
acid O
, O
or O
alpha O
- O
tocopherol O
( O
vitamin O
E O
) O
to O
show O
that O
peroxyl O
radical O
scavenging O
in O
unstimulated O
and O
PMA O
- O
or O
TNF O
- O
stimulated O
cells O
blocks O
the O
functions O
depending O
on O
NF B
- I
kappa I
B I
activation O
. O

Selection O
of O
optimal O
kappa O
B O
/ O
Rel O
DNA O
- O
binding O
motifs O
: O
interaction O
of O
both O
subunits O
of O
NF B
- I
kappa I
B I
with O
DNA O
is O
required O
for O
transcriptional O
activation O
. O

Using O
purified O
recombinant O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
proteins I
, O
optimal O
DNA O
- O
binding O
motifs O
were O
selected O
from O
a O
pool O
of O
random O
oligonucleotides O
. O

These O
findings O
demonstrate O
that O
interaction O
of O
both O
subunits O
of O
the O
heterodimeric B
NF I
- I
kappa I
B I
complex I
with O
DNA O
is O
required O
for O
DNA O
binding O
and O
transcriptional O
activation O
and O
suggest O
that O
transcriptional O
activation O
mediated O
by O
the O
individual O
rel B
- I
related I
proteins I
will O
differ O
dramatically O
, O
depending O
on O
the O
specific O
kappa O
B O
motifs O
present O
. O

These O
observations O
indicate O
that O
during O
chronic O
HIV O
infection O
of O
U937 O
cells O
, O
continuous O
NF B
- I
kappa I
B I
( O
p50 B
/ I
p65 I
) O
translocation O
results O
in O
p105 O
promoter O
upregulation O
with O
subsequent O
cytosolic O
NF B
- I
kappa I
B I
accumulation O
, O
ready O
for O
further O
translocation O
. O

These O
observations O
indicate O
that O
during O
chronic O
HIV O
infection O
of O
U937 O
cells O
, O
continuous O
NF B
- I
kappa I
B I
( O
p50 B
/ I
p65 I
) O
translocation O
results O
in O
p105 O
promoter O
upregulation O
with O
subsequent O
cytosolic O
NF B
- I
kappa I
B I
accumulation O
, O
ready O
for O
further O
translocation O
. O

Similarly O
, O
IL B
- I
2 I
activates O
NF B
- I
kappa I
B I
in O
the O
human O
monocytic O
cell O
line O
U O
937 O
, O
but O
not O
in O
resting O
human O
T O
- O
cells O
. O

Blockade O
of O
the O
DNA B
- I
binding I
complexes I
with O
an O
anti B
- I
Fos I
mAb I
demonstrated O
a O
direct O
participation O
of O
c B
- I
Fos I
in O
the O
AP B
- I
1 I
complexes I
induced O
by O
anti B
- I
AIM I
mAb I
. O

Blockade O
of O
the O
DNA B
- I
binding I
complexes I
with O
an O
anti B
- I
Fos I
mAb I
demonstrated O
a O
direct O
participation O
of O
c B
- I
Fos I
in O
the O
AP B
- I
1 I
complexes I
induced O
by O
anti B
- I
AIM I
mAb I
. O

Blockade O
of O
the O
DNA B
- I
binding I
complexes I
with O
an O
anti B
- I
Fos I
mAb I
demonstrated O
a O
direct O
participation O
of O
c B
- I
Fos I
in O
the O
AP B
- I
1 I
complexes I
induced O
by O
anti B
- I
AIM I
mAb I
. O

Blockade O
of O
the O
DNA B
- I
binding I
complexes I
with O
an O
anti B
- I
Fos I
mAb I
demonstrated O
a O
direct O
participation O
of O
c B
- I
Fos I
in O
the O
AP B
- I
1 I
complexes I
induced O
by O
anti B
- I
AIM I
mAb I
. O

Expression O
of O
M10 B
did O
not O
affect O
induction O
of O
HIV O
transcription O
mediated O
by O
the O
kappa B
B I
regulatory I
element I
or O
Tat B
. O

The O
kinetics O
of O
expression O
of O
the O
two O
genes O
were O
also O
slightly O
different O
, O
with O
c B
- I
fos I
mRNA I
reaching O
a O
peak O
at O
15 O
min O
after O
stimulation O
and O
c B
- I
jun I
at O
30 O
min O
. O

Nuclear O
transcription O
studies O
in O
vitro O
showed O
that O
LTB4 O
increased O
the O
transcription O
of O
the O
c B
- I
fos I
gene I
7 O
- O
fold O
and O
the O
c B
- I
jun I
gene I
1 O
. O
4 O
- O
fold O
. O

Nuclear O
transcription O
studies O
in O
vitro O
showed O
that O
LTB4 O
increased O
the O
transcription O
of O
the O
c B
- I
fos I
gene I
7 O
- O
fold O
and O
the O
c B
- I
jun I
gene I
1 O
. O
4 O
- O
fold O
. O

Modulation O
of O
normal O
erythroid O
differentiation O
by O
the O
endogenous O
thyroid O
hormone O
and O
retinoic B
acid I
receptors I
: O
a O
possible O
target O
for O
v B
- I
erbA I
oncogene I
action O
. O

Mutations O
in O
the O
Pit B
- I
1 I
gene I
in O
children O
with O
combined O
pituitary O
hormone O
deficiency O
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

Our O
results O
indicate O
that O
the O
AP B
- I
1 I
site I
at O
- B
150 I
bp I
represents O
a O
major O
, O
if O
not O
the O
only O
, O
site O
of O
PKC B
responsiveness O
in O
the O
IL B
- I
2 I
promoter I
. O

Our O
results O
indicate O
that O
the O
AP B
- I
1 I
site I
at O
- B
150 I
bp I
represents O
a O
major O
, O
if O
not O
the O
only O
, O
site O
of O
PKC B
responsiveness O
in O
the O
IL B
- I
2 I
promoter I
. O

Mice O
treated O
with O
antisense O
to O
NF B
- I
kappa I
B I
ODNs O
showed O
rapid O
regression O
of O
transplanted O
fibrosarcomas O
. O

Leukotriene O
B4 O
transcriptionally O
activates O
interleukin B
- I
6 I
expression O
involving O
NK B
- I
chi I
B I
and O
NF B
- I
IL6 I
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
chi I
B I
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B
- I
IL6 I
, O
while O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
, O
shown O
to O
otherwise O
confer O
IL B
- I
6 I
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

The O
signaling O
events O
mediating O
this O
effect O
appeared O
to O
involve O
the O
release O
of O
H2O2 O
, O
since O
LTB4 O
failed O
to O
induce O
NF B
- I
chi I
B I
or O
NF B
- I
IL6 I
in O
the O
presence O
of O
the O
scavenger O
of O
H2O2 O
, O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

[ O
Age O
- O
related O
changes O
in O
glucocorticoid B
and I
mineralocorticoid I
receptors I
in O
lymphocytes O
of O
healthy O
persons O
and O
patients O
with O
hypertension O
] O

Mutations O
affecting O
the O
5 B
' I
guanine I
residues I
of O
the O
kappa B
B I
site I
were O
unable O
to O
compete O
for O
these O
NF B
- I
kappa I
B I
- I
related I
proteins I
. O

However O
, O
no O
loss O
of O
DNA O
binding O
activity O
is O
observed O
, O
presumably O
reflecting O
the O
unique O
C B
- I
terminal I
domain I
that O
is O
distinct O
from O
that O
present O
in O
NF B
- I
kappa I
B I
p65 I
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive B
molecules I
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B
- I
leukocyte I
adhesion I
molecule I
1 I
( O
ELAM B
- I
1 I
) O
and O
intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
] O
. O

BSAP B
is O
encoded O
by O
the O
Pax B
- I
5 I
gene I
and O
has O
been O
highly O
conserved O
between O
human O
and O
mouse O
. O

NF B
- I
kappa I
B I
is O
a O
protein B
complex I
which O
functions O
in O
concert O
with O
the O
tat B
- I
I I
gene I
product I
to O
stimulate O
human O
immunodeficiency O
virus O
( O
HIV O
) O
transcription O
. O

We O
have O
found O
that O
the O
p49 B
( I
100 I
) I
DNA I
binding I
subunit I
, O
together O
with O
p65 B
, O
can O
act O
in O
concert O
with O
Tat B
- I
I I
to O
stimulate O
the O
expression O
of O
HIV B
- I
CAT I
plasmid I
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Stable O
expression O
of O
HB24 B
, O
a O
diverged B
human I
homeobox I
gene I
, O
in O
T O
lymphocytes O
induces O
genes O
involved O
in O
T O
cell O
activation O
and O
growth O
. O

A O
Tat B
- I
responsive I
element I
is O
found O
upstream O
within O
the O
viral B
promoter I
that O
in O
glial O
- O
derived O
cell O
lines O
allows O
transactivation O
in O
the O
absence O
of O
TAR B
. O

Further O
, O
we O
observe O
that O
TAR B
- I
deleted I
mutants I
of O
HIV O
- O
1 O
demonstrate O
normal O
late O
gene O
expression O
in O
glial O
cells O
as O
evidenced O
by O
syncytia O
formation O
and O
production O
of O
viral B
p24 I
antigen I
. O

Regulation O
of O
interleukin B
- I
1 I
beta I
production O
by O
glucocorticoids O
in O
human O
monocytes O
: O
the O
mechanism O
of O
action O
depends O
on O
the O
activation O
signal O
. O

Nuclear B
transcription I
factors I
that O
bind O
to O
elements O
of O
the O
IL B
- I
2 I
promoter I
. O

In O
addition O
, O
p65 B
gave O
per O
se O
, O
with O
low O
affinity O
, O
a O
protein B
- I
DNA I
complex I
that O
migrated O
more O
slowly O
than O
native O
NF B
- I
GM2 I
complex I
. O

In O
addition O
, O
p65 B
gave O
per O
se O
, O
with O
low O
affinity O
, O
a O
protein B
- I
DNA I
complex I
that O
migrated O
more O
slowly O
than O
native O
NF B
- I
GM2 I
complex I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

This O
suggests O
that O
the O
activation O
mechanism O
of O
the O
GM B
- I
CSF I
gene I
through O
the O
GM2 B
/ I
GC I
- I
box I
sequence I
is O
different O
from O
that O
of O
genes O
carrying O
the O
kappa B
B I
enhancer I
alone O
. O

Characterization O
of O
an O
immediate B
- I
early I
gene I
induced O
in O
adherent O
monocytes O
that O
encodes O
I B
kappa I
B I
- O
like O
activity O
. O

A O
DNA B
probe I
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila B
morphogen I
dorsal I
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat B
T I
cell I
complementary I
DNA I
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

A O
DNA B
probe I
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila B
morphogen I
dorsal I
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat B
T I
cell I
complementary I
DNA I
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

This O
protein B
- I
DNA I
complex I
comigrated O
with O
the O
complex O
obtained O
with O
the O
purified B
human I
p65 I
NF I
- I
kappa I
B I
subunit I
and O
binding O
was O
inhibited O
by O
I B
kappa I
B I
- I
alpha I
and O
- O
beta O
proteins O
. O

The O
v B
- I
erbA I
oncoprotein I
represents O
a O
retrovirus O
- O
transduced O
oncogenic O
version O
of O
the O
thyroid B
hormone I
( I
T3 I
/ I
T4 I
) I
receptor I
c B
- I
erbA I
( I
type I
alpha I
) I
. O

This O
erbA B
- I
binding I
site I
confers O
thyroid O
hormone O
responsiveness O
to O
a O
heterologous B
promoter I
in O
transient O
expression O
experiments O
and O
is O
a O
target O
for O
efficient O
down O
- O
regulation O
of O
CAII B
transcription O
by O
the O
v B
- I
erbA I
oncoprotein I
. O

This O
erbA B
- I
binding I
site I
confers O
thyroid O
hormone O
responsiveness O
to O
a O
heterologous B
promoter I
in O
transient O
expression O
experiments O
and O
is O
a O
target O
for O
efficient O
down O
- O
regulation O
of O
CAII B
transcription O
by O
the O
v B
- I
erbA I
oncoprotein I
. O

The O
effect O
is O
mediated O
by O
the O
NF B
- I
kappa I
B I
transcription B
factor I
which O
is O
potently O
and O
rapidly O
activated O
by O
an O
H2O2 O
treatment O
of O
cells O
from O
its O
inactive B
cytoplasmic I
form I
. O

ROI O
appear O
to O
serve O
as O
messengers O
mediating O
directly O
or O
indirectly O
the O
release O
of O
the O
inhibitory B
subunit I
I B
kappa I
B I
from O
NF B
- I
kappa I
B I
. O

More O
strikingly O
, O
the O
80 B
- I
kDa I
protein I
was O
downregulated O
in O
a O
dose O
- O
dependent O
fashion O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
; O
this O
effect O
was O
independent O
of O
the O
mode O
of O
lymphocyte O
activation O
and O
specific O
for O
the O
1 O
, O
25 O
( O
OH O
) O
2D3 O
metabolite O
of O
vitamin O
D3 O
. O

Previously O
, O
transcription O
of O
the O
c B
- I
fos I
gene I
has O
been O
reported O
to O
be O
transactivated O
by O
the O
viral B
transcription I
factor I
, O
Tax1 B
. O

In O
lymphocytes O
activated O
either O
by O
PHA B
or O
OKT3 B
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 B
- I
kDa I
species I
cross O
- O
reacting O
with O
a O
monoclonal B
antibody I
against O
the O
intestinal B
vitamin I
D I
receptor I
was O
detected O
. O

In O
lymphocytes O
activated O
either O
by O
PHA B
or O
OKT3 B
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 B
- I
kDa I
species I
cross O
- O
reacting O
with O
a O
monoclonal B
antibody I
against O
the O
intestinal B
vitamin I
D I
receptor I
was O
detected O
. O

Finally O
, O
RNA O
from O
activated O
lymphocytes O
was O
amplified O
by O
polymerase O
chain O
reaction O
using O
oligonucleotide O
primers O
flanking O
the O
196 B
base I
pair I
long I
region I
encoding O
the O
DNA B
- I
binding I
domain I
of O
the O
human B
intestinal I
receptor I
. O

These O
findings O
suggest O
that O
expression O
of O
the O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptor I
in O
lymphocytes O
is O
triggered O
by O
distinct O
and O
contingent O
signals O
, O
and O
that O
the O
protein O
and O
the O
mRNA B
encoding O
it O
are O
identical O
to O
the O
classical B
vitamin I
D I
receptor I
. O

The O
kappa B
B I
sequence I
( O
GGGACTTTCC O
) O
binds O
a O
factor O
, O
NF B
- I
kappa I
B I
, O
that O
is O
constitutively O
found O
in O
its O
functional O
, O
DNA O
binding O
form O
only O
in O
B O
lymphocytes O
. O

However O
, O
in O
either O
EL O
- O
4 O
( O
T O
) O
cells O
or O
S194 O
cells O
, O
both O
lower O
- O
affinity O
sites O
can O
be O
significantly O
induced O
by O
the O
tax B
gene I
product I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
, O
showing O
that O
NF B
- I
kappa I
B I
activity O
can O
be O
modulated O
even O
in O
a O
B O
- O
cell O
line O
that O
constitutively O
expresses O
this O
factor O
. O

Previously O
, O
a O
nuclear B
factor I
, O
IRF B
- I
1 I
( O
interferon B
regulatory I
factor I
1 I
) O
, O
which O
binds O
to O
type B
I I
IFN I
and O
some O
IFN B
- I
inducible I
gene I
promoters I
, O
was O
identified O
and O
cloned O
. O

A O
dimerization B
cofactor I
of O
HNF B
- I
1 I
alpha I
( O
DCoH B
) O
was O
identified O
that O
displayed O
a O
restricted O
tissue O
distribution O
and O
did O
not O
bind O
to O
DNA O
, O
but O
, O
rather O
, O
selectively O
stabilized O
HNF B
- I
1 I
alpha I
dimers I
. O

Transforming B
growth I
factor I
- I
beta I
suppresses O
human B
B I
lymphocyte I
Ig I
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
form I
of O
Ig B
mRNA I
. O

The O
murine B
and I
human I
factors I
are O
abundantly O
expressed O
in O
a O
variety O
of O
human O
and O
murine O
T O
- O
cell O
lines O
and O
can O
activate O
transcription O
through O
a O
tissue B
- I
specific I
GATA I
- I
binding I
site I
identified O
within O
the O
human B
T I
- I
cell I
receptor I
delta I
gene I
enhancer I
. O

The O
expression O
of O
active O
NF B
- I
kappa I
B I
might O
therefore O
also O
be O
regulated O
by O
the O
extent O
of O
processing O
of O
p105 B
. O

The O
29 B
- I
kDa I
proteins I
phosphorylated O
in O
thrombin O
- O
activated O
human O
platelets O
are O
forms O
of O
the O
estrogen B
receptor I
- I
related I
27 I
- I
kDa I
heat I
shock I
protein I
. O

We O
have O
isolated O
a O
human B
cDNA I
clone I
encoding O
a O
zinc B
finger I
protein I
( O
NF B
- I
E1 I
) O
that O
binds O
to O
the O
negative B
- I
acting I
segment I
of O
the O
kappa B
E3 I
' I
enhancer I
. O

We O
have O
isolated O
a O
human B
cDNA I
clone I
encoding O
a O
zinc B
finger I
protein I
( O
NF B
- I
E1 I
) O
that O
binds O
to O
the O
negative B
- I
acting I
segment I
of O
the O
kappa B
E3 I
' I
enhancer I
. O

NF B
- I
E1 I
is O
also O
the O
human B
homologue I
of O
the O
mouse B
delta I
protein I
, O
which O
binds O
to O
ribosomal B
protein I
gene I
promoters I
. O

A O
thymus B
- I
specific I
member I
of O
the O
HMG B
protein I
family I
regulates O
the O
human B
T I
cell I
receptor I
C I
alpha I
enhancer I
. O

The O
human B
T I
cell I
- I
specific I
transcription I
factor I
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine B
- I
rich I
elements I
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T B
cell I
- I
specific I
control I
regions I
. O

The O
human B
T I
cell I
- I
specific I
transcription I
factor I
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine B
- I
rich I
elements I
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T B
cell I
- I
specific I
control I
regions I
. O

TCF B
- I
1 I
alpha I
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA B
- I
binding I
regulatory I
proteins I
that O
share O
the O
HMG B
motif I
in O
that O
it O
is O
a O
highly B
tissue I
- I
specific I
RNA I
polymerase I
II I
transcription B
factor I
. O

Binding O
of O
the O
65 B
- I
kDa I
plus O
50 B
- I
kDa I
heterodimer I
to O
the O
HIV B
- I
1 I
enhancer I
can O
be O
negatively O
regulated O
in O
monocytes O
, O
providing O
one O
mechanism O
restricting O
HIV B
- I
1 I
gene I
expression O
. O

Binding O
of O
the O
65 B
- I
kDa I
plus O
50 B
- I
kDa I
heterodimer I
to O
the O
HIV B
- I
1 I
enhancer I
can O
be O
negatively O
regulated O
in O
monocytes O
, O
providing O
one O
mechanism O
restricting O
HIV B
- I
1 I
gene I
expression O
. O

Binding O
of O
the O
65 B
- I
kDa I
plus O
50 B
- I
kDa I
heterodimer I
to O
the O
HIV B
- I
1 I
enhancer I
can O
be O
negatively O
regulated O
in O
monocytes O
, O
providing O
one O
mechanism O
restricting O
HIV B
- I
1 I
gene I
expression O
. O

Formation O
of O
the O
protein B
- I
DNA I
complex I
with O
the O
C26 B
subfragment I
was O
positively O
affected O
by O
p40tax B
. O

Human O
tumor B
necrosis I
factor I
alpha I
gene O
regulation O
in O
phorbol O
ester O
stimulated O
T O
and O
B O
cell O
lines O
. O

Moreover O
, O
kappa B
1 I
- I
kappa I
3 I
can O
each O
be O
deleted O
from O
the O
TNF B
- I
alpha I
promoter I
with O
little O
effect O
on O
the O
gene O
' O
s O
inducibility O
by O
PMA O
. O

We O
have O
generated O
a O
monoclonal B
antibody I
, O
BZ1 B
, O
to O
BZLF1 B
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active B
, I
dimeric I
form I
and O
the O
inactive B
, I
monomeric I
form I
of O
the O
protein O
. O

We O
have O
generated O
a O
monoclonal B
antibody I
, O
BZ1 B
, O
to O
BZLF1 B
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active B
, I
dimeric I
form I
and O
the O
inactive B
, I
monomeric I
form I
of O
the O
protein O
. O

NF B
- I
kB I
is O
a O
eukaryotic B
transcription I
regulatory I
factor I
. O

Moreover O
, O
M B
- I
CSF I
- O
induced O
expression O
of O
the O
fos B
- I
related I
gene I
, O
fra B
- I
1 I
, O
was O
delayed O
compared O
to O
that O
for O
both O
c B
- I
fos I
and O
fos B
- I
B I
. O

DNA O
binding O
by O
all O
four O
of O
these O
Rel B
- I
related I
factors I
is O
blocked O
by O
selective O
chemical O
modification O
of O
lysine O
and O
arginine O
residues O
, O
suggesting O
that O
both O
of O
these O
basic O
amino O
acids O
are O
required O
for O
binding O
to O
the O
kappa B
B I
element I
. O

DNA O
binding O
by O
in B
vitro I
synthesized I
GR I
was O
blocked O
by O
the O
addition O
of O
sodium O
molybdate O
to O
the O
receptor O
preparations O
before O
steroid O
addition O
and O
thermal O
activation O
. O

Oligonucleotides O
containing O
the O
consensus B
GRE I
were O
the O
most O
efficient O
competitors O
, O
and O
fragments O
containing O
regulatory B
sequences I
from O
glucocorticoid B
- I
repressible I
genes I
were O
somewhat O
competitive O
, O
whereas O
single O
stranded O
oligonucleotides O
were O
unable O
to O
compete O
for O
mouse B
mammary I
tumor I
virus I
- I
long I
terminal I
repeat I
DNA O
binding O
, O
except O
when O
competitor O
was O
present O
at O
extremely O
high O
concentrations O
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

Five O
T O
- O
cell O
clones O
specific O
for O
a O
T B
- I
cell I
epitope I
located O
at O
the O
carboxyterminal B
region I
of O
HBxAg B
were O
established O
and O
found O
to O
belong O
to O
the O
CD2 O
/ O
CD4 O
- O
positive O
, O
CD8 O
- O
negative O
subtype O
. O

The O
NF B
kappa I
B I
independent I
cis I
- I
acting I
sequences I
in O
HIV B
- I
1 I
LTR I
responsive O
to O
T O
- O
cell O
activation O
. O

The O
rate O
of O
LTR B
- O
directed O
gene O
expression O
increased O
in O
response O
to O
treatment O
with O
either O
a O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
if O
either O
the O
NFAT B
- I
1 I
or O
NF B
kappa I
B I
binding I
sites I
were O
deleted O
, O
but O
failed O
to O
respond O
to O
these O
mitogenic O
stimuli O
if O
both O
sequences O
were O
absent O
. O

A O
transcription B
factor I
, O
NF B
- I
AT I
, O
which O
is O
essential O
for O
early O
T O
- O
cell O
gene O
activation O
, O
seems O
to O
be O
a O
specific O
target O
of O
cyclosporin O
A O
and O
FK506 O
action O
because O
transcription O
directed O
by O
this O
protein O
is O
blocked O
in O
T O
cells O
treated O
with O
these O
drugs O
, O
with O
little O
or O
no O
effect O
on O
other O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
. O

Two O
splice O
alternatives O
were O
identified O
that O
were O
not O
previously O
observed O
in O
human B
TCF I
- I
1 I
. O

Platelet B
- I
activating I
factor I
induces O
phospholipid O
turnover O
, O
calcium O
flux O
, O
arachidonic O
acid O
liberation O
, O
eicosanoid O
generation O
, O
and O
oncogene B
expression O
in O
a O
human O
B O
cell O
line O
. O

Interestingly O
, O
the O
MnlI B
- I
AluI I
fragment I
could O
suppress O
the O
basal O
- O
level O
activity O
of O
the O
conalbumin B
promoter I
in O
both O
Jurkat O
and O
HeLa O
cells O
. O

Thus O
, O
the O
novel O
enhancer O
element O
identified O
in O
this O
study O
is O
probably O
a O
target O
site O
for O
both O
positive B
and I
negative I
factors I
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 B
, I
S1 I
, I
S1 I
' I
, I
and I
S2 I
' I
subsites I
of O
cathepsin B
B I
and I
L I
, O
and O
not O
in O
the O
S1 B
and O
S1 B
' I
subsites O
of O
cathepsin B
D I
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF B
- I
kappa I
B I
and I
Sp1 I
binding I
sites I
present O
in O
the O
native B
long I
terminal I
repeat I
( O
LTR B
) O
, O
proviruses O
containing O
reconstructed B
LTRs I
with O
individual O
or O
combinations O
of O
NF B
- I
kappa I
B I
and I
Sp1 I
elements I
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

A O
2 O
- O
4 O
- O
fold O
increase O
in O
IFN B
- I
beta I
promoter I
transcription O
was O
observed O
in O
Sendai O
virus O
induced O
extracts O
, O
and O
deletion O
of O
PRDI B
and O
PRDII B
elements I
decreased O
this O
induced O
level O
of O
transcription O
. O

NF B
- I
kappa I
B I
activation O
by O
tumor B
necrosis I
factor I
alpha I
in O
the O
Jurkat O
T O
cell O
line O
is O
independent O
of O
protein B
kinase I
A I
, O
protein B
kinase I
C I
, O
and O
Ca B
( I
2 I
+ I
) I
- I
regulated I
kinases I
. O

NF B
- I
kappa I
B I
activation O
by O
tumor B
necrosis I
factor I
alpha I
in O
the O
Jurkat O
T O
cell O
line O
is O
independent O
of O
protein B
kinase I
A I
, O
protein B
kinase I
C I
, O
and O
Ca B
( I
2 I
+ I
) I
- I
regulated I
kinases I
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

However O
, O
as O
NF B
- I
kappa I
B I
is O
ubiquitous O
and O
the O
transcriptional O
activation O
through O
the O
B2 B
site O
is O
T O
cell O
specific O
, O
yet O
another O
T B
- I
cell I
- I
specific I
factor I
which O
synergizes O
with O
NF B
- I
kappa I
B I
should O
be O
considered O
. O

However O
, O
as O
NF B
- I
kappa I
B I
is O
ubiquitous O
and O
the O
transcriptional O
activation O
through O
the O
B2 B
site O
is O
T O
cell O
specific O
, O
yet O
another O
T B
- I
cell I
- I
specific I
factor I
which O
synergizes O
with O
NF B
- I
kappa I
B I
should O
be O
considered O
. O

The O
fusion B
cDNA I
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown B
locus I
, O
SIL B
( O
SCL B
interrupting I
locus I
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

Thus O
, O
in O
lymphocytes O
, O
growth B
- I
affecting I
genes I
other O
than O
immune B
receptors I
risk O
rearrangements O
. O

A O
closely O
related O
( O
if O
not O
identical O
) O
protein O
is O
found O
in O
both O
a O
human O
megakaryocytic O
cell O
line O
and O
purified O
human O
megakaryocytes O
; O
it O
binds O
to O
promoter B
regions I
of O
two O
megakaryocytic B
- I
specific I
genes I
. O

Furthermore O
, O
point O
mutations O
that O
abolish O
binding O
of O
NF B
- I
E1 I
result O
in O
a O
70 O
% O
decrease O
in O
the O
transcriptional O
activity O
of O
a O
megakaryocytic B
- I
specific I
promoter I
. O

Type B
- I
II I
estrogen I
- I
binding I
sites I
( O
type B
- I
II I
EBS I
) O
have O
been O
demonstrated O
in O
the O
human O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
using O
a O
whole O
- O
cell O
assay O
with O
( O
6 O
, O
7 O
- O
3H O
) O
estradiol O
( O
3H O
- O
E2 O
) O
as O
tracer O
. O

The O
relative O
binding O
affinity O
of O
quercetin O
, O
rutin O
, O
DES O
and O
TAM O
for O
type B
- I
II I
EBS I
correlated O
well O
with O
their O
potency O
as O
cell O
growth O
inhibitors O
. O

Moreover O
, O
hesperidin O
, O
a O
flavonoid O
which O
does O
not O
bind O
to O
type B
- I
II I
EBS I
, O
was O
ineffective O
in O
inhibiting O
cell O
growth O
. O

We O
show O
that O
ES O
- O
derived O
embryoid O
bodies O
express O
the O
full O
complement O
of O
mouse B
embryonic I
globin I
genes I
in O
the O
correct O
temporal O
order O
and O
that O
on O
further O
differentiation O
, O
a O
switch O
occurs O
to O
the O
fetal B
/ I
adult I
genes I
. O

We O
show O
that O
ES O
- O
derived O
embryoid O
bodies O
express O
the O
full O
complement O
of O
mouse B
embryonic I
globin I
genes I
in O
the O
correct O
temporal O
order O
and O
that O
on O
further O
differentiation O
, O
a O
switch O
occurs O
to O
the O
fetal B
/ I
adult I
genes I
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

ZRE B
- I
B I
is O
therefore O
not O
part O
of O
the O
R B
- I
inducible I
enhancer I
. O

Stimulation O
of O
a O
human O
T O
- O
cell O
clone O
with O
anti B
- I
CD3 I
or O
tumor B
necrosis I
factor I
induces O
NF B
- I
kappa I
B I
translocation O
but O
not O
human O
immunodeficiency O
virus O
1 O
enhancer O
- O
dependent O
transcription O
. O

The O
two O
latter O
signals O
were O
nevertheless O
able O
to O
induce O
NF B
- I
kappa I
B I
translocation O
with O
a O
pattern O
in O
the O
band O
- O
shift O
assay O
indistinguishable O
from O
that O
observed O
using O
phorbol O
ester O
. O

Two O
distinct O
forms O
of O
active B
transcription I
factor I
CREB I
( O
cAMP B
response I
element I
binding I
protein I
) O
. O

The O
expression O
of O
the O
antibody B
- I
encoding I
genes I
, O
the O
immunoglobulin B
( I
Ig I
) I
genes I
, O
is O
also O
restricted O
to O
B O
cells O
. O

It O
appears O
that O
the O
B O
cell O
- O
specific O
expression O
of O
Ig B
genes I
is O
mediated O
at O
least O
in O
part O
by O
cell O
type B
- I
specific I
Oct I
factors I
, O
and O
that O
there O
are O
both O
quantitative O
and O
qualitative O
differences O
between O
Oct B
- I
1 I
and O
Oct B
- I
2 I
factors I
. O

Induction O
of O
immediate B
early I
response I
genes I
by O
macrophage B
colony I
- I
stimulating I
factor I
in O
normal O
human O
monocytes O
. O

The O
c B
- I
jun I
gene I
expression O
was O
very O
transient O
and O
was O
not O
detectable O
by O
60 O
min O
after O
M B
- I
CSF I
addition O
. O

Inducible O
nuclear B
factor I
binding O
to O
the O
kappa B
B I
elements I
of O
the O
human B
immunodeficiency I
virus I
enhancer I
in O
T O
cells O
can O
be O
blocked O
by O
cyclosporin O
A O
in O
a O
signal O
- O
dependent O
manner O
. O

We O
have O
purified O
a O
new O
T B
- I
cell I
- I
specific I
factor I
, O
TCF B
- I
1 I
alpha I
, O
that O
is O
implicated O
in O
the O
activation O
of O
genes O
encoding O
a O
major O
component O
of O
the O
human B
T I
- I
cell I
receptor I
( O
TCR B
) O
. O

Curiously O
, O
the O
TCF B
- I
1 I
alpha I
binding O
element O
was O
inactive O
in O
vivo O
when O
removed O
from O
its O
neighboring O
elements O
on O
the O
TCR B
alpha I
enhancer I
and O
positioned O
in O
one O
or O
more O
copies O
upstream O
of O
a O
heterologous B
promoter I
. O

A O
powerful O
enhancer O
has O
been O
mapped O
to O
an O
18 B
- I
bp I
DNA I
segment I
located O
11 O
kb O
5 O
' O
to O
the O
human B
epsilon I
- I
globin I
gene I
within O
the O
dominant B
control I
or O
locus B
- I
activating I
region I
. O

DNA O
- O
protein O
binding O
assays O
with O
nuclear O
extracts O
from O
induced O
cells O
demonstrate O
a O
high B
molecular I
weight I
complex I
on O
the O
enhancer B
. O

Purified O
OTF1 B
from O
HeLa O
cells O
and O
OTF1 B
and O
OTF2 B
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy B
- I
chain I
promoter I
. O

NF B
- I
kappa I
B I
as O
inducible O
transcriptional B
activator I
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
gene I
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
and I
interleukin I
- I
2 I
genes I
, O
depending O
on O
promoter B
elements I
that O
bind O
the O
inducible B
transcription I
factor I
NF B
- I
kappa I
B I
( O
or O
an O
NF B
- I
kappa I
B I
- I
like I
factor I
) O
. O

Two O
kappa B
B I
- I
like I
motifs I
at O
positions B
- I
98 I
to I
- I
108 I
of O
the O
GM B
- I
CSF I
promoter I
were O
also O
recognized O
but O
with O
much O
lower O
affinities O
. O

Similar O
constructs O
controlled O
by O
NF B
- I
kappa I
B I
or O
the O
entire O
interleukin B
- I
2 I
enhancer I
show O
bimodal O
expression O
patterns O
during O
induction O
, O
suggesting O
that O
thresholds O
set O
by O
the O
concentration O
of O
transcription B
factors I
may O
be O
a O
common O
property O
of O
inducible B
genes I
. O

Similar O
constructs O
controlled O
by O
NF B
- I
kappa I
B I
or O
the O
entire O
interleukin B
- I
2 I
enhancer I
show O
bimodal O
expression O
patterns O
during O
induction O
, O
suggesting O
that O
thresholds O
set O
by O
the O
concentration O
of O
transcription B
factors I
may O
be O
a O
common O
property O
of O
inducible B
genes I
. O

In O
lymphoid O
cells O
, O
Z B
or O
R B
alone O
produced O
only O
small O
increases O
in O
EA B
- I
D I
promoter I
activity O
, O
whereas O
both O
transactivators B
together O
produced O
a O
large O
stimulatory O
effect O
. O

In O
lymphoid O
cells O
, O
only O
the O
upstream B
sequences I
are O
required O
for O
transactivation O
by O
the O
Z B
/ I
R I
combination O
, O
and O
the O
AP B
- I
1 I
site I
is O
dispensable O
. O

DNase O
footprinting O
analysis O
corroborated O
the O
functional O
data O
showing O
that O
a O
lymphoid B
- I
specific I
protein I
binds O
to O
the O
microB B
DNA I
motif I
. O

Interaction O
of O
fibronectin B
with O
VLA B
- I
5 I
receptor I
on O
CD4 O
cells O
induces O
the O
AP B
- I
1 I
transcription I
factor I
. O

Transcription B
factor I
IID I
( O
TFIID B
) O
binds O
to O
the O
TATA B
box I
promoter I
element I
and O
regulates O
the O
expression O
of O
most O
eukaryotic B
genes I
transcribed O
by O
RNA B
polymerase I
II I
. O

The O
cAMP B
- I
response I
element I
CRE B
, O
TGACGTCA O
, O
present O
in O
the O
21 B
base I
- I
pair I
sequence I
, O
appears O
to O
be O
essential O
for O
specific O
protein O
- O
TRE B
- O
DNA O
interactions O
because O
mutation O
of O
the O
two O
G O
' O
s O
destroys O
this O
complex O
. O

The O
' B
octamer I
' I
sequence I
, O
ATGCAAAT O
or O
its O
complement O
ATTTGCAT O
, O
is O
a O
key O
element O
for O
the O
transcriptional O
regulation O
of O
immunoglobulin B
genes I
in O
B O
- O
lymphocytes O
as O
well O
as O
a O
number O
of O
housekeeping B
genes I
in O
all O
cell O
types O
. O

In O
lymphocytes O
, O
the O
octamer B
- I
binding I
protein I
Oct B
- I
2A I
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B B
- I
cell I
specific I
gene I
expression O
, O
while O
the O
ubiquitous O
protein O
Oct O
- O
1 O
seems O
to O
control O
general O
octamer B
site I
- O
dependent O
transcription O
. O

Proteins O
that O
bind O
this O
octamer O
have O
been O
purified O
, O
and O
cDNAs B
encoding O
octamer B
- I
binding I
proteins I
have O
been O
cloned O
. O

Heat O
shock O
caused O
an O
increase O
in O
c O
- O
fos O
and O
c O
- O
jun O
mRNA O
levels O
and O
a O
decrease O
in O
c B
- I
myc I
mRNA I
levels O
in O
pre O
- O
B O
( O
Hyon O
) O
and O
T O
( O
DND O
- O
41 O
) O
cell O
lines O
as O
well O
as O
in O
freshly O
isolated O
normal O
human O
thymocytes O
. O

Mapping O
of O
B B
- I
cell I
epitopes I
of O
the O
human B
hepatitis I
B I
virus I
X I
protein I
. O

The O
transcription O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
is O
under O
the O
control O
of O
cellular B
proteins I
that O
bind O
to O
the O
viral B
long I
terminal I
repeat I
( O
LTR B
) O
. O

A O
novel O
T B
- I
cell I
protein I
recognized O
the O
palindromic B
sequence I
within O
site B
B I
and O
also O
bound O
estrogen B
- I
or I
thyroid I
hormone I
- I
response I
elements I
with O
lower O
affinity O
. O

It O
has O
previously O
been O
shown O
that O
9S B
, O
untransformed B
progestin I
, I
estrogen I
, I
androgen I
, I
and I
glucocorticoid I
receptor I
complexes I
in O
rabbit O
uterine O
and O
liver O
cytosols O
contain O
a O
59 B
- I
kDa I
protein I
[ O
Tai O
, O
P O
. O
K O
. O
, O
Maeda O
, O
Y O
. O
, O
Nakao O
, O
K O
. O
, O
Wakim O
, O
N O
. O
G O
. O
, O
Duhring O
, O
J O
. O
L O
. O
, O
& O
Faber O
, O
L O
. O
E O
. O
( O
1986 O
) O
Biochemistry O
25 O
, O
5269 O
- O
5275 O
] O
. O

We O
propose O
that O
ets B
- I
1 I
functions O
as O
a O
transcriptional O
activator O
of O
mammalian O
type O
- O
C O
retroviruses O
and O
speculate O
that O
ets B
- I
related I
genes I
constitute O
a O
new O
group O
of O
eukaryotic B
DNA I
- I
binding I
proteins I
. O

We O
have O
previously O
reported O
that O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
contain O
type O
II B
estrogen I
binding I
sites I
( O
type B
II I
EBS I
) O
. O

Proteins O
exist O
in O
leukocytes O
able O
to O
modify O
GTP B
- I
binding I
protein I
function O
in O
this O
manner O
, O
and O
their O
activity O
may O
be O
regulated O
by O
signals O
generated O
on O
phagocyte O
stimulation O
. O

The O
effect O
of O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
( O
OH O
) O
2 O
) O
D3 O
] O
, O
a O
steroid O
hormone O
with O
immunomodulating O
properties O
, O
on O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
proteins O
was O
examined O
in O
in O
vitro O
activated O
normal O
human O
lymphocytes O
by O
Western O
blot O
analysis O
. O

The O
effect O
of O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
( O
OH O
) O
2 O
) O
D3 O
] O
, O
a O
steroid O
hormone O
with O
immunomodulating O
properties O
, O
on O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
proteins O
was O
examined O
in O
in O
vitro O
activated O
normal O
human O
lymphocytes O
by O
Western O
blot O
analysis O
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct B
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin B
kappa I
light I
chain I
gene I
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct B
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin B
kappa I
light I
chain I
gene I
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

These O
observations O
demonstrate O
directly O
that O
there O
is O
de O
novo O
synthesis O
of O
NF B
- I
kappa I
B I
during O
human O
lymphocyte O
activation O
and O
suggest O
that O
this O
process O
is O
hormonally O
regulated O
. O

We O
previously O
identified O
the O
DNA B
consensus I
binding I
site I
recognized O
by O
the O
two O
DNA B
binding I
domains I
. O

The O
expression O
vector O
was O
cotransfected O
with O
the O
chloramphenicol B
acetyl I
transferase I
( I
CAT I
) I
reporter I
gene I
regulated O
by O
the O
thymidine B
kinase I
promoter I
containing O
GAL4 B
DNA I
binding I
sites I
into O
NIH O
3T3 O
, O
293 O
, O
K562 O
, O
and O
Jurkat O
cell O
lines O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat B
- I
related I
proteins I
, O
p94 B
and O
p95 B
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c B
- I
fos I
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid B
bcr I
/ I
abl I
, O
c B
- I
myc I
and O
p53 B
are O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c B
- I
fos I
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid B
bcr I
/ I
abl I
, O
c B
- I
myc I
and O
p53 B
are O

positively O
correlated O
with O
each O
other O
, O
but O
failed O
to O
relate O
to O
disease O
parameters O
, O
and O
( O
iii O
) O
acute O
and O
chronic O
in O
vivo O
exposure O
to O
IFN B
- I
alpha I
is O
accompanied O
by O
upregulation O
of O
c B
- I
fos I
and O
downregulation O
of O
c B
- I
myc I
mRNA I
levels O
in O
responder O
patients O
. O

In O
contrast O
to O
hematopoietic O
cells O
, O
I O
kappa O
B O
alpha O
- O
/ O
- O
embryonic O
fibroblasts O
show O
minimal O
constitutive B
NF I
- I
kappa I
B I
, O
as O
well O
as O
normal O
signal O
- O
dependent O
NF B
- I
kappa I
B I
activation O
that O
is O
concomitant O
with O
I B
kappa I
B I
beta I
degradation O
. O

In O
contrast O
to O
hematopoietic O
cells O
, O
I O
kappa O
B O
alpha O
- O
/ O
- O
embryonic O
fibroblasts O
show O
minimal O
constitutive B
NF I
- I
kappa I
B I
, O
as O
well O
as O
normal O
signal O
- O
dependent O
NF B
- I
kappa I
B I
activation O
that O
is O
concomitant O
with O
I B
kappa I
B I
beta I
degradation O
. O

Moreover O
, O
the O
induction O
of O
both O
Jak B
1 I
and I
3 I
, O
and O
STAT B
5 I
activity O
strongly O
correlated O
with O
the O
growth O
- O
promoting O
effects O
of O
IL B
- I
7 I
, O
suggesting O
that O
this O
signal O
transduction O
mechanism O
may O
play O
a O
key O
role O
in O
IL B
- I
7 I
- O
induced O
proliferation O
. O

Analysis O
of O
the O
expression O
of O
human B
I I
kappa I
B I
alpha I
protein I
in O
stable O
transfectants O
of O
mouse O
70Z O
/ O
3 O
cells O
shows O
that O
, O
as O
for O
the O
endogenous O
murine O
protein O
, O
exogenous O
I B
kappa I
B I
alpha I
is O
degraded O
in O
response O
to O
inducers O
of O
NF B
- I
kappa I
B I
activity O
, O
such O
as O
phorbol O
myristate O
acetate O
or O
lipopolysaccharide O
. O

Analysis O
of O
the O
expression O
of O
human B
I I
kappa I
B I
alpha I
protein I
in O
stable O
transfectants O
of O
mouse O
70Z O
/ O
3 O
cells O
shows O
that O
, O
as O
for O
the O
endogenous O
murine O
protein O
, O
exogenous O
I B
kappa I
B I
alpha I
is O
degraded O
in O
response O
to O
inducers O
of O
NF B
- I
kappa I
B I
activity O
, O
such O
as O
phorbol O
myristate O
acetate O
or O
lipopolysaccharide O
. O

By O
expressing O
mutant O
forms O
of O
the O
human O
protein O
in O
this O
cell O
line O
, O
we O
have O
been O
able O
to O
delineate O
the O
sequences O
responsible O
for O
both O
the O
ligand O
- O
induced O
phosphorylation O
and O
the O
degradation O
of O
I B
kappa I
B I
alpha I
. O

Finally O
, O
by O
studying O
a O
further O
series O
of O
patients O
, O
we O
could O
confirm O
that O
the O
decrease O
in O
Rap1 B
protein I
expression O
in O
heart O
failure O
, O
whatever O
its O
extent O
, O
was O
variable O
, O
and O
could O
strictly O
correlate O
the O
expression O
of O
Rap1 B
protein I
with O
the O
stimulatory O
effect O
of O
C B
. I
Sub I
. I
on O
Ca2 O
+ O
transport O
. O

T O
cells O
lack O
active O
NF B
- I
kappa I
B I
but O
express O
Sp1 B
as O
expected O
. O

Deoxycholate O
treatment O
of O
the O
cytoplasmic O
extract O
prepared O
from O
cells O
stimulated O
by O
TNF B
- I
alpha I
in O
the O
presence O
of O
Cu2 O
+ O
resulted O
in O
the O
release O
of O
NF B
kappa I
B I
from O
I B
kappa I
B I
alpha I
, O
indicating O
that O
Cu2 O
+ O
interferes O
with O
the O
dissociation O
of O
the O
NF B
kappa I
B I
- I
I I
kappa I
B I
complex I
. O

Neither O
phosphorylation O
nor O
degradation O
of O
I B
kappa I
B I
alpha I
was O
observed O
upon O
TNF B
- I
alpha I
stimulation O
in O
the O
presence O
of O
Cu2 O
+ O
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

In O
most O
cases O
, O
the O
transcriptional B
factor I
NF B
- I
kappa I
B I
is O
a O
heterodimer B
consisting O
of O
two O
subunits O
, O
p50 B
and O
p65 B
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel B
family I
. O

This O
novel O
enzyme O
is O
distinct O
from O
E6 B
- I
AP I
, O
the O
p53 B
- I
conjugating I
ligase I
, O
and O
from O
E3 B
alpha I
, O
the O
` B
` I
N I
- I
end I
rule I
' I
' I
ligase I
. O

To O
identify O
osteoblast B
- I
specific I
cis I
- I
acting I
elements I
and O
trans B
- I
acting I
factors I
, O
we O
initiated O
an O
analysis O
of O
the O
promoter B
of O
a O
mouse B
osteocalcin I
gene I
, O
an O
osteoblast B
- I
specific I
gene I
. O

To O
identify O
osteoblast B
- I
specific I
cis I
- I
acting I
elements I
and O
trans B
- I
acting I
factors I
, O
we O
initiated O
an O
analysis O
of O
the O
promoter B
of O
a O
mouse B
osteocalcin I
gene I
, O
an O
osteoblast B
- I
specific I
gene I
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

Upon O
cellular O
activation O
, O
expression O
of O
the O
L B
- I
selectin I
gene I
is O
downregulated O
at O
both O
the O
protein O
and O
mRNA O
levels O
. O

These O
results O
indicated O
that O
ATL O
cells O
constitutively O
overexpress O
the O
L B
- I
selectin I
gene I
that O
can O
be O
transactivated O
by O
HTLV O
- O
1 O
Tax B
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

Promoter O
function O
of O
the O
5 B
' I
flanking I
region I
of O
the O
thromboxane B
receptor I
gene I
was O
evaluated O
by O
transfection O
of O
thromboxane B
receptor I
gene I
promoter I
/ I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
chimera I
plasmids I
into O
platelet O
- O
like O
K562 O
cells O
. O

Proteins O
in O
the O
first O
group O
contain O
multiple O
HMG B
boxes I
, O
are O
non O
- O
sequence O
- O
specific O
, O
and O
recognize O
structural O
features O
as O
found O
in O
cruciform B
DNA I
and O
cross B
- I
over I
DNA I
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
is O
stored O
in O
the O
cytoplasm O
as O
an O
inactive O
form O
through O
interaction O
with O
I B
kappa I
B I
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
is O
stored O
in O
the O
cytoplasm O
as O
an O
inactive O
form O
through O
interaction O
with O
I B
kappa I
B I
. O

We O
have O
recently O
reported O
the O
establishment O
of O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
dependent O
cell O
- O
free O
activation O
system O
of O
NF B
- I
kappa I
B I
in O
association O
with O
the O
induction O
of O
I B
kappa I
B I
alpha I
phosphorylation O
. O

We O
have O
recently O
reported O
the O
establishment O
of O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
dependent O
cell O
- O
free O
activation O
system O
of O
NF B
- I
kappa I
B I
in O
association O
with O
the O
induction O
of O
I B
kappa I
B I
alpha I
phosphorylation O
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

TCF B
- I
1 I
mRNA I
was O
originally O
found O
to O
be O
expressed O
in O
a O
T O
cell O
- O
specific O
fashion O
within O
a O
set O
of O
human O
and O
mouse O
cell O
lines O
. O

Immunohistochemistry O
on O
a O
panel O
of O
human O
tissues O
revealed O
that O
the O
TCF B
- I
1 I
protein I
was O
found O
exclusively O
in O
thymocytes O
and O
in O
CD3 O
+ O
T O
cells O
in O
peripheral O
lymphoid O
tissues O
. O

Costimulation O
with O
anti B
- I
CD28 I
MoAb I
greatly O
enhanced O
the O
proliferative O
response O
of O
neonatal O
T O
cells O
to O
levels O
equivalent O
to O
those O
of O
adult O
T O
cells O
, O
whereas O
adult O
T O
cells O
showed O
only O
slight O
increases O
. O

Although O
IL B
- I
2 I
secretion O
was O
increased O
in O
the O
presence O
of O
anti B
- I
CD28 I
MoAb I
, O
neonatal O
T O
cell O
IL B
- I
2 I
production O
remained O
lower O
than O
in O
adults O
. O

Inhibition O
of O
endogenous B
C I
/ I
EBP I
proteins I
, O
using O
either O
an O
excess O
of O
C B
/ I
EBP I
binding I
sites I
or O
a O
trans B
- I
dominant I
negative I
inhibitor I
, O
demonstrated O
that O
C B
/ I
EBP I
proteins I
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV B
- I
1 I
LTR I
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

Inhibition O
of O
endogenous B
C I
/ I
EBP I
proteins I
, O
using O
either O
an O
excess O
of O
C B
/ I
EBP I
binding I
sites I
or O
a O
trans B
- I
dominant I
negative I
inhibitor I
, O
demonstrated O
that O
C B
/ I
EBP I
proteins I
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV B
- I
1 I
LTR I
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

However O
, O
transcription O
from O
crippled B
HIV I
- I
1 I
LTRs I
lacking O
C B
/ I
EBP I
sites I
can O
still O
be O
induced O
following O
activation O
of O
U937 O
cells O
. O

Since O
expression O
of O
the O
viruses O
is O
in O
large O
part O
regulated O
by O
the O
sequence B
elements I
in O
their O
long B
terminal I
repeats I
( O
LTRs B
) O
, O
this O
study O
was O
directed O
to O
an O
analysis O
of O
the O
regulatory B
elements I
in O
the O
HIV B
- I
2 I
LTR I
. O

The O
HIV B
- I
2 I
LTR I
was O
found O
to O
contain O
two O
enhancers B
. O

Other O
unidentified O
ETS B
- I
like I
factors I
present O
in O
Jurkat O
cells O
are O
also O
capable O
of O
binding O
GM5 B
. O

The O
effects O
of O
CsA O
on O
endothelial O
cells O
were O
also O
detected O
at O
the O
chromatin B
structure O
level O
, O
as O
DNasel B
hypersensitive I
sites I
within O
both O
the O
GM B
- I
CSF I
enhancer O
and O
the O
E B
- I
selectin I
promoter I
were O
suppressed O
by O
CsA O
. O

Protein O
phosphorylation O
has O
an O
important O
role O
in O
the O
regulation O
of O
these O
two O
factors O
: O
( O
1 O
) O
it O
induces O
the O
transactivating O
capacity O
of O
the O
AP B
- I
1 I
protein I
c B
- I
Jun I
; O
and O
( O
2 O
) O
it O
is O
involved O
in O
the O
release O
of O
the O
cytoplasmic B
inhibitor I
, O
I B
kappa I
B I
, O
from O
NF B
- I
kappa I
B I
, O
allowing O
translocation O
of O
the O
latter O
into O
the O
nucleus O
. O

Protein O
phosphorylation O
has O
an O
important O
role O
in O
the O
regulation O
of O
these O
two O
factors O
: O
( O
1 O
) O
it O
induces O
the O
transactivating O
capacity O
of O
the O
AP B
- I
1 I
protein I
c B
- I
Jun I
; O
and O
( O
2 O
) O
it O
is O
involved O
in O
the O
release O
of O
the O
cytoplasmic B
inhibitor I
, O
I B
kappa I
B I
, O
from O
NF B
- I
kappa I
B I
, O
allowing O
translocation O
of O
the O
latter O
into O
the O
nucleus O
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B
and O
CD28 B
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B
kappa I
B I
phosphorylation O
and O
NF B
- I
kappa I
B I
activation O
on O
the O
one O
hand O
, O
and O
JNK B
activation O
and O
c B
- I
Jun I
phosphorylation O
on O
the O
other O
. O

We O
are O
currently O
engaged O
in O
defining O
where O
the O
two O
signals O
integrate O
along O
the O
AP B
- I
1 I
/ O
NF B
- I
kappa I
B I
pathway O
. O

Enhancement O
of O
HIV O
- O
1 O
replication O
is O
related O
in O
part O
to O
increased O
DNA O
- O
binding O
activity O
of O
cellular B
transcription I
factors I
such O
as O
NF B
- I
kappa I
B I
. O

Increased O
intracellular O
stores O
of O
latent B
NF I
- I
kappa I
B I
may O
also O
result O
in O
rapid O
inducibility O
of O
NF B
- I
kappa I
B I
- O
dependent O
cytokine B
gene O
expression O
. O

Our O
data O
support O
the O
view O
that O
steroid O
- O
mediated O
cell O
death O
occurs O
by O
a O
process O
requiring O
direct O
interaction O
of O
steroid B
- I
receptor I
complexes I
with O
the O
genome O
. O

As O
this O
phosphorylation O
was O
independent O
of O
protein B
kinase I
C I
activity O
, O
we O
tested O
whether O
a O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( O
CaM B
kinase I
) O
might O
phosphorylate O
the O
Ets B
- I
1 I
protein I
after O
elevation O
of O
intracellular O
free O
calcium O
concentrations O
. O

GP B
Ib I
alpha I
promoter I
activity O
was O
evaluated O
by O
transfection O
of O
human O
erythroleukemia O
cells O
with O
reporter O
plasmids O
coding O
for O
the O
enzyme B
, O
luciferase B
. O

The O
results O
define O
essential O
cis B
- I
acting I
elements I
responsible O
for O
the O
expression O
of O
GP B
Ib I
alpha I
and O
provide O
insights O
into O
molecular O
events O
coinciding O
with O
the O
release O
of O
normal O
platelets O
into O
the O
bloodstream O
. O

The O
expression O
of O
MHC B
class I
II I
genes I
in O
mouse O
T O
cells O
can O
be O
reconstituted O
upon O
transfection O
with O
the O
human B
CIITA I
cDNA I
. O

Because O
HLA B
class I
II I
molecules I
present O
antigen O
to O
T B
cell I
receptors I
( O
TCRs B
) O
, O
we O
have O
searched O
for O
a O
TCR B
gene I
associated O
with O
the O
production O
of O
anti B
- I
Ro I
( I
SSA I
) I
antibodies I
. O

This O
RFLP B
pair I
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins B
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B
( O
P O
= O
0 O
. O
0004 O
) O
. O

This O
RFLP B
pair I
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins B
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B
( O
P O
= O
0 O
. O
0004 O
) O
. O

This O
RFLP B
pair I
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins B
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B
( O
P O
= O
0 O
. O
0004 O
) O
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs B
and O
HLA B
class I
II I
antigens I
previously O
associated O
with O
the O
anti O
- O
Ro B
( I
SSA I
) I
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci B
occur I
in O
response O
to O
Ro B
( I
SSA I
) I
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs B
and O
HLA B
class I
II I
antigens I
previously O
associated O
with O
the O
anti O
- O
Ro B
( I
SSA I
) I
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci B
occur I
in O
response O
to O
Ro B
( I
SSA I
) I
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs B
and O
HLA B
class I
II I
antigens I
previously O
associated O
with O
the O
anti O
- O
Ro B
( I
SSA I
) I
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci B
occur I
in O
response O
to O
Ro B
( I
SSA I
) I
. O

Human B
IL4 I
promoter I
- O
mediated O
transcription O
is O
downregulated O
in O
Jurkat O
cells O
stimulated O
with O
the O
NF B
- I
kappa I
B I
- I
activating I
cytokine I
tumor B
necrosis I
factor I
alpha I
and O
suppressed O
in O
RelA O
- O
overexpressing O
cells O
. O

Monocytic O
cell O
lines O
and O
normal O
peripheral O
blood O
monocytes O
were O
infected O
with O
HIV O
- O
1 O
in O
vitro O
and O
cultured O
in O
the O
presence O
or O
absence O
of O
F B
( I
ab I
' I
) I
2 I
fragments I
of O
monoclonal B
anti I
- I
CR1 I
or O
anti B
- I
CR3 I
Abs I
or O
with O
C3 B
fragments I
. O

Monocytic O
cell O
lines O
and O
normal O
peripheral O
blood O
monocytes O
were O
infected O
with O
HIV O
- O
1 O
in O
vitro O
and O
cultured O
in O
the O
presence O
or O
absence O
of O
F B
( I
ab I
' I
) I
2 I
fragments I
of O
monoclonal B
anti I
- I
CR1 I
or O
anti B
- I
CR3 I
Abs I
or O
with O
C3 B
fragments I
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B
- I
binding I
protein I
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

Purified O
MAR B
- I
BP1 I
migrates O
as O
a O
33 B
- I
kDa I
protein I
, O
and O
it O
can O
be O
found O
in O
nuclear O
matrix O
preparations O
from O
a O
number O
of O
different O
types O
of O
lymphoid O
cell O
lines O
. O

C B
/ I
EBP I
alpha I
is O
the O
major O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( O
C B
/ I
EBP I
) O
form O
binding O
to O
this O
site O
in O
nuclear O
extracts O
of O
U937 O
cells O
. O

Regulation O
of O
c B
- I
jun I
mRNA I
expression O
by O
hydroxyurea O
in O
human O
K562 O
cells O
during O
erythroid O
differentiation O
[ O
published O
erratum O
appears O
in O
Biochim O
Biophys O
Acta O
1995 O
Dec O
27 O
; O
1264 O
( O
3 O
) O
: O
409 O
] O

Because O
NF B
- I
kappa I
B I
activates O
many O
immunoregulatory B
genes I
in O
response O
to O
pro O
- O
inflammatory O
stimuli O
, O
the O
inhibition O
of O
its O
activity O
can O
be O
a O
major O
component O
of O
the O
anti O
- O
inflammatory O
activity O
of O
glucocorticoids O
. O

Transcriptional O
repression O
of O
the O
interleukin B
- I
2 I
gene I
by O
vitamin O
D3 O
: O
direct O
inhibition O
of O
NFATp B
/ I
AP I
- I
1 I
complex I
formation O
by O
a O
nuclear B
hormone I
receptor I
. O

The O
5 B
' I
flanking I
DNA I
also O
contains O
a O
cluster O
of O
three O
binding B
sites I
for O
the O
GATA B
family I
of O
transcription B
factors I
. O

Cysteamine O
treatment O
inhibited O
both O
expression O
of O
the O
IL B
- I
2 I
mRNA I
and O
secretion O
of O
IL B
- I
2 I
into O
the O
culture O
medium O
. O

We O
examined O
by O
northern O
hybridization O
the O
expression O
of O
Id2 B
and I
Id3 I
mRNA I
in O
human O
leukemia O
/ O
lymphoma O
lines O
and O
patient O
samples O
, O
as O
well O
as O
resting O
and O
activated O
normal O
human O
lymphocytes O
from O
peripheral O
blood O
( O
PBL O
) O
. O

Furthermore O
, O
sodium O
salicylate O
blocked O
the O
LPS O
- O
induced O
proteolytic O
degradation O
of O
I B
kappa I
B I
alpha I
, O
which O
prevented O
the O
nuclear O
translocation O
of O
c B
- I
Rel I
/ I
p65 I
heterodimers I
. O

A O
central O
role O
for O
a O
single B
c I
- I
Myb I
binding I
site I
in O
a O
thymic B
locus I
control I
region I
. O

c B
- I
Myb I
protein I
was O
strongly O
evident O
in O
T O
lymphoblasts O
in O
which O
the O
enhancer B
was O
active O
and O
was O
localized O
within O
discrete O
nuclear O
structures O
. O

We O
conclude O
that O
transcription O
activation O
by O
LEF B
- I
1 I
in O
vitro O
is O
a O
chromatin B
- O
dependent O
process O
that O
requires O
a O
functional O
trans B
- I
activation I
domain I
in O
addition O
to O
the O
HMG B
domain I
. O

Immunoprecipitation O
of O
the O
gp B
160 I
- O
induced O
nuclear O
extracts O
with O
polyclonal B
antibodies I
to O
Fos B
and O
Jun B
proteins I
indicates O
that O
AP B
- I
1 I
complex I
is O
comprised O
of O
members O
of O
these O
family O
of O
proteins O
. O

